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Abstract 
 
High mobility group nucleosome binding (HMGN) proteins belong to the superfamily of 
high mobility group (HMG) proteins. HMGN1 and HMGN2 are ubiquitously expressed in all 
vertebrates, and are most highly expressed in embryonic tissue. Moreover, HMGN1 and 
HMGN2 were found to be highly expressed in neural stem/progenitor cells in the mouse 
brain. Here, mouse embryonal carcinoma cells (P19 EC) were used as a model system to 
study the role of HMGN proteins in pluripotent stem cells. Previously, experiments using  
short interfering RNA (siRNA) technology to knockdown HMGN1 and HMGN2 have 
suggested that HMGN proteins are important for the expression of key pluripotent 
genes, Oct4, Sox2 and Nanog, in P19 EC cells (Mohan, 2012).  
The aim of this thesis was to develop a lentiviral system for the long term knockdown of 
Hmgn2, in order to investigate more fully the role of this protein in stem cell 
pluripotency and differentiation.  Constitutive and inducible lentiviral shRNAmir systems 
were tested and optimized, and a constitutive system was chosen for further work.  
HMGN2 knockdown in undifferentiated P19 EC cells resulted in the down-regulation of 
Oct4 protein levels. ChIP assays showed that HMGN2 binding over the Oct4 gene was 
absent in HMGN2 knockdown cells. Furthermore, binding of HMGN1 at this locus was 
increased in the absence of HMGN2. Consistent with the reduction in Oct4 expression, 
levels of the active histone modification, H3K4me3, were also decreased at the Oct4 
gene. These results support a role for HMGN2 in the regulation of Oct4 expression in P19 
cells, and imply that HMGN2 may be important for maintaining stem cell pluripotency.  
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Definitions/Abbreviations 
A/B compartment = genome can be 
divided into two compartment based on 
cell-type specific and associate with close 
and open chromatin.  
ACF = Asymmetric Crying Facies (Cayler 
Cardiofacial Syndrome) 
ALT = alternative lengthening of telomeres 
AP = (apurinic/apyrimidinic site), also 
known as an abasic site 
APP = Amyloid Beta (A4) Precursor Protein 
ART = ADP-ribosyltransferase 
Asf1= Anti-silencing function protein 1 
ATAC-seq = assay for transposase-
accessible chromatin using sequencing 
ATM = Ataxia telangiectasia mutated 
ATP-dependent chromatin = ATPase 
subunit that belongs to the SNF2 
superfamily of proteins. 
AZaC = 5-aza-2’-deoxy-cytidine 
BAC = bacterial artificial chromosome 
BAP1 = BRCA1 Associated Protein-1 
(Ubiquitin Carboxy-Terminal Hydrolase 
BER = base excision repair 
BLM = Bloom Syndrome, RecQ Helicase-
Like  
BMP = Bone morphogenetic proteins 
BRCA1 = Breast Cancer 1, Early Onset 
BRD4 = Bromodomain-containing protein 4 
Brg1 = Brahma-related gene-1 
Bromodomain = 110 amino acid protein 
domain that recognizes acetylated lysine 
residues 
BTG4 = B-Cell Translocation Gene 4 
CAP-G protein = Capping Protein (Actin 
Filament), Gelsolin-Like 
CBP = CREB-binding protein 
CCNB1= G2/mitotic-specific cyclin-B1 
protein 
CHD = Chromodomain Helicase DNA 
Binding Protein 
Chd7 = chromodomain helicase DNA 
binding protein 7 
ChIP-seq = combines chromatin 
immunoprecipitation (ChIP) with massively 
parallel DNA sequencing to identify the 
binding sites of DNA-associated proteins.  
Chromodomain = chromatin organization 
modifier 
CITRULLINE = α-amino acid 
Cmv = Cytomegalovirus 
C-Myc = V-Myc Avian Myelocytomatosis 
Viral Oncogene Homolog 
CNTF = Ciliary Neurotrophic Factor 
COMMD1 = Copper Metabolism (Murr1) 
Domain Containing 1 
CpG = CG sites are regions of DNA where a 
cytosine nucleotide is followed by a 
guanine nucleotide in the linear sequence 
of bases along its 5' → 3' direction. 
DICER = endoribonuclease Dicer or helicase 
with RNase motif 
DNasel hypersensitive site (DHS)= are 
regions of chromatin that are sensitive to 
cleavage by the DNase I enzyme. 
DNase-seq = (DNase I hypersensitive sites) 
sequencing 
DORSHA = Class 2 ribonuclease III enzyme 
DPN = Depleted Proximal Nucleosomes 
DSB = double-strand break 
DSRNA = Double-strand RNA 
EB = embryo bodies  
EC = embryonic carcinoma  
ELISA = enzyme-linked immunosorbent 
assay 
EpiSCs = epiblast stem cells 
ERK = extracellular-signal-regulated 
kinases (ERKs)/ classical MAP kinases 
ESCs = embryonic stem cells 
ESRRB = Estrogen-Related Receptor Beta 
EZh2 = Enhancer Of Zeste 2 Polycomb 
Repressive Complex 2 Subunit 
FGF2 = Fibroblast Growth Factor 2 (Basic) 
FGF4 = Fibroblast growth factor 4 
FGF5 = Fibroblast growth factor 5 
FIGLA = Folliculogenesis Specific BHLH 
Transcription Factor 
footprinting techniques = A DNase 
footprinting assay 
FOXA2 = Forkhead Box A2 
Fpr4 = histone chaperone FK506-binding 
protein 4 
Gag = Group-specific antigen 
GAL4-VP16 = S. cerevisiae GAL4 [1-147] 
fused with HSV2 VP16 [411-490]  
GATA6/4 = GATA Binding Protein 
GBX2 = Gastrulation Brain Homeobox 2 
Gcn5 = histone acetyltransferase GCN5 
GEAP = Glial E2F1-Associated Proteins 
GFAP = Glial fibrillary acidic protein 
GSK3 = Glycogen synthase kinase-3 
H2A = Histone H2A 
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H2A.Z = H2A Histone Family, Member Z 
H2Aub = histone H2A monoubiquitylation 
H2B = Histone H2B 
H2Bub1 = H2B monoubiquitination 
H3 = Histone H3 
H3.3 = histone H3.3 
H3K122ac = Histone H3 (acetyl K122) 
acetylated  
H3K14aC = Histone H3 acetyl Lys14 
acetylated 
HDACs = Histone deacetylases 
HDMs = Protein hold'em 
Histone chaperones a group of proteins 
that bind histones and regulate 
nucleosome assembly 
HIV = human immunodeficiency virus 
HMG = high mobility group  
HMOF = lysine acetyltransferase MOF 
(males absent on the first) 
HMT = Histone methyltransferases 
HOX = homebox gene 
HP = heterochromatin protein  
HP1= heterochromatin protein 1 alpha 
HR = homologous recombination 
HRE = hormone responsive element 
HSP68 = Mouse Hsp68 minimal promoter. 
ICM = inner cell mass  
IFN-ALPHA/beta = Alpha/Beta interferon 
iPSCs = induce pluripotent stem cells 
IR = ion radiation  
IRES = internal ribosome entry site 
IRF1/2 = interferon regulatory factor 1/2 
ISWI = imitation SWI of drosophila 
melanogaster 
JAK SIGNALING = Janus kinase 
Jmjd1a = Lysine (K)-Specific Demethylase 
3A  
Jmjd2c = Lysine (K)-Specific Demethylase 
4C 
JNK-mediated = The c-Jun N-terminal 
Kinase (JNK)  
KCR = lysine crotonylation 
KLF2/4/5 = Krüppel-like family of 
transcription factors 
LANA = latency-associated nuclear 
antigen 
LTR = Long terminal repeats 
MAPK = Mitogen-activated protein kinases 
MeCP2 = methyl CpG binding protein 2 
(Rett syndrome) 
MEFs = mouse embryonic fibroblasts  
MEK = Mitogen-activated protein kinase 
MIRNA = micro RNA 
 
MNase = Micrococcal Nuclease 
Moi = multiplicity of infuction  
MSC = bone marrow stromal stem cells 
Nanog = Homeobox Transcription Factor 
Nanog 
NBD = nucleosome binding domain  
NER = Nucleotide excision repair 
Nestin = acronym for neuroectodermal stem 
cell marker 
NCE = nuclear cell extract  
NEUN = Feminizing Locus on X-3, Fox-3, 
Rbfox3, or Hexaribonucleotide Binding 
Protein-3 
NFkB = nuclear factor kappa-light-chain-
enhancer of activated B cells 
NFRs = nucleosome free regions 
NLRP9 = NOD-like receptor family pyrin 
domain containing 9 
NLS = nuclear localization signal 
NODAL = signal transduction pathway 
NON-SET = non-SET domain-containing 
histone methyltransferase utilizes the 
enzyme Dot1 
NOTCH = a family of transmembrane 
proteins 
NPCs = neuro progenitor cells  
NSC = neuro stem cell 
nucleosome sliding is a result of energy- 
dependent nucleosome remodelling in vitro 
Oct4/6 = Octamer-Binding Transcription 
Factor 
O-GlcNAc = UDP-N-acetylglucosamine—
peptide N-acetylglucosaminyltransferase 
Olig2 = Oligodendrocyte transcription factor 
OPN = occupied proximal-nucleosome 
OTX2 = Homeobox protein OTX2 
P21 = cyclin-dependent kinase inhibitor 1 
P300 = transcriptional coactivator 
P300/CBP = coactivator family  
P38 = mitogen-activated protein kinases 
P53 = tumor suppressor p53 
PADI4 = Peptidyl arginine deiminase, type IV 
PAF = Platelet-activating factor 
Palmitoylated residues = covalent 
attachment of fatty acids 
PARP = Poly (ADP-ribose) polymerase 
Pax6 = Paired box protein Pax-6  
PCNA = Proliferating cell nuclear antigen 
PDGFRA = Platelet-derived growth factor 
receptor 
PGC = Primordial Germ Cell 
PHD fingers = plant homeodomain 
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PIAS = Protein inhibitor of activated STAT 
Pioneer factors are transcription factors 
that can directly bind condensed 
chromatin  
PITX2 =  Paired-like homeodomain 
transcription factor 2 
PKDMs =  protein lysine demethylases 
PKMTs =  lysine methyltransferases 
PKR =  Protein kinase RNA-activated 
Pol = polymerase  
PR = progesterone receptor  
PRC1/2 =  Polycomb Repressive Complex 
PrEn =  primitive endoderm 
PRMT5 =  Protein arginine N-
methyltransferase 5 
PTM = post-translational modification 
PURO = puromycine  
RA = retinoic acid  
Rad6 =  Ubiquitin-conjugating enzyme E2 
RCC1=  Regulator of chromosome 
condensation 
RD =  regulatory domain 
RING1B =  Putative E3 ubiquitin-protein 
ligase RING1b 
RISC =  RNA-induced silencing complex 
RNAP2 =  RNA polymerase II 
Rre =  Rev response element 
rRNA = ribosomal RNA  
RT-qPCR =  Quantitative reverse 
transcription PCR 
Rtt109 =  histone acetyltransferase 
Rtt109 
SAXS = Small-angle X-ray scattering 
SERINE/THREONINE Kinase Aurora-B = 
Serine/threonine-protein kinase component 
of the chromosomal passenger complex 
(CPC), a complex that acts as a key 
regulator of mitosis.  
SET = SET Nuclear Proto-Oncogene 
SFM = scanning-force microscopy  
Smarca4 = ATP-dependent helicase SMARCA4 
SMC protein = Structural Maintenance of 
Chromosomes. 
Snf21/Snf2h = ATP-dependent DNA helicase 
SONIC HEDGEHOG = shh  
Sox1/2/7/17 = sex determining region Y 
SSEA1= stage-specific embryonic antigen-1 
STAT = signal transducer and activator of 
transcription 
SIN = self-inactivating vector 
STORM = stochastic optical reconstruction 
microscopy 
SUMO-3 = Small ubiquitin-related modifier 3 
Suz12 = Polycomb protein SUZ12 
SV40 = Simian vacuolating virus 40 
SWI/SNF = SWItch/Sucrose Non-Fermentable 
TADs = Topologically associating domains 
Tat = Tyrosine Aminotransferase 
TBP = Transcription Initiation Factor TFIID 
TBP Subunit 
TBX3 = T-Box 3 
TCR = T cell receptor 
TEAD4 = Transcriptional enhancer factor 
TEF-3 
TFIIB/TFIIIA= Transcription Factor II/III B/A 
T-helper1 =  T helper cells 
Tip6 =  tension-induced/inhibited protein 
TSA =  trichostatin A inhibitor  
TSS = transcription starting sites  
Vsv-g =  Vesicular stomatitis Indiana virus 
WAS = Wiskott-Aldrich syndrome   
WCE = whole cell extract 
WNT =  complex protein network 
WRN =  Werner syndrome RecQ like helicase 
X-ray crystallography is a tool  used for 
identifying the atomic and molecular 
structure of a crystal 
Zfp42 =  Zinc finger protein 42 homolog 
ZP2/3/4 =  Zona pellucida sperm-binding 
protein 
λ5-VpreB1 is mouse genes express in B-cells  
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Chapter 1 Introduction 
1.1 Chromatin structure in eukaryotic cells  
Mammalian genomes are packed into nucleoprotein complex known as 
chromatin. Chromatin regulates all processes involving DNA, which include 
DNA synthesis, transcription, translation, DNA repair, and recombination 
(Tagami et. al., 2004). Chromatin can be described as euchromatin or 
heterochromatin. Euchromatin corresponds to the regions with high numbers 
of transcribed genes, whereas heterochromatin indicates the highly 
condensed regions of the genome and less transcribed genes.  
 
1.1.1 Nucleosome structure 
Chromatin contains a repeated subunit called the nucleosome, which 
consists of ~147 bp of DNA wrapped around an octamer of core histone 
proteins, and linker DNA that connects the nucleosomes to each other.  The 
histone octamer contains two molecules of each of the four core histones, 
H3, H4, H2A, and H2B (Zlatanova et. al., 1998) (Figure 1.1). Core histones 
are highly conserved essential proteins that are found in all eukaryotes, and 
they contain a high amount of the amino acids lysine and arginine. Histones 
have a positive charge that permits them to connect with DNA that has a 
negative charge. All four cores histone proteins have a long N-terminal 
domain and shorter C-terminal domain. Histone octamer consists of a 
modular assembly of two stable heterodimers of H2A/H2B and one H3/H4 
tetramer.   
The nucleosome structure is very highly conserved in all eukaryotic cells. 
Klug and colleagues using X-ray crystallographic analysis first observed 
nucleosome core particle structure in 1977. The structure of nucleosome 
was explained by several studies using electron microscopy and nuclease 
digest for offering a histone-DNA repeat structure of chromatin and 
providing the basic unit of the chromatin (Bryan Turner, 2005) (Figure 1.1). 
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1.1.2 Linker Histones  
In addition to the four core histones, a linker histone can bind to the outside 
of the nucleosome particle, where it also interacts with the linker DNA  
(Zhou et. al., 2015). To begin with, linker histone H1 was found as an 
additional protein within a array of nucleosomes compacted into the 30 nm 
of fiber (Figure 1.2). Linker histones H1 have many posttranslational 
modifications, and it can interact with non-histone proteins. Moreover, 
linker histones can regulate the essential cellular function such as gene 
transcription, mitotic chromosomes formation, and separation, embryonic 
stem cells, muscle differentiation, the genetic activity of heterochromatin 
and cell pluripotency (Zhou et. al., 2015). The role of linker histones was 
determined using the three-dimensional organization of the extended 
chromatin fiber. Histones were found to interact with linker DNA at or near 
the entry/exit point of the core particle, which close two turns of 
superhelical DNA around the histone octamer. Moreover, SFM image showed 
that eliminate linker histones caused an increase in linker length due to a 
release of some DNA from histone core (Zlatanova et. al., 1998). 
 
1.1.3 Histone variants  
In most eukaryotic cells, histone protein genes can be found in gene 
clusters, and some of them become active during S phase of cell cycle 
process. These four histones help to assemble nucleosomes and to pack new 
DNA synthesis. To start with histone H2A contain 129 amino acids residues. 
It includes H2A.Z and H2A.X. In yeast, H2A.Z was found to prevent involved 
in gene expression activities whereas H2A.X was found to contain in double-
strand DNA breaks as results of phosphorylation at serine residue at the C-
terminal region of H2A-X. Moreover, this phosphorylation was found to help 
proteins to enroll in DNA repair (Marino-Ramirez et. al., 2005). Histone H2B 
contains 125 amino acids residues, and it has a role in gametogenesis, male 
gametic cells, bovine, and human spermatozoa. Histone H3 consists of H3.3, 
CenH3, and H3.4. Histone H3.3 was not found in S phase, but it was found in 
active transcription chromatin whereas H3.4 was found in testis in 
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spermatocytes and CenH3 was found in centromeric chromatin. H4 is highly 
conserved histones, and it has contact with other histones. The protein 
contains 102 amino acids residues, and it is important for nucleosome 
assembly due to the formation of half of the H3-H4 tetramer of the core 
particle (Marino-Ramirez et. al., 2005) (Figure 1.2). 
 
 
Figure  1.1 Histone modification patterns in vivo and in vitro 
H3, H4, H2A and H2B histones are wrapped around 147 bp of DNA to form a 
nucleosome. The largest histone is H3 with 135 amino acid residues 
following H2A, H2B and H4 with 129,125 and 102 amino acids residues 
respectively. All four histones have long functional N-terminal region. This 
Histone region can undergo diverse post-translational modifications using 
the right combination and translation factors. These modifications cause a 
local and global change in chromatin condensation and gene expression. 
Modifications of histone are described in the text. This figure represents 
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histone variants and each histone H has amino acids residues in specific 
location that can be acetylated or methylated etc. on lysine (K) or serine (S) 
or tyrosine (T) or arginine (R). Black, modifications found in vivo in human; 
red, modifications found in mouse brain; blue, modifications found in vitro. 
Ac, acetylation; Ar, ADP-ribosylation; bu, butyrylation; cr, crotonylation; fo, 
formylation; gt, glutathionylation; ma, malonylation; me, methylation; Og, 
O-glcNAcylation; oh, hydroxylation; pr, propionylation; su, succinylation; 
ph, phosphorylation; ub, ubiquitination. Adapted from (Arnaudo and Garcia, 
2013).  
 
 
1.1.4 Structure of the chromatin fibre 
Previously, chromatin fibre structure was studied based on in vitro 
experiment to describe nucleosome folding model called 30-nm fibre using 
physiological salt concentration. At low ionic strength, the use of the 
mathematical model for understanding extends chromatin fibre revealed 
that chromatin fibre depends on the range of DNA entering and existence 
the core particle and the linker length (Zlatanova et. al., 1998). Moreover, 
to determine the fiber structure of chromatin, it was shown that N and C-
terminal of the core histone have associated with nucleosome and 
nucleosome interaction and interact with linker DNA and linker histones 
using imaging capabilities of SFM with conventional biochemical approaches. 
However, same experiments, which were in low ionic strength, were applied 
in high ionic strength to investigate the chromatin condensation  (Zlatanova 
et. al., 1998). However, detecting 30-nm fiber was failed using small-angle 
X-ray scattering (SAXS) and electron spectroscopic imaging experiments 
(Nishino et. al., 2012) Using SFM technology allowed a quantitative 
measurement of single fiber level and applying three dimensions for each 
nucleosome showed centre-to-centre distance. However, these technologies 
have limitations in lacking the molecular specificity and histone visual 
activity in nuclei. Many methods were used to study the chromatin fiber 
such as super-resolution nanoscopy called stochastic optical reconstruction 
microscopy (STORM) (Rust et. al., 2006), cryo-electron microscopy, 
synchrotron X-ray scattering (Nishino et. al., 2012) and a combination of 
electron spectroscopic imaging with tomography, three-dimensional images 
(Fussner et. al., 2012) were applied to visualize the structure of chromatin 
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fiber at interphase nuclei. Nonetheless, these studies did not address the 
organization based on single nucleosome and the way of chromatin 
modification during cell pluripotent and differentiation (Ricci et. al., 2015).   
 
Figure  1.2 : the model of chromatin structure 
A long DNA molecule with diameter 2 nm wrapped around a nucleosome, 
which contains core eight-histone octamer, with diameter 11 nm. The 
nucleosome and histone H1 form chromatosome. This nucleosome found to 
fold into 30 nm chromatin fibers. Then chromatin fibers formed loop 300 nm 
lengths. 300 nm length are more compressed fibers produced 700 nm fiber 
length, and subsequently, chromatid or chromosome was formed after tight 
coiling of 250 nm fiber which showed a high order organization 1400 nm 
duration of interphase nuclei or mitotic chromosome the picture adapted 
from (Anninziato, A., 2008) 
 
 
 
Chromatin accessibility can indicate by active regulatory regions 
techniques. These techniques are DNAase-seq (deoxyribonuclease I) and 
ATAC-seq (transposase-accessible chromatin using sequencing). They have 
been used to measure the region of chromatin where it can be accessible to 
regulatory factors regardless of cell heterogeneity (Cusanovich et. al., 
2015). A Recent study looked at cell-to-cell differences in chromatin using 
ATAC-seq technology for single cells from a mixture of mouse and human 
cell lines. From single cell interpretable results, it showed that NFkB 
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binding region was highly associated with chromatin accessibility, and it can 
be linked to extracellular signaling (Cusanovich et. al., 2015). 
 
1.1.5 Chromatin condensation in mitosis 
Changing the chromosome organization occurs during the cell cycle in the 
interphase chromosome. However, a study found that metaphase 
chromosome has same organization in different cell types (Naughton et. al., 
2013 and Tatsuya Hirano, 2015). These results were found spatial 
segregation into cell type called A/B compartment and TADs (Topologically 
associating domains) are lost and no evidence for new compartments or 
interaction within the chromosomal band was found using homogeneous 
mitotic interaction map. Therefore, although it was indicated that 
epigenetic memory involved in transcription factors and chromatin 
formation, which will be explained later, at certain loci, the high order of 
chromatin has to form a new chromatin in early G1 with no epigenetic 
memory (Bell and Straight, 2015).  
 
Chromosome condensation in bacterial and eukaryotic genome consists of 
two factors, DNA topoisomerase II and large protein complexes called 
condensins II and I. DNA topoisomerase II help to unwind the DNA strand 
during condensation process (Naughton et. al., 2013 and Tatsuya Hirano, 
2014). Maintaining this compaction needs proteins called structural 
maintenance of chromosome (SMC) proteins, which are the core subunit of 
condensins II and I (Bell and Straight, 2015). The function of condensins in 
eukaryotic cell cycle process occurs during a conformational change of the 
chromosomes in the initiation of separation and during the suppression of 
gene activity (Naughton et. al., 2013 and Tatsuya Hirano, 2014). Moreover, 
the function of condensins was demonstrated in two models; first one is that 
the similar condensins structure in vivo acts as a bridge offering interaction 
system between distance chromatins; second is that condensins regulate the 
high-order of packed chromatin to derive the condensation. For example, 
human (Hela cells) and Chicken (DT40) cells were used antibody CAP-G 
protein against condensins I to perform chromatin immunoprecipitation 
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sequencing (ChIP-seq). This analysis revealed that condensins I was around 
centromere and 7,825 binding peaks overlapping with transcription starting 
sites (TSS) for several genes and nearly 70% of those peaks were on (RNA 
polymerase II) RNAP2 gene. In addition, Chip-seq and RT-qPCR in human 
cells showed condensin I peaks was located in prometaphase cells that 
linked to RNAP2 peaks and gene expression inhibitors did not find a relation 
with condensin I in the mitotic chromosome. Moreover, ChIP-seq results 
showed the mitotic effect of TATA-binding protein (TBP) depletion, which is 
important protein for the pre-initiation complex in transcription initiation 
process, did not change the condensin I binding to TSS. Another isoform of 
condensin protein complex involved in a large scale of transcription 
repression such as mouse condensin II was found to bind to active enhancers 
and promoters and to be important for ordinary gene expression in 
interphase embryonic stem cells (Sutani et. al., 2015). 
 
1.2 Regulation of chromatin structure and gene expression  
1.2.1 Nucleosome positioning and gene expression 
Studies showed that nucleosome site around transcription starting site can 
modify the gene expression via repression or activation process (Buck and 
Leib, 2006). some factors, which can drive for easier access to their binding 
sites, are affected by nucleosome position such as free sites from 
nucleosome such as nucleosome close to linker DNA is more accessible than 
middle nucleosome. Transcription ability in many chromatin sites is 
influenced by many nucleosome properties including positioning, turnover 
and histone variation and modification, which play roles in gene regulation 
(Bai and Morozov, 2010). Nucleosome positions at specific region have been 
identified by the micrococcal (MNase) enzyme, which starts with chromatin 
crosslinked digested with micrococcal nuclease enzyme to generate 
mononucleosomes. This enzyme can digest linker DNA and remain the 
nucleosomal DNA undamaged. After MNase digest, the ligation-mediated 
PCR analysis was applied to map genomic, double-stranded MNase cleavages 
at the nucleotide level.  Another application is that after isolating DNA, a 
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nucleosomal fragment is performed using microarray or ultra high-
throughput sequencing. These applications offer an insight of chromatin 
structure and nucleosome position in different organisms. Genome-wide 
studies can provide a view of the nucleosome position in many genes. 
Promoter sites have less nucleosome due to its relation to transcription 
active sites; therefore, it is called nucleosome free regions (NFRs), which 
are located at the upstream of the transcription starting sites (TSS) such as 
high localizing position of +1 nucleosome at the downstream of TSS 
(Radman-Livaja and Rando, 2010 and Schones et. al., 2008). 
However, the influence of the nucleosomal position in a different organism 
can be varied reflecting the differences in transcription process or the core 
transcription mechanism such as TFIIB (Radman-Livaja and Rando, 2010 and 
Schones et. al., 2008). For example, in human T cells, the 5’ end of +1 
nucleosome is located at 40 bp from TSS in genes with elongated RNA 
polymerase II and +10 bp in inactive genes with a delay in RNA polymerase II 
(Schones et. al., 2008).  
Moreover, the regulation of gene expression through nucleosome can be 
divided into two classes. The first is the relationship between the 
nucleosome free region and transcriptional initiation, and the second one is 
the interaction between transcription starting site and intragenic 
nucleosome. Due to nucleosome conservation throughout the organisms, 
Tirosh and Barkai (2008) found two promoters linked to transcriptional 
plasticity, which identifies as changing the transcription level by owned 
gene under a different condition such as BRD4 in leukemia cells (Rathert et. 
al., 2015). These two promoters: one is large nucleosome free region (NFR) 
close to transcription starting site (TSS) with well-positioned nucleosome 
and the second one is the distribution of nucleosome dynamics close to 
starting place. These two promoters called depleted proximal nucleosome 
(DPN) and occupied proximal-nucleosome (OPN). DPN showed a less used 
region close to TSS such as histone H2A.Z, but more open region in far 
region whereas OPN showed high used region close to TSS, but less used 
area in the far region such as TATA box. For this reason; these strategies 
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were suggested for gene regulation in a different gene by chromatin (Tirosh 
and Barkai, 2008) (Figure 1.3) 
 
 
Figure  1.3 the differences between nucleosomal position and occupancy 
Upper panel presents the differences between occupancy and position in a 
cross-section of the nucleosome. Nucleosome occupancy determines the 
histone or nucleosome density away from nucleosome region whereas 
nucleosome position identifies nucleosome area with DNA. The lower panel 
presents the way that nucleosome occupancy and position measured. 
Nucleosome occupancy determines local density of nucleosome, which is the 
area under the curve whereas nucleosome position determines the standard 
deviation of the curve and how the spheres organized. Moreover, the 
nucleosome position determines how the two peaks separated. Low 
standard deviation means weak position whereas high position determines 
with two or more peak distance to each other (B Franklin Pugh, 2010). 
 
 
 
Besides, to nucleosome roles in DNA packaging, nucleosome organization, 
and nucleosomal positioning affect gene regulation. For example, breast 
cancer cells study was found the small part of estrogen and progesterone 
receptors were found linking to the cytoplasmic side of the cell membrane 
through palmitoylated residues. Progesterone receptor (PR) and hormonal 
gene regulation study showed that PR bound to small fraction of hormone 
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responsive element (HRE), which was identified to have high sensitivity to 
DNasel hypersensitivity region. Moreover, HRE was enriched with 
nucleosome before hormone influence and HRE within these enriched 
nucleosomes were remodeled with no expelling from hormone induction. In 
addition to HRE, PR binding sites bind to open chromatin region known as 
DNasel hypersensitive sites (DHS) using MNase digest and cell sequencing to 
apply genome-wide nucleosome mapping before hormone induction. The 
results showed high nucleosome enrichment on the sites that have PR 
binding after hormone stimulation. Thus, a sustained and efficient PR 
binding is organized by nucleosomes enrichment in region lacking of PRE 
(Ballare et. al., 2012). 
 
1.2.2 Nucleosome organization and gene expression in stem cells  
Stem cell biological differences and cell fate decision has been linked to 
chromatin influencing gene expression. Teif and colleagues (2012) identify 
the position of nucleosome over genomic of three different mouse stem 
cells, ESCs, MEFs and NPCs deriving from ESCs by mapping the nucleosome 
occupancy al. This experiment was performed using genome-wide paired-
end sequencing to map nucleosome position in mouse ESCs, NPCs and MEFs 
after MNase digest following ChIP-seq. in ESCs, some identified genes were 
nucleosome depleted region and nucleosome occupancy reduced to 40-80% 
in the same area in all participant cells. These transcription factors binding 
sites such as C-myc, Klf4, Stat3, Essrb, Sox2, Nanog and Oct4, and other 
factors such as p300 histone acetyltransferase, chromatin remodelers Chd7 
and Brg1 and DNase I-hypersensitivity sites, determined by ChIP-seq in ESCs 
cells. they found that nucleosome position in all three cell lines is one of a 
factor that affects DNA-protein binding affinity known as “pioneer factors” 
which can start the nuclear program. Furthermore, they found nucleosomal 
depletion in some promoter regions at transcription starting sites such as a 
Smarca4 promoter (Teif et. al., 2012). Another researcher used BAC 
solution-hybridization technique to increase the genomic pool of 
mononucleosome targeting promoter Nestin, Oct4, Olig2, Pax6, Sox1 and 
Sox2 in vivo and in vitro nucleosome occupancy in embryonic and 
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differentiated stem cells. They found that Oct4 and Sox2 controlled the 
their target and other differentiated genes. Moreover, they identify 
nucleosomal occupancy at active and inactive Sox2 and Oct4 binding 
regions. They found no significant change in vivo and in-vitro although there 
are some different distributions of nucleosome occupancies (Sebeson et. al., 
2015). 
 
1.2.3 The dynamic nature of nucleosome  
The active nature of nucleosomes was observed using X-ray crystallography 
and footprinting techniques (Cutter and Hayes, 2015). This technology 
revealed that nucleosome is highly dynamic and play essential roles in DNA 
accessibility by unwrapping and rebinding (breathing) transiently the 
surface of the nucleosome and regulating the position and density of 
nucleosome on the DNA sequence. Therefore, nucleosomes can provide 
thermodynamic as a barrier to binding factors (Cutter and Hayes, 2015). 
Besides thermodynamic for more access to DNA, remodelling factors such as 
nucleosome sliding and ATP-dependent chromatin, histone chaperones, 
chromatin-binding proteins such as non-histone proteins and linker histone 
H1 have roles in changing the nucleosomal structure and allow more 
accessibility to DNA sequence (Luger, 2006 and Luger and Hansen, 2005). 
 
1.2.4 Nucleosome dynamic and stem cells  
Nucleosome dissociation, which correlates with transcription factor binding, 
found to be linked with ATP-dependent remodeling systems such as 
nucleosome sliding and displacement, partial histone disassembly and 
substitution by histone variants (Voss and Hager, 2014). Moreover, ATP-
dependent remodelling systems consist of enzymes that use energy from 
ATP hydrolysis to interrupt the association between histone protein and DNA 
and alter the nucleosome structure. Stem cell researchers have identified 
chromatin-remodelling enzymes to be regulating the expression or to 
collaborate with pluripotent factors for controlling chromatin structure and 
transcriptional machinery. For example, SWI/SNF, ISWI, and CHD are ATP-
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dependent chromatin remodelling enzymes found to control many systems 
in embryonic stem cells (Saladi and Serna, 2010). Some of SWI/SNF and ISWI 
complexes contains Brig 1 subunit and Snf2h and Snf21 respectively. 
SW1/SNF has a role in self-renew and pluripotent maintenance and 
facilitate the process of differentiation whereas ISWI, Snf2h subunit can 
interact with nucleosome and unique biological function in heterochromatin 
replication and gene expression and Snf21 subunit has a role in fly 
development (Saladi and Serna, 2010). CHD is another ATPase subunit has 
roles in facilitating neuronal differentiation and affecting stem cell 
pluripotency state (Saladi and Serna, 2010). 
 
1.3 Histone post-translational modification  
 
An Important step in gene regulation and chromatin modification is 
posttranslational modification of histone. This modification in transcription 
and chromatin are affected by PTMs roles in recruitment specific factors or 
change the current location to erase previous interaction.   From histone 
variants, the N-terminal domain is the most accessible site due to its 
localization in nucleosome core. Histone’s tails are exposed to various 
modifications catalysed by writer enzymes such as acetylation, methylation, 
phosphorylation, ubiquitination, SUMOylation and other modifications 
(Bernstein et al., 2006 and Quina et al 2006).  
Some modification can change the charge of histone and DNA by acetylation 
or phosphorylation in favour of nucleosome stabilization. The molecular 
weights of these modifications consider measuring from light such as 
acetylation, methylation and phosphorylation or heavy such as 
ubiquitination and poly ADP ribosylation (Bernstein et al., 2006 and Quina et 
al 2006). Furthermore, besides gene expression and chromatin modification, 
PTMs are found to be involved in many systems such as cell cycles, signal 
transduction, protein-protein and cell-cell interaction and intracellular and 
extracellular communication (Wang et. al., 2014). The main regulatory 
factors of histone modification include posttranslational modifications such 
as acetylation, phosphorylation, methylation and ubiquitination of histones. 
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These histones modification are involved in chromatin function and nuclear 
processes regulation such as RNA and DNA transcription, DNA replication and 
DNA repair (Xu et. al., 2013).  
Epigenetic writers can add histone modification such as acetyl and 
methyltransferase, kinase and ubiquitinase, whereas eraser enzymes 
remove those histone modifications, such as deacetylase, phosphatase, 
demethylase, and deubiquitinase. In addition to writer and eraser enzymes, 
readers are domain regions that can identify histone modifications such as 
bromo- and chromo- domains, PHD fingers, and malignant brain tumour 
domain (Arrowsmith et. al., 2012, Marmorstain and Zhou 2014, Alexander 
Tarakhovsky 2010 and Blakey and Lltt 2016) (Figure 1.3). 
 
 
 
Figure  1.4 : the tools of epigenetics 
Writers, such as histone acetylase, kinases DNA and histone 
methyltransferase and ubiquitin ligases, present histone marks (orange 
circle) and can enhance the PTMs on either DNA or protein. Erasers, such as 
histone deacetylase and histone demethylase, can remove histone marks 
from chromatin organization and prepare these histones for other 
modifications. Readers include proteins with domain such as bromo-, 
chromo-, Tudor-, MBT-, PWWP-, and PHD-domains. These proteins can bind 
to specific modifications and it can interpret a particular form of histone 
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modification and impose the change in chromatin structure adapted from 
(Hojfeldt et. al., 2013).  
 
 
 
1.3.1 Histone acetylation  
The most common posttranslational modifications of histones are the 
acetylation and methylation of lysine located at the histone tails (Jenuwein 
and Allis, 2001). Acetylation defines an interaction between organic 
compounds when it introduced an acetyl group into it. Either histones or 
non-histones proteins can be acetylated.  Histone becomes acetylated by 
histone acetyltransferase (HATs) that derived the chromatin to be more 
open in favor of gene activation whereas decondensed the chromatin can be 
recruited using histone deacetylase (HDACs) (Eberharter and Becker, 2002 
and Shen and Casaccia-Bonnefil, 2008) (Figure 1.6).  
Histones hyperacetylation implicated to be related with active gene 
expression profiles. Moreover, some studies revealed that the acetylation 
could influence disruption of cellular processes such as DNA repair and 
replications (Trygve Tollefsbol, 2011). Moreover, in some modification 
acetylation in lysine residue 16 at histone H4 reduced the chromatin 
compaction and increases the gene expression in vivo and in vitro. In 
addition to H4K16ac, H3K155 and H3K122 are a novel acetylation sites on 
the lateral surface of the histone called dyad axis. This region is covered by 
one fiber of DNA where the histones bind to DNA. It was found that 
H3K122ac region has less nucleosome, but it enriched in transcription 
starting sites (TSS). Nevertheless, it shares the binding sites with other 
active gene markers such as H3K4me3, H2A.Z, and H3.3 and other 
enhancers such as H3K4me1 and H3K27ac. Another acetylated mark is 
H3K56ac, which may be active by p300, or GCN5 in human cells. H3K56ac 
occurs by interaction between histone chaperons (Asf1) and Rtt109. 
Moreover, it degraded during H3 synthesis and during G2 of cell cycle 
process. Therefore, it could have role as a response for DNA damage or in 
chromatin modification after DNA repair (Lawrence et. al., 2015).  
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Figure  1.5 schematic representation of histone acetylation in case of chromatin 
modification and transcriptional process. 
Lysine residues at the N-terminal tail of histone region of core histone 
proteins showed to be acetylated in H2B and H4 histones using histone 
acetyltransferase (writer) enzyme. This action helps to open the chromatin 
and promotes the transcriptional mechanism by binding to acetyl reader 
such as H3K9ac. On the other hand, the chromatin can fold to tertiary and 
secondary structure by histone deacetylase enzyme (HDACs) (eraser), which 
prevents the transcriptional process adapted from (Verdin and Ott, 2015).  
 
 
1.3.2 Histone methylation  
Methylated histone tails are found in arginine, lysines, and histidine.  
Monomethylated or dimethylated histones are found in arginine whereas 
lysines can have one, two, or three, methyl groups. Three enzymes, lysine-
specific SET domain containing histone methyltransferase (HMT), non-SET 
domain containing lysine methyltransferases and arginine 
methyltransferases, are responsible for the methylation of lysine and 
arginine regions and each of them involves the location of lysine (Trygve 
Tollefsbol, 2011). In contrast, histone demethylase (HDMs) can derive to the 
chromatin condensation using H3K9me3 and H3K27me3 based on target 
gene. It was found that this mechanism could mediate the inflammatory and 
metabolic disorders (Duygu et. al., 2013) (Figure 1.7).  
Methylation of the histone has a role in transcriptional regulation that could 
be related to activation, elongation, and repression. For instance, the lysine 
mono-, di- and a tri- methyl group of histone H3 (H3K4me, me2, and me3) 
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were found to be inactive promoters and it linked to transcription initiation 
and elongation. H3K4me3 was studied in mammalian cells showed the sharp 
peak of H3K4me3 at the transcription starting sites (TSS) of many genes 
besides it can positively regulate transcriptions through recruiting 
nucleosome remodelling enzymes and histone acetylates (Bernstein et. al., 
2006 and Zhou et. al., 2011). In embryonic stem cells (ESCs) and Epiblast 
stem cells (EpiSCs), chromatin studies revealed that H3k4me3 has been 
identified in the broad range of high CpG promoter content despite the 
expression profile. On the other hand, H3K27me3 correlate with repressed 
promoters, which determine the transcriptional silencing mode in 
mammalian (Zhou et. al., 2011 and Hemberger et. al., 2009). Moreover, the 
main Polycomb repressive complexes PRC1 and PRC2 target a large part of 
high CpG island content promoters. However, in mouse embryonic stem 
cells (ESCs) and Epiblast stem cells (EpiSCs), 20% of high CpG island content 
promoters bind to Polycomb repressive complex 2 (PRC2) and marked by 
H3k27me3 (Hemberger et. al., 2009 and Zhou et al., 2011)(Figure 1.6). 
 
 
Figure  1.6 diagram of the role of histone methylation in transcriptional process 
Histone methylation can stimulate either activation or repression of target 
gene. it is regulated by histone methyltransferase (HMTs) and histone 
demethylase (HDMs). HMTs derive the chromatin decondensation and gene 
activation using H3K4me3 whereas HDMs catalysed by H3K9me3 and 
H3K27me3 toward chromatin condensation and transcriptional inhibition. 
Adapter from (Duygu et. al., 2013) 
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1.3.3 Histone phosphorylation  
Histone phosphorylation occurs during cellular response to DNA damage 
repair, transcription regulation, and chromatin condensation in apoptosis 
and mitosis and meiosis cell cycle (Rossetto et. al., 2012).  For example, in 
mouse, H3 phosphorylation on T11 and T6 have involved in transcription 
regulation when they induced to androgen and to DNA-damage (Rossetto et. 
al., 2012). Another example, in chromosome compaction during mitosis, 
Histone phosphorylation regulates the serine/threonine kinase Aurora-B 
affecting H3 at serine location 10 and 28 (Figure 1.8) (Minarovits et. al., 
2016). Phosphorylated serine 10 at H3 recruits members of 14-3-3 protein 
families to open chromatin and transcriptional activation especially when 
there is K9 or K14 lysine close to serine 10 acetylated. This double 
modification confirms full transcriptional activation of Hdac1 and p21 genes  
(Minarovits et. al., 2016) and MAPK and p38 signalling in interphase stage at 
cell cycle analysis (Cheung et. al., 2000) (Figure 1.8). 
Phosphorylation has a high turnover rate around 30 min in 2-3 hours using 
isotopic pulse labelling method. It has been implied that Histone 
phosphorylation can regulate the nucleosome dynamic through changing the 
histone charge. For example, when the serine, threonine and tyrosine 
residues become phosphorylated, they obtain negative charge, which could 
cause repulsion against DNA. In contrast, adding nuclei residue to 
unphosphorylated histone tail protect the DNA from DNase I enzyme more 
than phosphorylated histone tail. This result suggests that when the 
repulsion charged on histone tails, it opens the nuclear DNA sequence 
(Blakey and Litt, 2016). Phosphorylated Histone H3 regulates induction of 
many genes by driving the extracellular signals in different cell types and 
possibility plays roles in transient derepression of promoters silenced by 
histone H3K9me3 (Minarovits et. al., 2016) (Figure 1.7) 
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Figure  1.7 phosphorylation of histone H3 in interphase and metaphase cell 
cycle 
The diagram represents the mechanism of histone phosphorylation at 
chromatin status in cell cycle analysis. The activation of MAP kinase and p38 
pathway (right diagram) showed activation in H3 kinase of mitogen such as 
Rsk1 or Msk1. Coincidently, this process occur when there is an activation of 
acetylation by histone acetyltransferase enzyme at lysine 9 and 14 which is 
located close to phosphorylated serine 10 at histone H3 tail region. Both 
actions derived the transcriptional activation in the interphase region in the 
cells. On the other hand, in the metaphase (right diagram) region, where 
the nucleosomes condensed into chromosome, another signalling pathway 
involved into chromatin condensation through H3 Kinase inhibition. 
(Adapted from Cheung et. al., 2000).  
 
 
 
1.3.4 Histone ubiquitination and Histone SUMOylation  
Ubiquitin is defined as a protein with the addition of 8.5-kDa polypeptide of 
78 amino acids using ubiquitin activation, conjugation and ligation enzymes. 
These enzymes are histone ubiquitin ligase and histone deubiquitinating 
enzyme. Histone ubiquitin ligase identified polycomb group protein RING1B 
that is responsible for H2A monoubiquitination at lysine 119. Moreover, in 
breast cancer gene BRCA1, ubiquitin ligase enzyme was found to cooperate 
with BRCA1 to increase the reaction of monoubiquitination H2A/H2A.X. On 
35 
 
 35 
the other hand, histone deubiquitinating enzyme acts as an eraser for 
ubiquitin modification and it involved in: silencing HOX gene, inactivating X-
chromosome and progression in cell cycles mediated by H2Aub. For example 
BRCA1 associated protein 1 (BAP1) was found to be H2A-specific histone C-
terminal hydrolase and it can remove monoubiquitin from H2A (Cao and 
Yan, 2012).  Histone ubiquitination involves in several process in nucleus 
including transcription, DNA repair, X-chromosome inactivation process, 
stem cells maintenance and differentiation (Wadosky and Willis, 2012).  
Another important ubiquitination of the histone is H2Bub1. This modification 
was found to regulate the transcriptional elongation stage, DNA replication 
and cell cycle. H2Bub1 occurred at lysine 123 in yeast and at lysine 120 in 
human and was found at low level in vivo. A group of researchers found that 
H2B ubiquitination regulated the H3K4me and H3K79me using Rad6 gene 
(ubiquitin-conjugating enzyme E2 in yeast) through trans-tail mechanism. 
Therefore, the results suggested that H2Bub1 has role in the regulation of 
transcription and gene silencing in heterochromatin region in yeast. Another 
study used chromatin immuniprecipitation analyses (ChIP) found that Rad6 
cooperatively with H2Bub1 may identify the ORF of target gene. This 
cooperation relay on other complex called PAF (it was found in human and 
yeast), which was found to be critical for activation and interaction with 
Rad6 complex. This direct relation between PAF and Rad6 complex could 
promote the elongation step of Pol II to generate H2Bub1 and the 
subsequent of H3K4me and H3K79me in the target gene (Laribee et. al., 
2007) (Figure 1.8).  
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Figure  1.8 the function of ubiquitination in histone H2B 
A diagram represents the dynamic of ubiquitination in chromatin. Ubiquitin 
was first added to histone H2B by BRE1/Rad6 complex. This action enhances 
the promoter POL II through PAF transcriptional elongation. However, in the 
other side of PAF complex, another complexes called COMPASS with SET1 
recruits H3K4me. When the ubiquitination existed in H2B, other complexes 
become activated such as 19S proteasome. During the transcription 
elongation, H2A/H3B dimer is removed by FACT (facilitate chromatin 
transcription) and enables Pol II elongation via chromatin. H2Bub1 can be 
removed by SAGA that linked with Ubp10 or Ubp8 for fixing the methylated 
histone. Question mark on ubiquitin at the H2A/H2B suggests that FACT may 
recruit the ubiquitination in this dimer during nucleosome disruption or 
reassembly. This disruption associated with proteasome and may help to 
establish methylated histone. Adapted from (Laribee et. al., 2007). 
 
 
Sumoylation is very similar to ubiquitination. It contains 101 amino acids 
polypeptide, approximately 10 kDa, with 18% sequence homology and 
different surface charge. PolySUMOylation is associated with stress response 
unlike monoSUMOylation is linked to regulating gene expression, nuclear 
transport, and protein-protein interaction regulation (Wadosky and Willis, 
2012) SUMOylation and ubiquitination share the same enzymes performance 
inactivation, conjugation and ligation (Wadosky and Willis, 2012 and 
Minarovits et. al. 2016). Histone SUMOylation connects with transcriptional 
suppression and it occurs in all four histone cores. For example, histone H3 
in Hela cells was found to be SUMOylated at lysine 19 (K19) (Hendriks et. 
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al., 2014). Another role of SUMOylation may affect the nucleosomal 
dynamics. For example, the interference between chromatin condensation 
and transcriptional suppression may be mediated when H4K2 is modified by 
SUMO-3. This could recommend the SUMOylation interfered with promoter 
and enhancers with direct interaction. On the other hand, histone 
SUMOylation may interact with many proteins indirectly in favour of 
chromatin regulation (Blakey and Litt, 2016).  
A novel SUMOylation was found in Wiskott-Aldrich syndrome (WAS) which is 
an X-linked immunodeficiency and autoimmunity arising from mutation in 
WAS protein. This mutation affects the regulation of chromatin in Thelper (TH) 
cells. Previous research found that there is promoter as coactivator of 
nuclear-WASp for transcriptional regulation in TH1 gene. The results showed 
WASp is linked with SUMOylation pathway throughout SUMO1. This relation 
was due to a SUMO motif in WASp in lysine 66, 76, 144, 147, and 235. 
Applying mutation at in WASp hindered NF-kB signalling in TH 1 cells. 
Furthermore, a mutation SUMOylation in WASp helped COMMD1 function as 
an inhibitor for NF-kB signalling to remove the NF-kB from DNA, activated 
HDAC6 and reduced the acetylation in H3K14ac at p300 promoter of NF-kB 
genes in TH 1 cells (Sarkar et. al., 2015) (Figure 1.9). 
 
 
 
Figure  1.9 the roles of SUMOylation deficient in nuclear-WASp chromatin 
signalling 
In normal case (left diagram) SUMOylated WASp helps to bind with p65 and 
target the promoter p300 in NF-kB signalling under acetylated H3K4 to 
derive the transcription process. In mutated SUMOylated WASp, there is less 
acetylated H3K14 and no p65 effects. In this case, HDAC6 activates the 
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WASp binding with COMMD1 and p300 to derive the chromatin compaction 
and repress the NF-kB signalling Adapted from (Sarkar et. al., 2015). 
 
 
1.3.5 Other large modifications  
Using NAD+ as a substrate, ADP-ribosylation is formed by the addition of an 
ADP-ribose modified residues on protein; thus, it imparts a negative charge. 
ADP-ribosyltransferase (ART) modifies Glutamate residues histone.  There 
are three forms of this protein named mono-, poly- ribosylation (PARP) and 
O-acetyl- ADP-ribosylation. It was found that mono-ADP-ribosyltransferase is 
the main of all the core histones and linker histone H1. This cooperation can 
involve in cell cycle stage or response to genotoxic stress, proliferation 
activity and differentiation termination (Minarovits et. al., 2016 and Trygve 
Tollefsbol, 2011). For example, a study was found in single strand break, 
PARP1 seems to have some roles in histone through poly-ADP-ribosylation 
the linker histone H1, but PARP2 prefer core histone. Moreover, they 
observed when PARP1 and PARP2 become poly-ADP-ribosylation, C- and N- 
terminal at the histone H1 and H2B cause relaxation in chromatin for access 
the single strand break repair. (Trygve Tollefsbol, 2011 cited from 
Kreimeyer et. al. 1984).  
Deminiation is named to remove methylated arginine forming citrulline, 
which is not possible to be methylated. This irreversible reaction derived by 
peptidyl arginine deiminase 4 (PADI4) causing a structural modification in 
histone H3 and H4. Therefore, citrullination may involve in chromatin 
structure and gene regulation (Minarovits et. al., 2016).   
Histone proline isomerize are a post-translational non-covalent modification 
of histone tails and it can naturally interconvert between cis- and trans 
backbone conformation. In yeast, Isomerization is slow from minute to hours 
to fold the protein (Monneau et. al., 2013). Moreover, proline isomerases 
were shown to be facilitated the interconversion between cis- and trans-. 
This function may affect the stability of histone tails leading to effect on 
gene expression. For example, Nelson and colleagues (2006) identify Fpr4 
binding to the N-terminal tail of histone H3 and H4 through nucleolin-like 
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domain and found two substrates of Fpr4 called H3P30 and H3P38 that are 
close to Fpr4 binding sites. Modified H3 tail was found methylated in lysine 
K36 by set2 histone methyltransferase. This indicates that there is 
communication between H3P28 substrate and methylated H3K36 (Nelson et. 
al., 2006 and Bannister and Kouzarides 2011). 
Histone modification O-linked B-N-acetyl glucosamine, O-GlcNAc, is an 
unchanged acetylated hexosamine sugar linked through glycosyl linkage. 
This histone was found in cytosolic, nuclear and mitochondrial proteins and 
mark histone cores. Therefore, it affects major cellular signalling 
mechanisms (Bond and Hanover, 2015 and Minarovits et. al., 2016).  
Histone lysine crotonylation (KCR) is a novel histone modification that has 
an active role in post-meiotic testis. It marks a group of X/Y genes that is 
active in haploid spermatids (Montellier et. al., 2011). Moreover, it was 
found that p300, which is histone acetyltransferase, derived to histone 
crotonylation is a strong transcriptional activator than histone acetylation in 
Hela cells based on the nature of intracellular of crotonyl-CoA. This could 
have major effects between cellular metabolism and gene expression 
(sabari et. al., 2015) 
 
1.3.6 Methylation and acetylation of non-histone proteins 
Non-histone proteins are important members of chromatin architectures 
that maintain chromatin condensation causing to form high-order structure 
and decompaction causing more chromatin accessibility leading to more 
gene expression. Some proteins are responsible for chromatin high order 
structure such as HMG, HP1, MeCP2, polycomb group proteins, and PARPs. 
Many studies focused on the methylation of non-histone proteins such as 
histone lysine demethylases (PKDMs) and histone methyltransferase (PKMTs) 
due to their influences in many cellular functions such as cell signalling 
transduction and tumorigenesis (Carr et. al., 2015). Non-Histone acetylation 
was reported in few studies although it involves in cell signalling, 
transcription and protein stability, cancer, apoptosis and cell cycle. P53 
protein can be acetylated in lysine 120, 164, 370, 372, 373, 381, 382, and 
386. For example, when p53 become acetylated lysine at position 120, it 
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enhances the expression of a gene that is involved in DNA damage-induced 
apoptosis using hMOF and tip6 (Singh et al., 2010). 
 
1.4 Chromatin in embryonic stem cells  
 
Embryonic stem cells (ESCs) originated from inner cell mass before the 
implantation stage (see section 1.2). Genomic DNA arranged into chromatin, 
which influences the transcription, translational and other regulation 
processes. Besides the organization of chromatin, studying chromatin in 
stem cell is considering a significant challenge due to stem cell existence in 
pluripotent and some somatic cells and the difference in chromatin 
organization between embryonic stem cells and differentiated cells. 
Chromatin found in pluripotent stem cells with less condensed and more 
hyperdynamic related proteins. These chromatin features play important 
roles in stem cell maintenance and self-renewal (Mattout and Meshorer, 
2010).  
Chromatin features in stem cells were observed by genome-wide study in 
mouse and human stem cells when researchers found that methylation and 
acetylation of histone H3 at lysine 4 was more dominant than DNA 
methylation. This action caused an increased in embryonic stem cells 
activities throughout the genome (Chen and Dent, 2014). Coincidently, some 
embryonic stem cells genes deriving the cell differentiation enrich with high 
conserved noncoding elements (HCNEs). One this modification was found to 
have a large region of H3K27me3 hindering a small area of H3K4me3 termed 
“bivalent chromatin.” in pluripotent stem cells lineage, Oct4, Nanog, and 
the Sox2 binding domain was mapped using genome analysis. It was found 
around 50% of bivalent domain occurred with at least one binding site of 
these transcription factors such as Oct4 and Nanog interaction. Moreover, it 
was found that more transcription factors committed to bivalent domain 
tend to be in the poised state whereas many of bivalent domains have a 
correlation with Oct4, Sox2, and Nanog. However, in differentiation state, 
transcription factors show to be active or repressive. In fact, the bivalent 
domain associated with Polycomb response elements and Trithorax-group 
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proteins that were found to provide epigenetic memory for cell committed 
lineage (Bernstein et. al., 2006). Nevertheless, current research found that 
some bivalent sites in ESCs are modified based on cell culture condition. For 
example, the standard serum medium for mouse stem cells contains 
pluripotent cells in addition to some differentiated cells showing cells 
heterogeneity in morphology and gene expression. on the other hand mouse 
stem cells cultured in no serum medium with two inhibitors, GSK3, and MEK, 
tend to show high enrichment in H3K4me3, H3ac, and H4ac, but low level in 
H3K27me3 and almost no heterogeneity exist (Chen and Dent, 2014) (Figure 
1.10). 
 
 
Figure  1.10 chromatin organization in pluripotent and differentiated stem cells 
Stem cells in 2i medium (serum free media) show more active marks 
(H3K4me, H3ac, and H4ac) than repressive mark (H3K27me3) whereas stem 
cells in medium with serum show cell heterogeneity, bivalent markers 
causing by heterogeneity, more repressive marks, and active mark. The 
differentiated cells, stem cells committed to differentiation contain more 
repressive mark than active marks and more repressive marks, H3K9me2 and 
H3k9me3. Adapted from (Chen and Dent, 2014). 
 
 
1.4.1 Chromatin structure in stem cells  
This project uses embryonic carcinoma cells, which are a malignant cell 
similar to embryonic stem cells. Therefore, it is important to consider 
whether the chromatin structure in embryonic stem cells is different to that 
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in somatic cells and cell lines. Embryonic Stem cells and differentiated stem 
cells such as neural or cardiac stem cells contain signals that help to 
distribute epigenetic modification through the changes in chromatin 
structure and transcriptional process. A study of human embryonic stem 
cells (H1) examined higher-order of chromatin structure from the lower 
position of the chromosome using chromosome-span haplotypes.  It found 
significant changes in chromatin structure at these posts. Moreover, the 
study highlighted chromatin structure varieties among homologs 
chromosome. They found high similar to genome folding sections (A/B 
compartment) whereas only 0.6-2.3% of genome differences indicated 
between alleles in each lineage. These small changes in genome influenced 
chromatin structure between alleles regions in homologs chromosome 
(Dixon, et. al., 2015) (figure 1.11) 
 
 
Figure  1.11 the diagram for chromatin accessibility and modification in 
pluripotent, differentiation, and reprogramming stem cells. 
This chart represents the difference between chromatin organization from 
pluripotent stem cells to differentiated stem cells and vice versa. Chromatin 
in pluripotent cells shows genes, such as Oct4, Sox2, and Nanog, are 
enhanced by downstream regulatory factors such as transcription factors, 
RNA Pol II, p300, mediator and active enhancer. While downstream factors 
increased gene transcriptional process, the same target gene promoted by 
upstream factors such as active CTCF, and histone modification such as 
H3K4me3 and H3K27ac. Differentiated stem cells for the same gene undergo 
to silence events. However, The committed cells derive active 
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differentiated genes such as Brachyury in mesoderm, Gata4 in endoderm, 
and Nestin in the ectoderm. In this case, inactive enhancer and target 
pluripotent gene lied on silenced chromatin under repressive marker 
H3K27me3. In inducing pluripotent stem cells (cell reprogramming), the 
differentiated cells reactive the silenced pluripotent markers, Oct4, Sox2, 
Klf4 and Myc to generate embryonic stem cell like.   Adapted from (Shchuka 
et. al., 2015). 
 
 
1.4.2 Chromatin accessibility in stem cells 
Besides chromatin structure modification, accessible chromatin can be 
affected by histone modifications and ATP-dependent chromatin remodeling 
(Delgado-Olguin and Recillas-Targa, 2011). Moreover, genome-folding 
section (A/B compartment) may affect the chromatin accessibility (Dixon 
et. al., 2015). Besides, chromatin accessibility can influence the structure 
of chromatin through the transcriptional process by changing the regulatory 
proteins in distinct gene loci (Meshorer and Misteli, 2006). For example, the 
stem cells genome-wide study showed that BRG1 (ATPase subunit of 
SWI/SNF-BRG1 chromatin remodeling complex) was found to share the 
location with other pluripotent markers and the loss of BRG1 caused 
termination in self-renew and cell reprogramming. These finding suggesting 
that the complexes of SWI/SNF-BRG1 are critical for pluripotent cell 
process. However, there is another factor that supports the self-renewal 
called LIF (leukemia inhibitory factor) throughout activating the STAT3 
signaling pathway. Another study showed that SWI/SNF-BRG1 complex 
maintain open-chromatin status throughout STAT3 signal when it antagonists 
with Polycomb group proteins complex (Chen and Dent, 2014). Histone 
modification, H3K9me3 is linked with heterochromatin sites in pluripotent 
and reprogramming cells. These regions organized in 10 nm chromatin fibers 
similar to the open chromatin region. However, some of closed chromatin 
regions in stem cells such as, iPSCs, have been derived from unique 
transcriptional activities such as Oct4, Sox2, Klf4, and Myc, which able them 
to access chromatin, change the enhancers and permit the binding of other 
factors and vice verse (Figure 1.13) (Shchuka et. al., 2015). 
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1.4.3 Histone modification in embryonic stem cells  
Monitored gene expression is important to maintain and establish cell 
identity in stem cells. One of the methods to control gene expression is by 
chromatin modification, which was found to control gene expression. 
Histone modification factors and chromatin remodeling can change the 
access of regulatory protein to DNA sequence. Therefore, the four histone-
codes can be read in trans-acting factors to translate the chromatin 
organization and gene activity by becoming acetylated, methylated, 
phosphorylated, ubiquitinated, SUMOylated, or any other modification 
changes (Lunyak and Rosenfeld, 2008 and Schmittwolf et. Al., 2005). 
 
1.4.3.1 Histone acetylation and methylation in stem cells 
A study found that histone acetylation was found stimulating neuronal stem 
cells (NSC) to differentiate to hematopoietic stem cells in trans. Previously, 
it was known The resistance activity of histone acetylation transferase 
(HATs) and deacetylases (HDACs) control the level of histone acetylation. 
However, much microbial such as Streptomyces can inhibit the HDACS and 
One of these inhibitors is trichostatin A (TSA) that can indirectly stimulate 
the acetylation of histones, cell cycle arrest and apoptosis. Moreover, 
Inhibitor 5-aza-2’-deoxy-cytidine (AzaC) can bind to DNA covalently and 
prevent to retain methyltransferase (Dnmt1), which allow an increase in 
demethylation (Schmittwolf et. al., 2005). In this study, they treated 
neurosphere cells with TSA inhibitor for acetylation combined with AzaC 
inhibitor for methylation before transplantation. They found that treatment 
elevates the level of H4 acetylation and reduce the level of methylation at 
CpG Island in protein 2 (MeCP2). They conclude that the treatment 
increased the histone acetylation and decreased cytidine methylation 
(Schmittwolf et. al., 2005). Another study found that modification in 
epigenetic may allow generating neuronal from non-neuronal stem cells 
such as bone marrow stromal stem cells (MSCs). This study demonstrated 
the addition of histone deacetylase inhibitor such as Valproic acid can turn 
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the bone marrow stromal cells to neuronal stem cells (NSCs) (Woodbury et. 
al., 2002).  
Activation the transcription was one of the factors that associated with 
histone acetylation and methylation. Tight marks of histone H3 on lysine 4 
acetylation and methylation are more likely to contribute to establishing an 
active epigenetic profile, such as λ5-VpreB1 locus in stem cells, not by 
generalized histone acetylation and methylation of histone H3 lysine 4. To 
confirm this hypothesis, this study used Mouse lambda5-VpreB1 locus 
marked by histone acetylation (H3k4ac) and histone lysine 4 methylation 
(H3K4me) at individual sites in ESCs. These epigenetic marks distribute from 
modification sites to genes at the later stage of B-cell development. Next, 
the large active chromatin was found to establish pre-B-cell when the genes 
are fully expressed.  The recommendation in this study was that epigenetic 
mark is crucial for achieving transcriptional accomplishment for lambda5 
and VpreB1 genes at the early stage of pluripotent ESC stage to establish 
the region for bivalency (Szutorisz et. al., 2005). Another study was on 
Neocortex extracted from E18 rat embryo to study the epigenetic regulatory 
mechanism of gene transcription and differentiation such as FGF2, CNTF, 
STAT and GFAP. In this experiment, ChIP experiment was performed against 
H3K4me and H3K4ac. They found that ChIP for anti-H3K4ac on the STAT-
binding site of GFAP promoter was high due to CNTF with irreversible action 
by FGF2 treatment whereas ChIP for anti- H3K4me increased in FGF2 
binding and suppression in H3K9me in GEAP promoter (Song and Ghosh, 
2004).  
Another evidence showed that acetylated histone is associated with active 
transcription such as Klf4 and C-myc. Klf (Kruppel-like factor) family are 
transcription factors involved in cell differentiation and proliferation. 
P300/CBP, the protein with the binding protein, was found to be associated 
with histone acetylation by being recruited to the specific region of DNA 
using other transcription factors such as p53 and KLF6 interaction with 
p300. Besides KLF6, in human cancer cells, KLF4 was found to be acetylated 
by p300 in, which is important for transactivation. In addition, Klf4 
inhibition by mutating p300 or overexpression of Klf4 was shown to be 
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directly interacting with Klf4 and it suggested the KLF4 regulate histone 
acetylation differently at the promoter of target genes (Evans et. al., 2007). 
Same results were observed in C-myc interact with histone acetyltransferase 
(HAT) including p300 and CBP and it may induce histone acetylation which 
permits Oct4 and Sox2 to bind to their target loci in inducing pluripotent 
stem cells (Takahashi and Yamanaka, 2006).  
Histone methylation was identified as a bivalent modification, which 
contains large sites of histone H3 at lysine 27 and small sites of histone H3 
at lysine 4 methylation in mouse embryonic stem cells. These modified 
histones are catalysed by trithorax- and polycomb-group proteins. 
Methylation of lysine 27 of histone H3 (H3K27me) is associated with silence 
chromatin and transcriptional repression whereas Histone H3 methylated 
lysine 4 (H3K4me) is defined as active chromatin associated with 
transcription factor genes that have roles in embryonic development and 
lineage specification such as HOX genes (Bernstein et. al., 2006). One of 
polycomb-group proteins in drosophila embryo called Polycomb repressive 
complex (PRC2) have roles in maintaining the structure of repressive 
chromatin through the function of chromatin modifiers such as enhancers of 
zeste (EZh2), embryonic ectoderm development protein (Eed) and 
suppressor of zeste 12 (Suz12), histone methyltransferases responsible for 
depositing H3K27me3 mark on chromatin. However, the study did not 
explain fully embryonic stem cells model deficiency for PRC2 component. 
Mutant ESCs showed growth lost of H3K27me but remain able for self-
renewal and maintain normal morphology (Lunyak and Rosenfeld, 2008). 
Moreover, the factors of DNA sequence-specific can provide a site for 
catalysed specific enzymes that can remove or add the modification and 
substrate of the enzyme. For example, leaving the self-renewal state is 
accomplished via altering the covalent modification of the histone such as 
increasing silencing-associated histone H3k9me2 and H3K9me3 which marks 
on chromatin and removed H3K27me (Lunyak and Rosenfeld, 2008). 
Moreover, ESC transcription factor Oc4 was found to regulated H3K9me2 and 
H3K9me3 demethylase genes, Jmjd2c and Jmjd1a, Together those genes 
Jmjd2c and Jmjd1a in knockdown condition, it led to stem cell 
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differentiation with a reduction of lineage marker genes (Lunyak and 
Rosenfeld, 2008).  
 
1.4.3.2 Histone phosphorylation in stem cells 
Phosphorylation on histones has frequently occurred at specific sites 
throughout cell division. It was found binding at serine, threonine or 
tyrosine residues and catalysed by an amount of protein kinase and 
dephosphorylation by phosphatases (Ding and Wu, 2015). Previously, it was 
mentioned that phosphorylation involved in chromatin condensation. One of 
the mechanisms of signalling for maintaining self-renew is Jak2 signalling 
and for chromatin modulation is ERK pathway.  For example, in mESCs, LIF-
independent role for Jak signalling has been demonstrated in the 
phosphorylation of histone H3 on tyrosine 41. This circumstance caused a 
decrease in heterochromatin protein 1 alpha (HP1α) binding site on 
pluripotent genes (Fagnocchi et al., 2015). Mutated Jak2 can possibly 
phosphorylate and impede Protein arginine N-methyltransferase 5 (PRMT5) 
preventing histone arginine methylation. Consequently, it favours for 
uncontrolled haematopoietic progenitor cell expansion (Fagnocchi et al., 
2015). However, MAP kinase signalling supports differentiation of stem cells 
during JNK-mediated H3 serine 10 phosphorylation of its target genes 
(Fagnocchi et al., 2015). Other mechanisms of singling called ERK pathway. 
It can regulate PRC2 deposition at developmental genes, by phosphorylating 
the RNA polymerase II at serine 5 and establishing poised domain (Fagnocchi 
et al., 2015).  
 
1.4.3.3 Histone ubiquitination and SUMOylation in stem cells 
Ubiquitination in embryonic stem cells was reported to affect the self-
renewal and differentiation. For example, BMI1, proto-Oncogene polycomb 
ring finger, is important for self-renewal and maintenance of hematopoietic 
and neural stem cells (Cao and Yan, 2012). Moreover, in mouse stem cells, 
ubiquitinated H2A has an ability to stop RNA polymerase II during regulator 
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gene development and RING1A and RING1B subunit loss cause a release in 
silencing RNA polymerase II and other genes (Cao and Yan, 2012). During 
cell development and epigenetic regulation, histone ubiquitination (H2A) 
was found to play important roles in chromatin compaction at target site 
through Polycomb-group proteins PRC1 and PRC2 in ESCs (Endoh et. al., 
2012). 
Besides ubiquitination, histone SUMOylation may have roles in DNA damage 
repair and possibly in telomere activity in eukaryotic cells and probably in 
human stem cells, reproductive cells and cancer cells. Telomerase that 
maintain telomere integrity in those cells, function by adding TTAGGG 
repeats on telomeres.  However, there is an alternative mechanism in 
cancer for retain the telomere integrity (ALT) which depends on the 
association with DNA repair mechanism. Similarly, some DNA repair protein 
was found to be affiliated with SUMOylation substrates such as Blm and Wrn. 
Nevertheless, sumoylation activity on DNA damage repair protein from 
telomere side in eukaryotic whereas in yeast SUMO and PIAS deletion caused 
an increase in telomere length (Bischof and Dejean, 2007). 
 
1.5 High mobility proteins family (HMG) 
 
Another nonhistone is high mobility group proteins (HMG) is a superfamily 
and it contains HMGA, HMGB and HMGN proteins existing in all vertebrate 
cells. Each protein has subgroups of proteins and other DNA or chromatin 
binding motifs. The functional motifs of HMG proteins associated with DNA 
and nucleosome to modify chromatin and gene expression (Postnikov and 
Bustin, 2015). For example when HMGB1 and HMGB2 become acetylated at 
lysine 2 through CBP, it caused an increase in DNA binding ability (Figure 
1.8) (Stros,, 2010). Each member of HMG proteins interacts with chromatin 
differently. This means, that all HMGs promote toward open chromatin and 
form a change in transcription, replication and DNA repair mechanism.  
Moreover, they can interact with other regulatory factors and bind directly 
to DNA to alter the transcriptional process (Postnikov and Bustin, 2015) 
(FIGURE 1.12).  
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Figure  1.12 the localization of HMGN, HMGB, and HMGA in the 
nucleosome 
HMGNs (red circle) are DNA-protein binding sites. They bind to nucleosome 
core domain. HMGBs (yellow circle) bind to linker DNA. HMGA (green circle) 
bind to miner groove in AT rich DNA.  
 
Further roles of HMG proteins are highly regulated by their post-
translational modification including: acetylation, methylation, 
phosphorylation, and ADP-ribosylation etc. These biochemical modifications 
are dynamic and rapidly responsive to intra and extra cellular signaling 
event since different families of HMG proteins have distinct modification 
profiles, hence different biological implication. HMGA, HMGB and HMGN 
share phosphorylation, acetylation, histones interaction and roles in cancer 
(Zhang and Wang 2009).  
 
1.5.1 HMGA and HMGB 
High mobility group A (HMGA) non-histone chromatin proteins is 
characterized by short repeat located in the minor groove of DNA called 
“AT-hook” motif (Ozturk et. al., 2014) and it is high positive charge except 
high negative charge in C-terminal region (Sgarra et. al., 2004). It contains 
HMGA1a, HMGA1b, HMGA1c and HMGA2 (Ozturk et. al., 2014). HMGA1 
proteins came from alternative splicing of HMGA1 gene, which was found to 
be important for development and diagnostic of cancer. For example, 
human breast cancer cell lines showed high expression level of HMGA1 in 
tumorigenesis rather than benign cell lines (Maurizio et. al., 2016). 
Moreover, HMGA can be modified based on their roles in chromatin 
formation, transcription and embryonic development (Ozturk et al., 2014).  
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At the chromatin structure level, HMGA acetylation can help to 
decondensed chromatin structure and gene expression by moving the 
histone H1 whereas it can help to condense the chromatin and inhibit the 
transcription using histone H1. At promoter and enhancer level, many 
transcription factors and HMGA bind to DNA resulting either facilitating 
transcription factors binding to DNA or HMGA interact with DNA and these 
factors to form a complex. HMGA interaction with transcription factor can 
be described as high or low affinity interaction to explain the interaction 
with enhancers or promoters in favour of DNA binding (Sgarra et. al., 2004).  
High mobility group box family (HMGB) is non-histone chromosomal proteins 
in mammals. HMGB is highly conserved and contains two L-shape DNA 
binding domains named HMG boxes A and B, which highly binding to DNA 
independently, and 30 amino acids of the C-terminal tail (Ueda and Yoshida, 
2010). The L-shape binds to minor groove of DNA non-specifically (Reeves, 
2010). It is the most abundant proteins in mammals and composed of: 
HMGB1, HMGB2, HMGB3, and HMGB4. The period of binding HMGB with 
chromatin is very short (Figure 1.8) (Ueda and Yoshida, 2010).  
Beside HMGB binding to DNA in high affinity, it involves in many nuclear 
process such as transcription and replication. HMGB interact with DNA at 
entry/exit region of nucleosome similar to histone H1. However, HMGB 
binding help to assemble the chromatin remodeling proteins such as 
ACF/CHARC to derive the nucleosome sliding. Moreover, HMGB has role in as 
transcriptional repressor. It can bind to TATA binding protein to form 
complexes, which can prevent forming other complexes at preinitiation 
stage of transcription mechanism. Furthermore, HMGB tight binding to 
chromatin has roles in apoptotic cells, which can inhibit the protein from 
releasing from dying cells and affect the immune response (Reeves, 2010).  
 
1.6 HMGN  
HMGN is a subgroup of the high mobility group proteins, but it targets the 
nucleosomal binding domain (Figure 1.8). HMGNs family contains five 
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members: HMGN1, HMGN2, HMGN3a, HMGN3b, HMGN4, and HMGN5. All 
HMGNs share five features: nuclear localization signal, conservative, 
nucleosomal binding domain positive change, same nucleosomal core 
particle sequence (RRSARLSA), and C-terminal regulatory domain region 
(Postnikov and Bustin, 2015) (Figure 1.9).  
They are ubiquitously expressed in all vertebrate. At chromatin level, 
DNAase hypersensitivity sites were the preferable binding location for 
HMGNs proteins.  Therefore, HMGNs were found to change the global and 
the local chromatin structure. Besides chromatin remodeling, histone 
modification, transcription mechanism and cell cycle are affected by HMGNs 
proteins. Histone H1 domain associated with DNA close to nucleosome dyad 
axis and beside linker DNA. This global domain of H1 helped to stabilize the 
wrapping DNA around histone variants. In addition, histone H1 General 
structure of Nucleosome core particles can be identified by all HMGNs 
proteins. Therefore, it was found that HMGNs bind to nucleosome, which 
interact with two the same HMGNs molecules (Figure 1.8). Moreover, HMGN 
was found to be located near linker DNA. This suggest that there may be 
overlapping between HMGNs and H1 domain at linker DNA which may affect 
the chromatin modification. One of histone H1 role is to help and promote 
the chromatin condensation whereas HMGNs may help to access chromatin 
throughout the binding site of histone H1 to nucleosome and connecting 
HMGNs with acidic patch in H2A-H2B dimer besides the binding sites of the 
N-terminal of H3 (Postnikov and Bustin, 2015).  
 
1.6.1 The structure and the functional domain of HMGN proteins 
HMGNs in vertebrates bind to nucleosomes core particles (CP) and histones. 
Nucleosomal binding domain (NBD) sequence in all HMGN contains RRSARLSA 
residues (Figure 1.9), which are  the core-binding domain that is the 
building block of chromatin fibre. HMGN proteins except HMGN5 consist of 
four parts: two nuclear localization signals (NLSs) at the N-terminal domain, 
regulatory domain (RD) at the C-terminal, and nucleosomal binding domain 
(NBD). Regulatory domain (RD) can facilitate chromatin decompaction and it 
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can influence the HMGN activities on histone posttranslational modification 
(Kugler et. al., 2012). On the other hand, HMGN5 contains long C-terminal 
domain about 300 amino acids in mouse and 200 amino acids in human. This 
domain interacts with linker histone H1 in positive charge (Bustin et al, 
1995) (Figure 1.13).  
 
 
 
Figure  1.13 the protein sequences of HMGN1, HMGN2, HMGN3, HMGN4 and HMGN5 
All HMGN proteins contain around 100 amino acids except HMGN5 contains 
around 300 amino acids. HMGN proteins contain nuclear localization signal 
(NLS1 and NLS2), nucleosomal binding proteins (NBD) and regulatory domain 
(RD).  The N-terminal region has nuclear localization signal (NLS1, bright 
green) very conservative throughout the all HMGN proteins and it contains 4 
amino acids. Nucleosome binding proteins (NBD, light purple) contains very 
conserved sequence called nucleosomal core binding domain which contains 
eight amino acids, RRSARLSA (bright red), and the red star above some of 
them indicates the specific binding sites to nucleosome. The rest of NBD are 
variable among HMGN proteins. The C-terminal regions contain nuclear 
localization signal (NLS2, bight green) and regulatory domain (RD, cyan) and 
both are different in protein sequences. HMGN5 is the only HMGN proteins 
member that contains extra sequence around 300 amino acids at the C-
terminal region. However, all the mentioned domains are functional in 
HMGN proteins. Adapted from (Postnikov and Bustin, 2010).  
 
 
Several studies identified HMGNs amino acids residues that interact with 
chromatin and regulates transcriptional process. To begin with, the 
nucleosome core binding of the HMGN2 plays an autonomous functional 
domain. Since nucleosomal core binding domain was found between 
residues 15 to 40 amino acids in HMGN1 and HMGN2, Crippa and colleagues 
(1992) used gel retardation assays to identify the Hmgn1 and Hmgn2 
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interactions with core particles comparing with recombinant HMGN2 from 
bacteria. The Nucleosome core binding sites of HMGN2 (HMG-17) plays an 
autonomous functional domain. Mobility shift application was shown that 
single nucleosomal core particle contains two binding sites either HMGN1 or 
HMGN2. These proteins bind near the gate points of nucleosomal DNA of the 
core. They found the location between 17 and 47 amino acids residues in 
HMGN1 and HMGN2 encoded by two exons and it is very conserved during 
the evolution (Crippa et. al., 1992) 
In addition, the regions between 17 to 47 amino acids residues were specific 
for binding HMGN2 core particles to DNA. Study on this region suggested 
that conformational change occurs in the core particles. Moreover, this 
region maintains most of HMGN2 properties. On the other hand, HMGN1 gel 
shift assays and DNase I digestion found an increase in radius of gyration and 
temperature of nucleosomal core particles. Removing the histones tails of 
HMGN1/2 using proteolytic digestion caused an elimination and separation 
between proteins and peptides. This indicates that there is interaction 
between core particles domain and histone tails. Therefore, there are a 
similarity between The structure of HMGN2/1 and many transcriptional 
activators, which many of them have modular organization, may facilitate 
multiple cooperation, interactions, increasing the specificity and flexibility 
of multicomponent structure such as functional transcription complex 
(Crippa et. al., 1992).  
Another study highlighted the functional domain in HMGN1/2 proteins and 
examined the binding condition between proteins and core particles 
domain. Postnikov and colleagues (1994) used gel shift assays to study the 
interaction between mutant HMGN1/2 from human and nucleosomal core 
particles from chicken erythrocytes. They found that non-cooperative 
binding occurred at low ionic binding between HMGN1/2 proteins and 
nucleosome core particles whereas cooperative binding occurred at high 
ionic binding between HMGN1/2 and nucleosome core particles. Low ionic 
strength indicates that the binding of HMGN1 or HMGN2 with nucleosome 
core particles generates two extra lower bands reflect the concept of one or 
two HMGN molecules bind to one nucleosome core particles. In contrast, 
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only two molecules of HMGN binds to one nucleosome core particle. Under 
mutation condition, gel shift assay for non-cooperative binding showed no 
effect in the binding to nucleosome core particles. However, cooperative 
binding showed some changes in single amino acid residues by replacing the 
alanine with proline at position 21 and change lysine with cysteine at 
position 26 in the nucleosomal binding domain of HMGN1. These changes 
caused a decrease the binding affinity between protein and core particle 
domain (Postnikov et. al., 1994). The deletion Region from 17-47 bp 
corresponded to the entire nucleosomal binding for HMGN2 and it 
incorporated into chromatin but failed to enhance the transcription 
(Trieschmann et. al., 1995). Then, the use of Cross-linking experiments 
revealed that HMGN2 was found to be near histone H2A located between 
histones octamer and DNA (Crippa et. al., 1992 and Trieschmann et. al., 
1995).  
The amount of HMGNs proteins binding to nucleosome in chromatin was 
identified by gel shift assay in pervious studies. The organization behavior of 
HMGNs such as HMGN1 and HMGN2 in cellular chromatin found to be very 
similar and to act as homodimers binding to nucleosomes that contains two 
molecules of either HMGN1 or HMGN2 proteins in vitro and in vivo. However, 
this binding found to have no influence in histone modification in vivo and in 
vitro. In fact, HMGN1 and HMGN2 organization throughout the chromatin 
fiber not fully understood. Possibly, HMGN1 and HMGN2 distribute in 
chromatin in two ways: one of them is random distribution and the other is 
clustered distribution, which can be either mixture of heterogeneous 
HMGN1 and HMGN2 homodimers or homogeneous separation of HMGN1 and 
HMGN2 homodimers. This organization was studied on mouse thymus or 
chicken erythrocytes using micrococcal nuclease digestion. This study found 
that HMGN2 is distributed into specific regions that have nucleosome 
assembly lacking HMGN1, enrich in core histones, and hold six attached 
HMGN1 to nucleosome. this results could be agreed with the connection of 
hmgn2 to nucleosome that could control the 30 nm of chromatin fiber 
(Postnikov et. al., 1997).   
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Although many studies attempted to determine the protein nucleosomes 
complexes using X-ray crystallography such as proteins called LANA and 
RCC1, The structural basis of HMGNs-nucleosome complexes is unknown. 
Therefore, Kato and colleague (2011) used nuclear magnetic resonance 
spectroscopy (methyl-TROSY) for macromolecules to manage the histone 
methyl groups in Ile, Leu and Val (ILV) residues in the nucleosome and to 
determine the HMGN2 binding sites. They found that Leu6482 in H2A and 
Val45γ2 and Leu103δ2 in H2B showed a large chemical shift changes (Figure 
1.10). Moreover, the N-terminal region 19-30 residues of the NBD was found 
to influence the same methyl groups which are very close to negative 
charged residues in an acidic patch of the H2A and H2B dimer surface. 
Another experiment was performed to measure the distance between 
HMGN2-nucleosome complexes called paramagnetic relaxation enhancement 
(PRE). This experiment showed, that N-terminal region at amino acids 
residues proline (PRO28 and PRO44) in HMGN2 affect the methyl group in 
the C-terminal part of H2A. On the other hand, the N-terminal part of H3 
indicates that C-terminal region of the binding domain is close to where DNA 
entry and exit the region of the lysine residues in the nucleosome. 
Therefore, either HMGN2 fully bound or only from NBD sites to nucleosome 
binding showed more opposition to thermal denaturation unlike the HMGN2 
in free state. In addition, the NBD location at entry/exit region may act as 
antagonist to ATP-dependent chromatin remodelling factors by tightening 
the DNA movements in the nucleosome or preventing the remodelling 
factors from binding to nucleosomes. These results agreed with other results 
that showed HMGNs reduce the chromatin compaction induced by linker 
histone H1 in vitro, but at the same time H1 competes for binding with 
chromatin in vivo (Kato et. al., 2011). Furthermore, the acidic region (C-
terminal region) of the HMGN1 proteins can reduce the down regulation of 
transcription of the histone H1 and chromatin condensation (Ding et. al., 
1997) (Figure 1.14). 
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Figure  1.14 the interaction map of nucleosome-binding proteins (NBD) of HMGN2 
A. Histone modifications, H2A, H2B, H3, and H4, from mouse mapped for 
nucleosome binding interaction regions. HMGN2 NBD region has around 27 
amino acids and some of them specifically bind to nucleosome. Some of 
these amino acids residues are in blue colors represent Arg/Lys residues 
whereas the amino acids in pink colors represent Ser24 and Ser28. In 
nucleosome, the core Histones H2A (orang), H3B (red), H3(blue) and 
H4(green). These histones showed methylated group in nucleosome where 
HMGN2 NBD interact with them. B. HMGN2 interactions show NBD (cylinder 
shape) region interact with histones H2A (light yellow), H4 (light green) , H3 
(light blue),  H2B (light pink) and the red oval indicates the acidic patch 
region. Different colors of HMGN2 represent different amino acids residues. 
The long tail represents C-terminal region of HMGN2 and around this region 
there are globular domain of H1 (gH1) (dashed orange oval). This region is 
found to be around DNA entry/exit point. Adapted from (Kato et. al., 2011)/  
 
 
1.6.2 The role of HMGN proteins in vertebrate 
Several evidence showed that the role of HMGNs affect the architecture of 
chromatin fibre in several aspects. First, HMGNs proteins can affect the 
chromatin dynamic by changing the chromatin remodelling factors. Second, 
HMGNs proteins can induce the chromatin decondensation by modulating 
the interaction with histone H1. Third, HMGNs proteins can affect the 
chromatin fibre by influencing several histone Post-translational 
modifications (Reeves, 2015). As consequence of chromatin remodelling 
influencing, HMGNs proteins seem to act as transcriptional coactivators 
and/or transcriptional regulators, DNA replication, DNA repair and possibly 
nucleosomal spacing in vitro and in vivo.  
57 
 
 57 
 
1.6.3 HMGN proteins and chromatin architecture  
To begin with, it was found that HMGN presents in nuclear of all vertebrate 
cells. It involve in chromatin architecture and dynamics. Several studies 
applied minichromsome from several organisms such as Xenopus egg 
extract, Hela nuclear extract, and Drosophila oocyte extract. All these 
studies found that HMGN proteins enhance the rate of transcription using 
either Pol II or Pol III promoters and replication using SV40 origin of 
replication (Bustin, 2001).  
For example, a combined HMGN1 and HMGN2 into native nucleosome caused 
functional increased in the transcription of active chromatin and chromatin 
remodeling in Xenopus laevis egg extract. The study used a minichromosome 
contains an extract of 5S rRNA genes from Xenopus and these two elements 
were combined in the egg with HMGN1 and with no HMGN1. They found that 
active RNA polymerase II and likely increase the HMGN1 and HMGN2 caused 
an accessibility of active 5S rRNA gene, which was previously found to be 
affected by addition of histones and TFIIIA (TBP factor). Consequently, the 
chromatin assembly mixture formed after an increase in 5S rRNA activity. 
Moreover, the presences of HMGN1/2 increase the open-chromatin regions; 
thus more proteins facilitate the RNA polymerase accessibility (Trieschmann 
et. al., 1995).  
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However, combining the HMGN1 and 2 into native nucleosome increase the 
function of transcription for active chromatin and chromatin remodeling. It 
was found that 30% of the HMGN1/2 sequence is conserved. Both proteins 
were found to have similar cellular function and both have to incorporate 
into chromatin using transcriptional enhancement assay and micrococcal 
nuclease digestion was used for this aspect. Moreover, the influence of 
nuclease digests of chromatin brought by HMG binding to preassembled 
chromatin opposite to the effect of HMG incorporation into nascent 
chromatin. When both hmgn1/2 incorporate into nascent chromatin, the 
rate of digestion by nuclease enzyme increased using micrococcal nuclease 
digest to identify kinetics of proteins digestion instead of nucleosomal 
spacing. On the other hands, when inhibition of transcriptional activity 
occur using nucleosomal binding domain of HMGN1/2 (Region from 17-47bp), 
the nucleosomal binding domain alone did not enhance the transcription 
potential of chromatin (Trieschmann et al., 1995).  
This cooperation binding of HMGN1/2 into nucleosome cores were found to 
produce homodimer complexes using antibodies against purified proteins 
and analyzed by ELISA, western blots and radioimmunoassay. However, 
under non-cooperative condition the full length of HMGN1/2 are required 
for keeping the homodimeric mode of binding to core particles using low 
ionic strength solution (Postnikov et. al., 1995).  
Another example used minichromsome of Xenpus eggs and micrococcal 
nuclease showed that HMGN2 involved in chromatin assembly and 
nucleosome spacing. To elaborate, the period of removing HMGN2 from 
chromatin fiber during DNA replication step to perform the chromatin 
assembly is critical to obtain active chromatin. On the contrary the addition 
of HMGN2 after chromatin assembly had no effect on transcription process. 
Furthermore, chromatin during the replication required deposition of H3-H4 
tetramer and assembly of two H2A-H2B dimers to form nucleosome spacing. 
Like Xenopus, mammalians when the chromatin assembled in the absence of 
Mg2+-ATP, they digest faster using micrococcal nuclease than in the 
presence of Mg2+-ATP. Nevertheless, the presence of HMGN2 has major 
effects on the structure of chromatin assembled when MG2+-ATP is absence. 
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In this case, it showed well-defined nucleosomal spacing and the 
nucleosome ladder that was obtained from chromatin assembled with 
HMGN2 displayed extreme separation and diminished backgrounds between 
bands. Nucleosomal spacing occurs due to the stabilization of core particles 
by HMGN2 (Crippa et. al., 1993). However, micrococcal nuclease assays 
showed that hmgn2 proteins helped to define the boundaries of nucleosomal 
core particles beside improve the nucleosomal spacing, but not necessarily 
the HMGN2 acts as nucleosomal spacing factor (Crippa et. al., 1993). The 
association between HMGN2 and the dynamic of chromatin was confirmed in 
tissue culture cells (Hock et. al., 1998).  
From Protein Data Bank, it revealed that HMGN proteins could have high 
developmental disorder and diseases relation such as cancer. However, 
HMGNs are different from each other based on amino acid composition. 
Therefore, HMGNs proteins have roles in the regulation of cellular 
transcriptional profile. The expression profile in cell specific manner was 
tested on mouse embryonic fibroblast (MEFs) using retrovirus to knockout or 
overexpressed HMGNs. The structure of HMGN1, HMGN2 and HMGN3a are 
similar in size unlike HMGN5 whereas HMGN3b contains a lacks of 21 C-
terminal residues. The knockout was performed on HMGN1, HMGN3 and 
HMGN5 unlike HMGN2 knockout that was embryonic lethal in MEF cells. 
Overexpression experiment was performed on HMGN1/2/3a and HMGN5 on 
MEF cells. The knockout results showed that no overlap was identified in 
knockout, but changes in gene expression involve up and down regulation in 
transcriptional level, which influence the chromatin structure and regulate 
and correct the transcriptional process (Rochman et. al., 2011) 
 
1.6.4 HMGN proteins and linker histone H1  
The association between linker histone H1 and HMGN family affects the 
chromatin dynamic and nucleosome. It was known that HMGNs beside 
histone H1 cooperate in nucleosome and either positively or negatively 
stimulate the chromatin modification activities using enzymes. Histone H1 
secured the chromatin structure from decompaction, which prevent the 
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activity of HATs enzyme and nucleosome remodeling complexes. However, 
HMGNs proteins enhance the chromatin decompaction, more nucleosomal 
accessibility and in some cases promote the transcription and replication 
(Catez et. al., 2003). Previously, it was shown that HMGN and histone H1 
overlap between each other close to dyad axis of the nucleosome. This 
location between HMGN and H1 may be important for their interaction and 
chromatin remodeling. Possibly the C-terminal domain has more negative 
charge amino acids located near to linker DNA and it may interact with H1 
at the mentioned site. Moreover, due to the role of H1 as promoter for 
chromatin compaction opposed to the role of HMGN as promoter for 
chromatin decompaction, this may inhibit the binding of H1 to nucleosome. 
However, HMGN role as a promoter toward chromatin decompaction can 
interfere with acidic patch of H2A-H2B dimer and with N-terminal domain of 
H3 to facilitate the internucleosomal interaction activities (Postnikov and 
Bustin, 2015). For example, in vitro study investigated the chromatin 
assembly that showed histone H1 was able to induce toward chromatin 
remodeling using ATP dependent SWI/SNF. On the other hand, HMGNs 
enhance open-chromatin and it is possible to promote the chromatin 
remodeling (Postnikov and Bustin, 2015).  
 
1.6.5 HMGN proteins and transcriptional activation  
HMGNs proteins affect transcriptional regulations, DNA repair and 
embryonic development due to the chromatin modification. For example, 
Paranjape and colleagues (1995) found that HMGN2 (HMG17) has a role as 
“transcriptional coactivator” because they found that either in Hela cells or 
drosophila embryo when HMGN2 was added to chromatin, it increases the 
GAL4-VP16, which contains amino-terminal 147 amino acid residues of yeast 
GAL4 proteins fused to a fragment of the herpesvirus VP16 protein that has 
potent transcriptional activation region, activated transcription. On the 
contrary when GAL-VP16 is absence, the HMGN2 has no stimulation for 
general transcription factors by RNA polymerase II unlike Trieschmann and 
colleagues (1995) results. Moreover, in Xenopus system, it was shown that 
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HMGN2 did not increase the transcription initiation by RNA polymerase III. 
However, same system revealed that using RNA polymerase II could increase 
the efficiency of transcription initiation in the presence of HMGN2 
(Paranjape et. al., 1995). 
 
1.6.6 HMGN proteins and DNA repair  
HMGNs proteins control the DNA repair efficiency throughout cellular repair 
mechanisms. Two Studies investigated nucleotide excision repair (UV-
induced DNA damage) (NER) knockout, heterogeneous knockout and wild 
type of HMGN1 in mice and mouse embryonic fibroblast stem cells (MEF). 
The cells lacking of HMGN1 became more sensitive to UV light four times 
than heterogeneous knockout mice (Reeves, 2015). Beside nucleotide 
excision repair (NER), double-strand break (DSB) raised by many DNA cuts. 
This mechanism is recognized by all cells to ensure the genomic stability. 
Hmgn1 knockout in mice and MEF cells showed high sensitivity to ionizing 
radiation (Reeves, 2015). Another experiment performed by Briger and 
colleagues (2003) showed the influence of HMGN1 in TCR and the ability of 
HMGN1 in helping cells to survive after these cells experienced IR. Following 
this damage the cells DNA repaired itself by the association of NBD of 
HMGN1 to nucleosome and facilitate the chromatin accessibility from 
secondary and tertiary structure.  Moreover, in MEF experiment due to the 
hmgn1 knockout encountered to IR, the damaged cells did not managed to 
terminate the cell cycle check point G2/M. therefore, it is possible that 
hmgn1 has function in the mechanism of ATM (Birger et. al., 2003). The 
third DNA repair mechanism is base excision repair (BER) pathway, which 
remove the base leaving an apurinic/apyrimidinic (AP) site using enzyme 
lesion-specific DNA glycosylases. Knockout hmgn1 in MEF cells showed the 
regulation of HMGN1 in nuclear enzyme poly (ADP-ribose) polymerase 
1(PARP-1) which was found high in BER reaction, AP sites and DNA strand 
breaks. However, the knockout hmgn1 with untreated PARP-1 was found 
lower than wild-type hmgn1 in MEF cells. This possible interaction between 
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HMGN1 and PARP-1 is regulated by protein-protein interaction using 
immunofluorescence-imaging experiments in vivo (Reeves, 2015).   
 
1.6.7 The role of HMGN1 and HMGN2 in mouse embryonic stem cells 
(ESCs) and Epiblast stem cells (EpiSCs) 
All HMGN proteins show high expressions during the embryonic stage, then 
gradual down-regulation. The down-regulation may cause changes in 
chromatin organization and in the cellular transcription. HMGN expression 
showed major alterations during the developmental program (Hock et. al., 
2006). In mouse early embryonic development gene expression and 
microarray profiling was used to examine the number of genes that were 
expressed in oocytes, two cells, eight cells and blastocyst stages. 
Comparison performed between oocytes and blastocysts identified major 
differences in some genes “oocyte specific genes” including HMGN2. Gene 
transcriptional profiles suggested that these genes may have possible 
implication in early bovine development and embryonic genome activation. 
Genes were expressed in the first week of embryonic development maternal 
genes, shared regulation of transcription and cell cycle. This regulation 
showed rapid degradation following fertilization such as NLRP9, FIGLA and 
ZP2/3/4 and gradually degrading transcription such as CCNB1, HMGN2, and 
BTG4. NLRP9 and HMGN2 showed similar expression profile in the 
microarray data during bovine early embryonic development in vitro (Vallee 
et al., 2009). Previously it was shown that knockdown of expression of 
HMGN1 and/or HMGN2 in mouse was found to cause delay in cell cleavage 
during the preimplantation development (Mohamed et al., 2001 and Hock 
et. al., 2006). On the other hand in Xenopus embryo overexpression of 
HMGN1 and/or HMGN2 resulted in malfunction in closed blastopore and 
head structure, distorted body axis and loss of mesodermal competence of 
animal cap (Korner et. al., 2003 and Hock et. al., 2006).  
Recently, Deng and colleagues (2015) examine the role of HMGN1 and 
HMGN2 in mouse embryonic fibroblast (MEFs). Although HMGN1 and HMGN2 
are widely expressed in vertebrate cells particularly in embryonic stem 
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cells, it was argued that they are functional redundant due to ubiquitous 
expression and competition in NBD region. Therefore, an investigation was 
made using HMGN1 and HMGN2 and double HMGN1/2 knockout mice from 
HMGN1 and HMGN2 knockout mice. MEFs cells were collected from three 
knockout mice to examine the expression and chromatin profiles with lack 
of HMGN1 and/or HMGN2. They found that DNase I hypersensitive sites 
(DHSs) were reduced due to the loss of HMGN proteins, which affect the 
chromatin remodeling sites. The majority of DHSs are located in promoter 
and enhancers, moreover in the majority of HMGN1/2 knockout MEFs cells, 
DHSs were found in enhancer regions. Furthermore, DNase I digestion in 
knockout HMGN1/2 was found to be more accessible to regions that have 
reduction of DNase I hypersensitive sites; however at the same level new 
DHSs sites were found in knockout cells that were not found in wild type 
cells. Unlike new DHSs sites in knockout cells, most of the regulatory sites 
that were formed became less accessible to DNase enzyme. Furthermore, 
histones modification, H3K4me1, H3K4me3 and H3K27ac did not change in 
knockout HMGN1/2. This suggested that HMGN-mediated chromatin could 
act as a mediator for other regulatory factors to interact with chromatin 
such as PCNA and ATP-dependent nucleosome remodeling complexes. In 
addition, the loss of HMGN1/2 showed enhanced in H1 binding leading to 
reduce the DNA accessibility at chromatin regions using DNase I digestion. 
Therefore, HMGN1/2 may act as modulator for other regulatory factors and 
chromatin modifications; thus they play important roles in maintaining the 
DHS profiles (Deng et. al., 2015). 
 
1.7 Pluripotent stem cells of mouse  
Embryonic stem cells are pluripotent cells that have the ability for self-
renewal and differentiation to any type of cells. At the early stage of 
blastocyst, mammalian embryo developed to two different types of cell 
populations: trophectoderm (TE) and inner cell mass (ICM). Trophectoderm 
cells develop to trophoblast giant cells and placenta from trophoblast stem 
cells. This is controlled under the activation of transcription factor Tead4, 
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as well as down regulation of pluripotent genes Oct4, Sox2 and Nanog in the 
cleavage-stage embryo.  
Inner cell mass (ICM) cells form at embryo day E3-E3.75. These inner cell 
mass (ICM) activate Oct4 as main transcription factor, followed by other 
transcription factors Sox2, Nanog, Esrrb, Tbx3, and FGF4. These cells give 
raise to primitive endoderm (PrEn) and epiblast naïve stem cells. Primitive 
endoderm (PrEn) cells are extra embryonic lineage and form the yolk sac of 
the embryo. Transcription factors Gata6/4, Sox17/7 and Pdgfra become up 
regulated in these cells. Epiblast Naïve stem cells derived from ICM of 
blastocysts express pluripotency associated factors such as Oct4, Sox2, 
Nanog, Tbx3, Klf2/4/5 and Esrrb (Nichols and Smith, 2012; Patra et al., 
2011 and Plusa and Hadjantonakis 2014). Naïve cells also are also controlled 
by the levels of negative regulators such as transcriptional repressors, 
transcription factors, the regulators of mRNA stability and translation and 
regulators of nuclear transport (Kalkan and Smith, 2014). After that epiblast 
naïve stem cells undergo to implantation process. Then the primitive 
ectoderm epiblast form in two stages: formative (early post implantation at 
E5.5) and primed (late post implantation E6.5). At the early post 
implantation a subset of  transcription factors shows over expression such as 
FGF5, Oct6, Otx2 (Kalkan and Smith 2014) Pitx2, Sox17, Nodal, Foxa2 
(Boroviak et al., 2014 and Tesar et al 2007) These cells are the signs of the 
development of epiblast cells until it extends to gastrulation (Ohtsuka and 
Dalton, 2008 and Prelle et al, 2002). Pluripotent cells developed into three 
germ layers: ectoderm, endoderm and mesoderm (Ohtsuka and Dalton, 
2008). Several studies identified that pluripotent stem cells are found in two 
distinct states: naïve ICM exists in mouse and human stem cells and primed 
post-implantation epiblast was found in epiblast stem cells in human 
(Nichols and Smith 2009 Welling and Geijsen, 2013) (Figure 4.1) .   
Martin and Evans (1975) is the first study, which succeeded to isolate 
pluripotent cells from teratocarcinoma stem cells. These cells were 
polyclonal derivatives from undifferentiated cells and primordial germ cells 
similar to embryonic stem cell at the early stage. For this reason they were 
called embryonic carcinoma (EC) cells (Wobus et al., 1984, Prelle et al, 
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2002 and Welling and Geijsen, 2013). However, other researchers thought 
that these cells are neither ICM/Epiblasts cells nor primodial germ cells due 
to spontaneous re-implantation and phenotypic similarity with embryonic 
stem cells (Peter Andrew 2002).   Many studies have used EC cells to 
establish experimental foundation in culturing embryonic stem cells. The 
reason for this was that EC cells if they are able to transplant into ectopic 
sites, often influence blastocysts developing normal tissues in chimeric mice 
(Wobus et al., 1984, Prelle et al, 2002 and Welling and Geijsen, 2013). 
Moreover, these cells, that are similar to ESCs in morphology, gene 
expression profiles and functional ability when injected to form chimera, 
can generate three germ layers in vitro and in vivo.   
 
1.7.1 The formation of mammalian embryo and gene expression profile 
Similar to EC cells are murine ES cell lines derived from inner cell mass 
(ICM) of blastocysts, 8-cell embryos, or from pluripotent cells that were 
generated from ectoderm of implantation-delayed blastocysts (Prelle et al, 
2002). To begin with, germ cells derived from pluripotent primed epiblast 
cells called primodial germ cells (PGCs). These cells develop oocytes in 
females and spermatozoa in male. Zygotes (totipotent) form after 
fertilization forming renewable and consistence mammalian life cycle. 
These cells are the early stage of Inner cell Mass (ICM) cells.  
Murine ESCs encode genes that are important in the development of germ 
cells. These germ cells can be only from post-implantation cell type, which 
continually express the pluripotent genes, Oct4, Sox2 and Nanog (Welling 
and Geijsen 2013) (Figure 1.15).  
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Figure  1.15 Summary of Pluripotent lineages profile of mouse embryo.  
Schematic representation in the peri-implantation mouse development and 
gene expression (1) Oocytes: around the embryonic day 1.5 (E1.5), oocytes 
has two cells undergo cleavage process that generate embryo. (2) Morula; 
around the embryonic day 2.5 (E2.5), the first pluripotent cells in the 
embryo shows 8 cells of pre-inner cell mass (ICM) which express some genes. 
(3) Early blastocyst; around the embryonic day E3, trophectoderm and ICM 
cells were generated from Morula. Subsets of different genes, which are 
highly expressed in this stage (green box), indicate the mouse ES cell 
developmental identity. (4) Mid blastocyst; around the embryo day 3.75, 
ICM still at the pre implantation stage before epiblasts development; 
however, some genes were activated in this stage such as GATA4/6 whereas 
Nanog gene showed down regulation. (5) Late blastocyst stage appears 
around embryonic day E4-4.5. Trophectoderm cells develop placenta under 
the activation of Tead4 gene and ICM cells give rise to primitive endoderm 
(PrE) and Epiblast (Naïve state-pluripotency). These cells develop before 
the implantation process and activate some of Naïve genes such as Klf2/4/5, 
nanog, Tbx3, Esrrb, Gata6/4,Sox7/17, and Tfcp112. (6) early post 
implantation, which is around embryonic day E5.5. This stage called 
formative stage that lineage of specific cells emerge. Moreover, list of 
genes start to become activated such as fgf5, otx2, sox17 and oct6. (7) 
Primed stage or late post implantation at the embryonic stage E6.5 before 
specialized cells lineages emerge (gastrulation) by activating new subset of 
genes such as Foxa2 and Cer1. Core pluripotency factors become activated 
from E4; then they become downregulated thorough cell development to 
primordial germ cells and somatic cells. Adapted from (Niwa Hitoshi, 2007; 
Patra et al., 2010; Patra et. al., 2011; Ohtsuka and Dlton 2007; Welling and 
Gijsen, 2013; Plusa and Hadjantonakis, 2014; Boroviak et al., 2014; Kalkan 
and Smith, 2014; Nichols and Smith, 2012).  
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1.7.2 Embryonal carcinoma cells  
Teratomas are tumours, which occur in germ cells in the ovary or testis. 
Generally these tumours are benign when found in the ovary (benign ovarian 
cysts) whereas similar tumours found in the testis are mostly malignant 
(Teratocarcinoma). These tumours derived from germ cell tumours (GCTs) 
mostly cause testicular cancers (Andrews Peters, 2002). P19 is an embryonic 
carcinoma stem cell line derived from murine embryonic teratocarcinoma 
stem cells in C3H/He mice from the time period of embryo day 7 to the 
testes of an adult male mouse (Choi et al 2012 and Chen et al, 2014). 
The first stable pluripotent stem cells were isolated from teratocarcinoma. 
Moreover, these cells contain benign tumour cells and embryonic carcinoma 
cells. These cells contain random of differentiated cells, which found during 
the early stages of embryo development. These cells have the ability to re-
transplant to another host maintaining an undifferentiated state (Peter 
Andrews, 2002).  
The P19 EC stem cell line has the ability to differentiate into all three germ 
layers and the molecular pathways that may explain the self-renewal 
pathway and differentiation have been established. Moreover, the P19 cells 
are an appropriate model for EC and ES because the cells can grow in 
monolayers and without feeder layers. Moreover, they are easy to study 
expression of ectopic genes that are important for self-renewal  and 
maintaining an undifferentiated state. (Choi et. al., 2012 and Chen et. al, 
2014).  
The characterization of embryonic carcinoma (EC) cells is very similar to 
normal embryonic stem cells (ESCs). EC cells derived from primary tumours 
possess euploid male karyotype (40:XY) (Angello et al., 1997 and Heyden 
and Defize 2002). P19 is defined as embryonic carcinoma stem cells that 
have normal mice euploid male karyotype (40:XY). These cells were isolated 
from 7.5 days embryos that stem from C3H/He female mice. Some mice can 
form Teratocarcinoma from early embryos. P19 EC cell lines are a 
preferable in-vitro model to investigate the molecular mechanisms of early 
mammalian development. P19 can differentiate to normal cardiac myocytes 
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with embryonal bodies under dimethylsulfoxide (DMSO) (Skerjanc Ilona 1999 
and Qin et al., 2013), (Angello et al., 1997 and Heyden and Defize 2002), 
and normal neuronal cell under Retinoic acid inducers. This is because EC 
cells can differentiate to all three germ layers: endoderm, mesoderm and 
ectoderm (Bain et. al., 1994). 
Another reason for P19 as preferable model is that establish heterozygous 
for x-linked alleles (Jones-Villeneuve et al, 1982 and Heyden and Defize, 
2003). P19 can grow as an undifferentiated primary cancer stem cell and 
small amount of endoderm with no factors or feeder cells in vitro (Jones-
Villeneuve et al, 1982. Recently P19 embryonal carcinoma cells were 
investigated by Riego and her colleagues (1995) who examined the 
interferons (IFNs) that generate heterogeneous family of cytokines in P19 
EC. Moreover, it was shown that IFNs and IRFs responsible in cell growth and 
differentiation in embryonic carcinoma (EC) cells. They found that IFN-alpha 
genes were identified in early embryos and P19 EC cells. However, IFN-
alpha expressed in P19 EC cells unlike IFN-beta. IRF-2 expression was found 
in early stage of P19 cells (Riego et. al., 1995). 
  
1.7.3 Epiblast Stem cells  
Epiblast stem cells are pluripotent cells that generate during the cell 
division within inner cell mass. These cells give rise to three germ layers, 
endoderm, ectoderm and mesoderm. They express the pluripotent marker 
sox2, oct4, and nanog at the early epiblast cells stage; however, they do not 
express Zfp42 and they less express Gbx2 unlike ICM. In the late epiblast 
stem cells FGF5 and Nodal were expressed after the implantation unlike 
mouse ES cells (Brons et al., 2007). In mouse embryos, it revealed that hsp 
68, IRF1, IFN-alpha are highly expressed in two cells embryos. However, in 
P19 cells RNA expression levels of IFN-alpha, hsp68, and APP genes highly 
express from post cleavage stage of the embryos whereas IRF1 expresses 
later stage of embryo (Yeom et. al., 1996).  
EC P19 cells are considered as epiblasts cells of the early post-implantation 
blastocyst development. The derivation of the cell lines affects the 
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pluripotent gene expression such as Oct4. Embryonic stem cells, embryonal 
carcinoma stem cells and embryonic germ cells were used to test the 
expression level of Oct4 gene. Embryonic stem cell (ESCs) derived from 
blastocysts, which generate high production of germline chimeras. However, 
Embryonic carcinoma (EC) P19 cells were generated from early to mid-
gastrulation embryos. It has similar properties of the epiblasts, but this type 
of cells has different developmental stages and only some of epiblasts cells 
derived from totipotent cells. This was suggested that Oct4 expression has 
different regulation roles in these cells (Yeom et. al., 1996) (Figure 16.1).  
 
Figure  1.16 mouse embryonic stem cell development based on Oct4 expression 
The box represents the stem cells express Oct4 gene at different 
developmental stages whereas the circle arrows represent indicates 
different stage of stem cell development. P19 EC cell is not on the black 
arrow line to show that not all the epiblast stem cells are totipotent stem 
cells that are precursor of primodal germ cells.  
  
1.7.4 Teratocarcinoma stem cells (P19) and neuronal development  
Previously, it was mentioned that P19 cells could differentiate to neuronal 
stem cells using retinoic acids induction; consequently, neuroectoderm, 
neurons and glia is developed from neuroepithelial-like germinal cells close 
to mammalian central nervous system. At functional level, these 
differentiated cells can express neuronal markers and neurofilament and it 
can exhibit neuronal mechanisms. Under retinoic acids (RA) exposure twice 
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or three times, P19 cells can generate only 15% of neuronal cells whereas 
the rest of differentiated cells are unknown or lack of neuronal properties 
(Nye et. al., 1994). Therefore, P19 has been used as a model for neuronal 
differentiation and studying signalling molecules such as Wnt, Notch, BMP, 
and Sonic Hedgehog (Marikawa et. al., 2009). Furthermore, P19 can be used 
as model to investigate possible neurodegenerative treatment such as 
Parkinson (Noh et. al., 2012).  
For instance, a study used activation of Notch1 gene to investigate 
neurogenesis regulation in P19 cells using overexpression of mNotch proteins 
in differentiated P19 cells. it was found that mNotch overexpression in 
differentiated P19 cells caused suppression in neurogenesis and myogenesis. 
Moreover, Undifferentiated P19 cells can expression embryonic cell surface 
marker (SSEA1) which is a glycolipid antigen found in preimplantation 
embryo at the inner cell mass and primitive ectoderm. When P19 cells 
induced by RA, SSEA1 reduced and filament protein (Nestin) increased after 
4 days of RA induction. Then another population called neurons is raised 
after Nestin reduction. Nestin expression is an indication of neuroepithelial 
and myotomal cells (Nye et. al., 1994). However, it loses its expression 
during the neural precursors development. Mature neuron is developed by 
neurofilament and NeuN expression. During P19 cell developed to glia cells 
after 12 days of RA induction. The overexpression of Notch gene in P19 cells 
did not affect the development to glia cells and GFAP marker showed 
increase level in the same cells. This showed that Notch gene may not 
affect the differentiated state, but it may have role in developing 
neuroepithelial cells to a neuron (Nye et. al., 1994).  
Several cell culture protocols have been developed to reduce the 
contamination of non-neuronal cells. For example, Monzo and colleagues 
(2012) developed low serum medium method to overcome low neuronal 
cells rate. Performing the P19 neuronal differentiation initiate by plating 
the P19 cells as suspension cells and induced them with RA to form 
embryoid bodies (EBs) then neuronal precursor cells. However, this method 
did suspend generation of proliferative non-neuronal cells and only 2% was 
found to be mature neuron after 12 day of culture (Monzo et. al., 2012). 
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Another method was performed by Nakayama and colleagues (2014) using no 
serum medium and no formation of suspension culture. This method showed 
that increase in neurogenesis about 50% with no glia formation within 6 days 
after the RA induction (Nakayama et. al., 2014).  
 
1.8 Approaches to identify the function of a protein  
 
Targeting the gene using homologous recombination techniques (loss of 
function) aids understanding of the biological roles of the gene and its 
protein by disrupting the gene open reading frame in mouse. One of the 
most common methods is knockout gene in mice. This method involves a 
drug resistance marker replacement of genetic coding region (Hall et al., 
2009). However, some knockout genes can be lethal to the mice although 
conditional knockout mice were developed to overcome this issue. On the 
other hand, studying RNA of gene function in vitro can be unclear. 
Interference RNA interference (RNAi) provides a novel tool for studying loss 
of gene function using endogenous pathway. The use of knockdown methods 
in vitro and in vivo can generate long-term specific gene silencing in the 
target model. Moreover, it can eliminate the expression of genes in brain 
and hematopoietic stem cells while reducing the issue of a lethal model in 
vivo or in vitro (Tiscornia et al., 2002).  
RNA interference (RNAi) has expanded the understanding of loss of function 
for some genes in development and disease. It is an innate defense 
mechanism in mammalian systems that protects the cells against viruses and 
other activities caused by transposable elements. However, RNAi has been 
used as an alternative pathway to the gain of function or deletion of genes 
using homologous recombination (HR). RNAi technologies use a natural gene-
silencing phenomenon as an advantage to knockdown the expression or 
block mutant genes (Fellmann and Lowe, 2014, and Rytlewski and Beronja, 
2015). 
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1.8.1 RNA Interference pathway  
RNAi is endogenous mechanisms that can mediate the gene silencing. This 
can be used as a powerful tool to study the biological role of specific genes. 
This tool can be used in cell culture using delivery system of chemically 
synthesized siRNAs or shRNAs. Constitutive gene silencing of shRNA is derivn 
by RNA polymerase III (U6 or H1) promoters. This system showed a sufficient 
knockdown of target gene. However, the lack of sufficient the level of 
knockdown can cause limitation during the analysis of genes that are 
important for cell survival, cell cycle analysis and development. Moreover, 
the long period of knockdown of certain genes may cause nonphysiological 
responses (Gupta et al., 2004). 
RNAi mechanisms involve nucleases and ATP dependent process in the 
cytoplasm and can be divided into two steps. The first step is the formation 
of double stranded siRNA. RNase III enzymes Dicer and Dorsha cleave the 3’ 
end of shRNA that contain miRNA and the 5’ end loop (Aagaard and Rossi, 
2007). Drosha forms a microprocessor complex, which contains an RNase III 
family enzyme, DiGe orge syndrome critical region gene 8 (DGCR8). DGCR8 
consists of two double stranded RNA-binding domain (dsRBDs). DGCR8 can 
determine the pri-miRNA and single strand RNA sites. Drosha recognizes the 
cleavage region of around 11bp leaving around 65-70 nt of precursor miRNA 
(pre-miRNA) (Wilson and Doudna, 2013). The long sequence double strand 
RNAs form after pre-miRNA is exported to the cytoplasm. They have a 
specific siRNA of 21-23 base pair long for particular genes at the 3’ end and 
there are around 2-5 nucleotide that allow to be recognized by Dorsha and 
Dicer (Aagaard and Rossi, 2007 and Rychahou et al, 2006). This dsRNAs 
mimics the innate immune response from antivirus through increasing the 
interferon-linked pathway. One of the important interferon-based defence 
mechanisms is the cellular dsRNA-dependent protein kinase (PKR) which can 
cause inhibition of translation (Rana, 2007 and Garcı´a et. al., 2007).  
The Second step is the use of the effector RNA induced silencing complexes 
(RISC). Either synthetic or endogenous siRNA, which are formed as a small 
double-stranded RNA from the first step, are incorporated into the RISC 
protein complex (Hammond, 2005 and Rychahou et al, 2006). RISC is a 
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complex that contains a splicing protein Argonaute that can recognize 
siRNA. When RISC binds to the siRNA sequence, a destruction of RNA 
transcription occurs by activating RISC, leading to knockdown of the mRNA 
of the gene of interest. This process results in translational repression 
(Figure 1.12) (Aagaard and Rossi, 2007 and Nowotny and Yang, 2009). 
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The endogenous mechanism of RNAi  
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Figure  1.17  RNAi mechanism and the formation of siRNA 
A. the formation of double stranded pre-miRNA with stem loop structure; 
the pre-miRNAs require enzymatic activity and ATP release to generate 
double helix siRNA. B. RNA-induced silencing complex (RISC) activation 
process.  Unwinding the 5’ end of the siRNA duplexes using piRNA guide 
strand at the PIWI domain in the Arganote-2 region with the help of 
thermodynamic activity help to generate the siRNA with Arganote-2 
recognition site. Arganote-2 helps to identify the complementary sequence 
at the endogenous mRNA and binds with siRNA. This process causes mRNA 
degradation.    
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1.8.2 RNAi in the nucleus: (shRNAs and siRNA) 
Two different pathways can trigger the RNAi mechanism. Firstly, 21 base 
pair duplexes of siRNAs can be directly cleaved by dicer enzyme and the 
effects are transient. Secondly, nuclear synthesis of shRNAs can be used 
based on miRNAs synthesized from DNA vectors (Aagaard and Rossi, 2007). 
Both types of molecules can control gene expression by RNAi process. It was 
shown that siRNA contains a hairpin structure and it can be expressed in 
cells using DNA plasmid construct derived by RNA Polymerase III (Pol III) 
promoter. Although siRNA and shRNA use a similar process, there are some 
differences in terms of their actions, off target effects and applications 
(Rao et. al., 2009).  
 
shRNA is synthesized in the nucleus of the cells. Once it formed as pre-
miRNA, it integrated in to the genome.  ShRNA can transfer to the cytoplasm 
throughout viral plasmid or deliverer to involve into RISC activity (Figure 
1.12). It was mentioned that shRNAs use the endogenous miRNA pathway, in 
particular miR-30 based shRNAs (Rao et. al., 2009). The advantages of 
having a DNA based strategy is in the easiness of delivery and the production 
of shRNAs. The expression vectors can generate shRNAs that have sense, and 
antisense within the 21 mer. In between them there is a short 5-6 residues 
terminator sequence. When the transgene expression cassette is transcribed 
in vivo, the shRNA fold back to form a hairpin structure using cellular 
nucleases, and the shRNA is cleaved to generate  siRNAs (Aagaard and Rossi, 
2007).  
ShRNAmir can be designed to better targeting the siRNAs process and give 
high level of knockdown efficiency. The design of shRNAmir uses the RNAi 
natural enzymatic process by RNase III Drosha. This permits more Dicer 
recognition and specificity. ShRNAmir can use the RNAi pathway that is 
processed in the nucleus by Drosha and cytoplasm by Dicer and RISC 
complex.  This causes more siRNAs to be produced and specific mRNA 
degradation. Unlike siRNA, shRNAmir showed limited rate of enzymatic 
process in living cells and less off target effects (Fewell and Schmitt, 2006). 
The idea of adding miR-30 as part of shRNA construct is that miR-30 can 
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provide efficient knockdown through RNA polymerase II promoter. The main 
reason of choosing miR30 was due to the well characterization of pre-miRNA 
transcription and functional process toward miRNA in vitro and in vivo 
(Cullen 2004 and Stegmeier et al., 2005). 
 
1.8.3 Constitutive versus inducible RNAi systems  
Vectors used in this project are bicistronic vectors, which permit high 
transfection efficiency and enhanced report gene expression for recognizing 
the transduced cells from non transduced cells such as PGFP and PRFP. 
These vectors were designed based on HIV-1 which is considered to be the 
most extensively utilized in gene therapy applications using gene transfer 
vector systems. 
The use of stable long-term expression is essential to study gene behaviour 
in vitro and in vivo for therapeutic reasons such as neurodegenerative 
diseases (Eleftheriadou and Mazarakis, 2015). Using constitutive systems can 
be preferable in some studies that show high transfection rates and it can 
spread to more mature cells types such as in mouse midbrain (Bensadoun et 
al., 2000). The disadvantages of long constitutive gene knockdown using 
shRNA can generate a secondary effect which is inappropriate to study 
important gene function that highlight the growth of cancer cells 
(Wiederschain et al 2009).  
On the other hand, the use of inducible knockdown gene using shRNA is 
preferable to study some genes. For example, demonstrating the function of 
tumour suppressor genes and oncogenes in epithelial cancer cell lines (law 
et al, 2012) was challenging using stable gene expression methods. 
Therefore, developing an inducible system to modulate the gene expression 
in spatially and temporally controlled manners is important. An Inducing 
agent regulates inducible gene silencing. Moreover, inducible shRNAs need 
several clone selection to produce stable cell lines (Wiederschain et al 2009 
and Shuen et al., 2015).  
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1.9 Vectors for RNAi systems  
1.9.1 The characteristic of single lentivector for inducible knockdown 
vector (pSLIK-CD4) 
pSLIK stands for single lentivector for inducible knockdown. The design of 
pSLIK inducible system is slightly different than the pTRIPZ.  Ubi-c promoter 
drives a different cell surface selectable marker, CD4, whereas in pTRIPZ, 
puromycin is a drug selection marker . Moreover, pSLIK uses TRE to express 
GFP and miR30-shRNA. Furthermore, it has constitutive part derived by Ubc-
I promoter to express reverse tetracycline transactivator (rtTA) and it 
associated with bicistronic elements IRES that express cell surface marker. 
These elements allow pSLIK to be tracktable and inducible of one gene or 
multiple genes knockdown system.  
pSLIK-CD4 was design to limit the issue of leaking expression and low 
transgene expression level in vivo. Furthermore, this system supports the 
constitutive expression using the GFP to recognize the transduced cells and 
CD4 for cell sorting. The TRE driven by rtTA3 expression can obtain high 
expression level in the present of Dox (Shin et. al., 2006). 
 
1.9.2 The characteristic of pGIPZ and pTRIPZ  
Open-bio system manufacture design two different plasmids a constitutive 
plasmid named pGIPZ and inducible system named pTRIPZ (see chapter 2 
material and methods, figure 2.3).  
pGIPZ and pTRIPZ lentivirus construct was designed based on Puromycin 
drug selection. Streptomyces Alboniger bacterium makes puromycin. It 
contains PAC gene that encodes a puromycin ZV-acetyl transferase (PAC). S. 
Alboniger cells contain N-acetyl puromycin. Exposing living cells to 
Puromycin showed an active N-acetylate-puromycin since the ribosomes are 
very sensitive to puromycin in vitro. Activating the N-acetylation of 
antibiotic inhibits the protein synthesis NH2 group that can stimulate 
puromycin. The puromycin mechanism occurs during the translation by 
inhibiting the peptide chain elongation in living cells (Azzam and Algranati, 
1973 and Vara et. al., 1985). Thus, cloning and expressing the PAC gene in 
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living cells has advantage as selectable marker for puromycin resistance 
(Vara et. al., 1985 and Luna et. al., 1987). PAC gene is encoded in pGIPZ 
(constitutive system) and pTRIPZ (inducible system) vector backbones 
(open-biosystem). Therefore, affected cells become puromycin resistant. 
Thus stable cell lines were studied under certain amount of puromycin 
which were tested on wild type cells.  
pGIPZ (Figure 2.3, A) and pTRIPZ (Figure 2.3, B) lentiviral vectors use 
MicroRNA (miRNA) based on hairpin developed by Dr Greg Hannon and Dr 
Steve Elledge (thermo scientific open biosystem pGIPZ, and pTRIPZ 
shRNAmir). miRNAs have been used in backbone of shRNA sequences. This 
design creates a configurative recognition as a natural substrate of the RNAi 
pathway. Moreover, the use of miRNA in shRNA backbone allows a stable 
and regulative expression from RNA polymerase II (Pol II) promoters. 
Furthermore, miRNA based on shRNA design enables the “polycistronic 
tandem“ shRNA vectors and linked to reporter genes such as green 
florescent protein (Fellmann and Lowe, 2014). In addition, the natural 
occurring of miRNA to generate the desire shRNA can have a potent gene 
silencing without toxicities (Manjunath et. al., 2009 and Chang et al., 2006). 
Zeng and et al (2002) use artificial and endogenous human mir-30 to show 
the mRNA expression for selected target genes in human cells in vivo. They 
transfect both artificial and endogenous mir-30 with plasmid pCMV-mir30 in 
293T/17 cell. They found that artificial mir-30 similar to endogenous mir-30 
under RNAi construct can act as siRNA to knockdown the target gene and it 
can stabilize the gene silencing in human cells. This stable inhibition of 
target gene can be expressed using viral vectors, which permit the miRNA 
production in mammalian cells. Furthermore, the expression of inhibitor 
miRNA works effectively as a part of miRNA (2002). Next, miRNA can reduce 
the effects of RNAi by interacting with miRNA processing machinery 
(Aagaard and Rossi, 2007). 
pTRIPZ (inducible system) Tetracycline based systems (Tet-On system) can 
drive the expression of shRNAmir in pTRIPZ system in the presence of 
Doxycycline (manual technical pTRIPZ). Tet-on system contains two elemen 
transgenes that work together: the transgenic transcription factors (rtTA) 
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,and the ic tetracycline-inducible promoter (TRE) (Buchholz, 2012 and TRIPZ 
technique manual). pTRIPZ was designed after pSLIK. Like pSLIK vector, 
pTRIPZ uses TRE promoter to drive the RFP turbo following the miR30-
shRNA, and the Ubc-I promoter to drive the rtTA-IRES-PURO cassette. 
pTRIPZ vector gives tighten regulation of shRNA expression in many cell 
types (Shin et al., 2006 and Hu and Luo, 2012 ) . Doxycycline (dox) is a 
widely used antibiotic. It can pass through the placenta barriers and brain 
tissues. Moreover, it has less cellular toxicity and it can bind to all kinds of 
tetracycline receptors (TetR) efficiently (Corbel and Rossi, 2002). In the 
presence of Doxycycline, the structure of rtTA changes. This change allows 
rtTA to bind to DNA and drive the expression of shRNAmir from the TRE 
promoter. On the other hand, when there is no Doxycycline, rtTA cannot 
bind to DNA or regulate the expression of shRNAmir (Buchholz, 2012) (Figure 
1.12).  
However, inducible systems have some disadvantages. First, the leaking 
expression can raise an issue in the absence of inducer such as rtTA. 
Second, the drug toxicity from TRE and/or inducer (rtTA) can affect the cell 
phenotype. Third, expressing other genes than the target genes by using 
rtTA may produce off target effects (Meerbrey et al., 2011).  
To maintain siRNAs activities in mammalian cells, constitutive vectors were 
designed based on shRNA. These constitutive vectors contain promoters (Pol 
II or Pol III) that can drive Transgene expressions in vivo and in vitro (Leung 
and Whittaker, 2005). 
pGIPZ was designed from Hannon-Elledge libraries. They used Lentiviral 
vectors to obtain high transduction efficiency, and they can transduced non-
dividing cells such as neurons. pGIPZ vector ( open biosystems, Huntsville, 
USA) was a modified version from a pervious vector called pPRIME vector 
from the same library. It uses CMV promoter to derive the expression 
cassette turboGFP-IRES-puro following by miR30-shRNA. Cells with pGIPZ 
depend on transduction status not on the expression level of shRNA due to 
the independent expression of reporter and shRNA  
Internal ribosome entry site (IRES) sequence was found in picornavirus RNAs 
by Jang et. al. ,and Pelletier and Sonenberg in 1988. Two mechanisms 
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promote the translation in eukayotic cells: first, the association of 
eukaryotic initiation factors called elfs to 5’ end Cap structure of the mRNA; 
second, the limited elfs association to 5’ untranslated region (UTR) of mRNA 
called IRES. This translational process can be achieved by some metabolic 
conditions (Amorim et al., 2014). In eukaryotic cells, IRES allow the 
initiation of translation of RNA, which can permit the expression of more 
than one protein from a polycistronic transcription unit. Bicistronic 
application vectors became more preferable for expressing two proteins. 
One protein is used as a marker such as reporter gene, GFP/RFP, or cell 
surface marker, CD4, whereas the other protein can express the target 
gene. The advantages of using bicistronic vectors in vivo or ex-vivo is the 
high selection of transgene by marker expression. Nonetheless, the first 
gene in a bicistronic expression vector stimulates the cap-dependent 
translation while the second gene is activated in an IRES depended manner. 
This means that the positive selection determines the transcriptional 
efficiency; Moreover, IRES expression for the second translational protein 
shows no interference with first translational protein (Martinez-Salas, 1999, 
and Hellen and Sarnow 2001). 
 
1.9.3 Delivery of RNAi triggers (shRNAmir30) 
Lentiviral system delivered RNAi has been shown to be more efficient for 
integration in to the human genome (Stewart et al., 2003) and mouse cells 
(Kuhn et al., 2007). Moreover, due to the mutation in U3 region of LTR, the 
transcriptional process in lentivirus is inactive (Stewart et al., 2003). 
Furthermore, lentivirus showed better transduction of cycling 
haematopoietic or cancer cells (Kuhn et al., 2007).  
The natural function of retrovirus and lentivirus is to integrate into the host 
genome and provide a long expression of transgenes through viral genomic 
backbone. Therefore, the main usage of applying viruses is to generate a 
stable transgene expression for gene therapy purposes. The advantages of 
using lentivirus over retrovirus is that lentivirus can transduce dividing as 
well as non dividing cells.It can be used for long-term expression of a 
transgene as well as to acommodate large transgene sequences in the viral 
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plasmid (Manjunath et. al., 2009) 
 
1.9.4 Lentiviral transduction systems for gene delivery  
The common use of lentivirus is HIV-based Lentiviral vector. Furthermore, in 
clinical trial, it was found that the use of envelop HIV-based Lentiviral 
vector is safe and no sign of mutagenesis or any recombination virus side 
effects. However, it highlighted the fact that lentivirus gene therapy still at 
the early stage and there is positional risk of biosafety from using HIV as a 
vehicle (Manjunath et al., 2009).  
Minimizing the viral genome component is achieved by introducing the 
different components of the viral genome in 3-4 plasmids to produce a 
transduced virus. These plasmids contain: the packaging cassette that may 
contain one or two plasmids, the vector expression cassette and the envelop 
cassette. The packaging elements are gag and pol genes which encode the 
structural and enzymatic proteins that is important to form the viral 
particles called tat transactivator element, tat, that can drive the full 
expression of RNA vector. Packaging vector also contains rev gene that 
express the Rev protein. This protein is essential for nucleocytoplasmic 
transport of full length of RNA and viral RNA. RRE is called rev responsive 
elements. It is a cis elements that binds to Rev to regulate 
nucleocytoplasmic export. These elements pertinent to post-transcriptional 
mRNA processing events are retained and the full length is achieved using a 
heterologous constitutive promoter (CMV) and polyadenylation signals 
(SV40). 
The packaging vector started with the first generation with all HIV-1 
accessory genes, which raised a concern about bio-safety. The second 
generation eliminates all the accessory genes except the Rev and Tat 
elements. The third generation splits the viral vectors into three vectors 
(Pol/gag, Rev and VSV-g), which are made safer to use without the Tat gene 
(Cockrell and Kafri, 2007). The last generation has been used by pSLIK-
shRNAmir-CD4. Vector expression cassette is a plasmid that contains target 
shRNA/ shRNAmir. It contains self-inactivating vector (SIN), which showed 
significant improvement in vector safety. SIN deletion of the 
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enhancer/promoter elements in the U3 at the 3’LTR increase the vector 
safety profile. The safety improvement was the reduction of the expression 
of packaging vector, which reduce the chance for vector mobilization 
through the infection with HIV virus (Cockrell and Kafri, 2007 and Manjunath 
et al., 2009 and Zufferey et al., 1998). Improved the transgene expression 
and transduction efficiency of the lentivirus vector was performed through 
the incorporation with two elements: the woodchuck hepatitis virus post-
transcriptional regulatory element (WPRE) and the central polypurine tract 
(cPPT) (Cockrell and Kafri, 2007). The Envelop cassette contains vesicular 
stomatitis virus G protein (VSV-G). VSV-G protein has three main 
advantages, which are considered to be one of the major developments in 
lentivirus. First, VSV-G protein can generate pseudotypes with envelope 
replacement, such as rabies virus G protein and Ross river virus 
glycoprotein, in various species and cell types. Second, it can be applied to 
many host cells and tissues. Third, it can maintain the structure of viral 
particles during the ultra-centrifugation (Petersen et al, 2014 and Cockrell 
and Kafri, 2007). 
Open Biosystem uses five Lentiviral packaging vectors offering more safety 
profiles (Figure 1.13). The expression of gag-pol and tat-rev are driven by 
TER promoters, which can only apply when there is tTA expressed in the 
cells. pTLA1-ENZ vector contains RT-IN (pol) which is packaged by in-frame 
fusion with accessory vector called virion-associated protein Vpr. This 
vector is derived from HIV-2 LTR promoter, which is trans-activated by the 
Tat protein. VSV-g and SV40 elements are part of pTLA1-ENV derived by CMV 
promoter. pTLA1-TOFF has the tTA element regulated by CMV promoter. 
This element is critical for the gag-pol and Tat-rev expression vectors. 
pTLA-1-TAT/REV is controlled by TRE promoter. This vector has IRES, which 
is a bicistronic element in between TAT and REV.  
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Figure  1.18 open biosystem Trans-Lentiviral packaging vectors (technical 
manual open bio-systems). Each plasmid is explained in the text. 
 
 
1.9.5 Measuring the MOI for tittering the Lentiviral particles 
Measuring the Titre of lentivirus can predict the viral efficiency of the 
target cells by calculating the Multiplicity of infection (MOI) (Zhang et al., 
2004).  
TU/ml= number of Green cells* dilution factors* the amount of virus with 
medium. 
MOI= (TU/ml) / the number of total cells/ml 
MOI represents the ratio of viral titration to the number of cells for 
transduction. Lentivirus vectors mediated gene transfer can be hindered by 
low gene transfer efficiency or other inhibitory molecules (Zhang et. al., 
2004 and Shearer and Saunders 2015). Other factors that also influence the 
transfection efficiency of the viral vector are high Lentiviral transduction 
into target cell, which may cause insertion mutagenesis of genomic 
sequences which give an off target effects. These effects occur when there 
are several integrations. To overcome these issues, it  is favourable to 
determine the number of infected units of viral supernatant. Serial dilution 
of the virus particles can obtain an acceptable range of transduction 
efficiency. Furthermore, focus on single integration (copy number) per cell 
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can reduce the off target effect (Zhang et. al, 2004, Shearer and Saunders 
2015 and Connolly 2002). 
In stem cell research, the range of effective MOI in hematopoietic stem cell 
and gene therapy remains unclear. Moreover, the period of time for the 
target genes to affect on the results of gene expression is unknown. 
Therefore, two points were highlighted: the MOI in vitro is not consistent 
with clinical application and the common use of reporter gene, GFP, in 
preclinical evaluation (Wahlers et. al., 2001). 
The generation of safe, stable and high_titer Lentiviral has been shown 
promises in gene therapy. The expression of target gene depends on the 
three packaging vectors to produce Lentiviral particles. To generate stable 
producer cell line is challenging. However, it will help generating large 
batches of vectors to apply in vivo and in vitro. Another limitation is the 
amount of vector titration can be variable from cell to cell depend on VSV-g 
viral vector particles (Klages et al, 2000). 
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1.10 Background to this project 
 
Previously, siRNAs were used to transiently knock down Hmgn1 and/or 
Hmgn2 in the P19 cell line (Mohan 2012). Hmgn1/2 knockdown in 
undifferentiated P19 cellos resulted in downregulation of the pluripotent 
markers Oct4, Sox2 and Nanog. Repeated siRNA transfections allowed the 
knockdown of Hmgn1/2 in  P19 cells differentiated into neuronal cells via 
embryoid bodies. Day 3 neuronal cells showed a reduction of Hmgn1 and 
Hmgn2 mRNA expression in the double knockdown. However, at the protein 
level only around half of the protein was lost. Rest, Zfp521, Nse, and GlyT2 
were downregulated into the Hmgn1/2 double knockdown whereas Nestin, 
Map2, NF-160, Nmda receptor subunit 2, GlyT1a expression showed 
upregulation (Mohan, 2012). These experiments were difficult to reproduce 
due to variability in siRNA transfection levels, cytotoxicity following 
transfection, and variability in the efficiency of differentiation 
 
1.11 Aim 
This aim of this project was to develop a lentiviral system to knockdown 
Hmgn2 expression in embryonal carcinoma cells.  This system would be used 
to determine the role of Hmgn2 in pluripotent stem cells, with particular 
focus on regulation of key pluripotency factors.  
1.12 Hypothesis  
 
These experiments aim to test the hypothesis that Hmgn2 modulates 
chromatin structure and regulates the transcription of key transcription 
factors associated with pluripotency.  
1.13 Project Outline  
The work presented here uses lentiviral vectors to knock down Hmgn2 
expression, thus avoiding repetitive transfection and cytotoxicity. 
Constitutive (pGIPZ) and doxycycline-inducible (pSLIK and pTRIPZ) shRNA 
vectors were compared for their ability to achieve a high level of 
knockdown in P19 EC cells. FACS was used to monitor the efficiency of viral 
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transduction, and changes in gene expression were assayed using qRT-PCR, 
western blotting, FACS and immunofluorescence. ChIP was using to assay 
changes in chromatin structure following Hmgn2 knockdown.  
 
1.14 Objectives 
 
The main objectives can be summarised as follows: 
1. To optimise conditions for lentiviral transduction of P19 cells 
2. To compare the pSLIK, pTRIPZ and pGIPZ lentiviral systems for their 
ability to knockdown Hmgn2 expression and choose the best system for 
further experiments.  
3. To investigate whether Hmgn2 knockdown affects the expression and 
chromatin binding of various transcription factors associated with 
pluripotency 
4. To investigate whether Hmgn2 knockdown affects Hmgn1 binding, 
H3K4me3 and H3K27me3 at the Oct4 and Nanog gene loci.   
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Chapter 2 Materials and methods  
2.1 Materials  
2.1.1 Gateway cloning system  
Reagents and samples  
 
TE buffer PH 8.0  (10mM Tris-HCL, PH 8.0, 1mM EDTA) 
 
shRNA sequences for HMGN1 and HMGN2 were designed at Qiagen company  
 
Names  (entry vector)  Catalogue  Stock Concentration  
HMGN1-3 in PEN-TGm1 C09879B 4ug  
HMGN2-1 in PEN-TGm1 C09879C 4ug 
HMGN1-2 in PEN-TGm1 C09879A 4ug 
Scramble in PEN-TGm1 C09879D 4ug 
 
Destination vectors  Catalogue  Stock concentration  
pSLIK-CD4  L70DDLUTICXA 250 ug/ul  
pSLIK-HYGRO L55DDLUTIHX 202.91 ug/ul 
 
LR Recombination Reaction  
 
Gateway LR Clonase II plus enzyme Mix catalogue number: 12538-120 
 
LR recombination 
component  
Reaction sample Negative control  Positive control  
Entry clone  1ul 1ul - 
Destination clone  1ul 1ul 1ul 
TE buffer  2ul 3ul 3ul 
Clonase II 
enzyme 
1ul - 1ul 
Total  5ul 5ul 5ul 
 
 
2.1.2 PSLIK and pGIPZ, pTRIPZ vectors and packaging vectors  
PSLIK-CD4, pSLIK-hygromycin, and pENtgMRC3 
 
PSLIK vectors on bacterial strap were purchased from Add-gene Company 
without shRNA sequences  
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Constru
ct 
barcode 
Constru
ct name 
Vector details Vector 
size 
Digest 
fragme
nt  
Bacterial 
selection 
Mammal
ian 
selectio
n 
Ecoli-
propag
ation-
strain  
L55DDL
UTIHXA 
pSLIK-
Hygro 
shRNA Lentiviral 
Expression;  Ubi-c 
promoter driven 
rtTA3-IRES-Hygro 
13918 KpnI: 
10173; 
2403; 
1342 
Ampicilli
n 
Hygrom
ycin 
DB3.1 
L70DDL
UTICXA 
pSLIK-
CD4 
shRNA Lentiviral 
Expression;  Ubi-c 
promoter driven 
rtTA3-IRES-delta CD4 
(human) 
13770 KpnI: 
10173; 
2321; 
1276 
Ampicilli
n 
CD4 DB3.1 
P30ETR
EMIRAG 
pEN_Tm
iRc3 
shRNA expression; 
miR30-based 
topology; TRE Pmin 
promoter;  Entry 
vector backbone;  
+ccdB in parent; 
Multiple unique sites 
d/s of TRE 
4587 BsrG1: 
1889, 
1478, 
773, 
447 
Gentami
cin 
-- DB3.1 
 
PGIPZ and pTRIPZ  
 
PGIPZ was purchased from thermo scientific with shRNA sequences  
 
Vectors names  Barcode 
name 
Vector size Bacterial 
selection 
Mammalian 
selection 
pGIPZ-shHMGN2 V3LMM-
480381 
14345 Zeocin and 
ampicillin  
Puromycin  
pGIPZ-shHMGN2 V3LMM-
516968 
14575 Zeocin and 
ampicillin 
Puromycine 
pGIPZ-shHMGN2 V2LMM-
55514 
14656 Zeocin and 
ampicillin 
Puromycin  
pGIPZ-shGAPDH RH54371 14766 Zeocin and 
ampicillin 
Puromycin  
pGIPZ-shNon-
silencing 
RH54346 14676 Zeocin and 
ampicillin 
Puromycin 
pGIPZ-shEG5 RH54480 13565 Zeocin and 
ampicillin 
Puromycin 
 
PTRIPZ empty vector was gift from Professor Peter D. Adam, Beatson 
Institute, Glasgow G61 1BD. shHMGN2 were transformed following the 
protocol from thermo scientific and it was performed by Dr Katherine west.  
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Packaging vectors  
 
Vectors name  Barcode name  Vector size Manufacture  
PSLIK-CD4 and pSLIK-HYGRO (3rd generation packaging vectors ) 
pCMV-VSV-G 8454 6363bp Add-gene 
pRSV-REV 12253 4174bp Add-gene 
pMDLg/pRRE 12251 8895bp Add-gene 
pGIPZ and pTRIPZ (trans-packaging mix)  
Trans-lenti shRNA 
Packaging kit  
TLP5913 Five Mix-
packaging 
vectors  
Thermo scientific  
 
2.1.3 Lentiviral reagents  
Reagents  Manufacture  Catalogue 
number 
Lentiviral system  
Lipofectamin 2000 Invitrogen  11668-019 pSLIK  
OptIMEM  Gibco  31985-062 pSLIK  
ULTRA cultural  Lonza g1234 pSLIK , pGIPZ and 
pTRIPZ 
CacL  Thermo scientific  TLP5913 pGIPZ and pTRIPZ 
HBSS buffer  10x Thermo scientific  TLP5913 pGIPZ and pTRIPZ 
 
 
2.1.4 Lentiviral transduction kits  
Kit name  manufactu
re 
Catalogue 
number 
System  
Amicon ultra-15 
centrifugal 
filter device 
Millipore UFC91002
4 
Fast filtration with the capability for high 
concentration factors and easy concentrate 
recovery from dilute and complex sample 
matrices 
Lenti-x geoStix  Clontech  631243 confirming the presence of lentivirus in 
packaging cell supernatants 
Transdux  System 
Bioscience  
LV850A-1 Enables high transduction rates of virus 
into most cells, even those that are 
resistant to infections. 
Polyberen Sigma  107689 The presence of polybrene Can efficiently 
serve as the method of transduction for 
many Cell types, some cells are more 
difficult to transduce. 
Lenti-X™ 
Concentrator 
Clontech  PT4421-2 concentrating lentiviral stocks 
Lenti-X™ p24 
Rapid Titer Kit 
Clontech 632200 quickly determine the titre of any HIV-1-
based lentiviral supernatant 
using standard ELISA methods 
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2.1.5 Plasmid purification, transformation, and electrophoresis   
DNA Plasmid purification  
 
QIAprep spin Miniprep Kit catalogue number 27104 
 
Qiagen plasmid plus midi kit catalogue number 12943  
 
Transformation  
 
Solid Lysogeny broth (LB) in 1L  
Reagents  Company  Catalogue 
number  
Concentration  
Lysogeny broth 
(LB) bacteria 
medium  
Sigma-Aldrich  L3022-1KG 20g/l 
NaCL    5 g/l 
Agar    10g/l  
To be complete up to 1000ml with dH2O  
 
Liquid Lysogeny broth (LB) in 1L  
Reagents Company  Catalogue 
number 
Concentration 
Lysogeny broth 
(LB) bacteria 
medium  
Sigma-Aldrich  L3022-1KG 20g/l 
NaCl    5g/l 
To be complete up to 1000ml with dH2O  
 
Subcloning Efficiency™ DH5α™ Competent Cells from Invitrogen catalogue 
number 18265-017 
 
Screening using restriction digest  
Reagents  Catalogue number  Concentration at 1x 
Buffer 1  B70015  10X conc.  4ul 
BSA 0121005  10mg/UL  1ul 
DNA ----- 1ug 
Kpn1 (NEB) 1425 10000U/ml 0.5 ul 
DH2O                         Up to 40ul 
 
 
Gel electrophoresis  
To prepare Buffer and dyes   
50x TAE  
242g TRIS BASE  
57.1ml Acetic acid  
18.69 EDTA 1hr for 1L  
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Product  Manufacturer Product Code 
P19 CELL LINES with alphaMEM 
Medium (MEM)-alpha 
containing 
deoxyribonucleotides, 
ribonucleosides and 
ultraglutamine 1 
Lonza BE02-002F 
New born calf serum 7.5% Source 
Bioscience,  
7.03Hi 
Fetal bovine serum 2.5% Sigma F9665 
P19 cell lines with DMEM/F12  
Advanced DMEM/F12  GIBCO  12634-010 
New born calf serum 10%    
Glutamax 100x Gibco   
HEPES (transduced cells 
only) 100x 
Gibco   
Hepa cell lines  
DMEM with glutamine  Gibco  10566-016 
FBS 10%  Sigma F9665 
E14 cell serum free    
NDiff 227  500ml  Stem Cell 
Sciences 
SCS-SF-NB-02 
LIF-recombinant    
 
ESGRO, Millipore,  10^7 U/ml, 500 U/ml final 
MEK inhibitor 
 
SelleckCHem 1 µM final, PD0325901 Cat. 
S1036)  50 ul of 10 mM stock 
in DMSO 
GSK3-B inhibitor  
 
SelleckCHem 3 µM final, CHIR99031 Cat. 
S1263) ,150 ul of 10 mM 
stock in DMSO 
HEK392/17   
DMEM GLUTAMAX  Gibco  10566-016 
FBS 10% Sigma F9665 
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BPB 300bp  
1kb loading ladder  
75ul H2O  
5ul ladder  
20ul LB (loading buffer).  
 
Xylene cyanol dye 4kb 
25mg xylene cyanol in 10ml  
6 X of leading buffer in 30% glycerol  
DNA ladder  
Reagents  Manufacture  Product number  
100 bp DNA ladder NEB N32315 
1 Kb DNA ladder Invitrogen 10787-018 
 
2.1.6 Cell lines  
Cell lines Reference  Source  
P19 cell lines Passage 
14 
(McBurney and Rogers, 
1982) 
P19 EC cell line was 
provided by Dr. Andrew 
Hamilton, Institute of 
Cancer Sciences, 
University of Glasgow 
Mouse hepatoma line 
Hepa-1 
(West et. al., 2004) From ATCC,  
E14 cell lines (Hooper et. al., 1987) From Cambridge 
HEK293T/17 (Pear et. al., 1993) From Adam west lab  
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2.1.7 Drug reagents  
Drug names Manufacture  Catalogue number  
Puromycine  Sigma  P7255-25MG 
Hygromycin b Sigma  H3274-50MG 
Doxycycline  Sigma  D9891-1G 
 
 
2.1.8 Molecular biology reagents  
RNA extraction:  
 
RNeasy mini kit catalogue 74104 from qiagen  
 
 
CDNA formation: 
 
Reagent  Manufacturer Product 
Number 
Oligo DT 100UM  Bioscience   
100 mM dNTP set Invitrogen 10297018 
FastStart Universal SYBR 
Green Master (Rox) 
Roche 04913914001 
Super script III  INVITROGEN  18080-044 
Proteinase K Sigma P5568 
RNase A Fermentas EN0531 
RNase OUT Invitrogen 160000840 
RNase H NEB M0297 
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Oligonucleotides  
 
Oligonucleotides were ordered from IDT or MWG Eurofins used as primer for 
RT-PCR  
Gene Primer Sequence  Primer 
Efficiency 
Hmgn1 
 
Forward 
Reverse 
AGAGACGGAAAACCAGAGTCCAG 
CGTGATGGATGCTTAGTCGGA 
1.98 
Hmgn2 Forward 
Reverse 
AAAAGGCCCCTGCGAAGAA 
TGCCTGGTCTGTTTTGGCA 
1.96 
Oct4 Forward 
Reverse 
CGTTCTCTTTGGAAAGGTGTTCA 
GGTTCTCATTGTTGTCGGCTTC 
1.98 
Nanog Forward 
Reverse 
ACCTGAGCTATAAGCAGGTTAAG 
TCAGACCATTGCTAGTCTTC 
2.0 
Sox2 Forward 
Reverse 
GGAACAGCATGGCGAGCGG 
CGTTCATGTGCGCGTAGCTG 
1.96 
α-tubulin Forward 
Reverse 
ACCCACGGTCATCGATGAAGTT 
TCCTTGCCAATGGTGTAGTGGC 
1.98 
-Actin Forward 
Reverse 
GTGAAAAGATGACCCAGATC 
GTGTGGGTGACCCCGTCTCC 
1.97 
C-myc  CTGTTTGAAGGCTGGATTTCC 1.92 
Klf4   AACCTATACCAAGAGTTCTCAT 2.40 
 
 
Oligonucleotides for QPCR-ChIP 
 
Oligonucleotides were ordered from Eurofins for Oct4 and Nanog genes 
primer design around the TSS  
Gene Primer Sequence  Primer 
position 
Oct1 
 
Forward 
Reverse 
GTGAGCATGACAGAGTGGAGGAA 
TCTCTGGCCCTCTCCATGAAT 
-1781 
Oct2 Forward 
Reverse 
GTGGGTAAGCAAGAACTGAGGA  
TGGAGAGCCTAAAACATCCATT 
-399 
Oct3 Forward 
Reverse 
CAATGCCGTGAAGTTGGAGA 
TCACTTACCTCCTCGGGAGTTG 
+410 
Oct4 Forward 
Reverse 
TCAAGGCTTCTCACCTCCAGA 
ACAGAGAAAGCAAGGCAGCAG 
+2070 
Oct5 Forward 
Reverse 
GCTGCCTCACTCACTCTGTTTG 
TGGCTGAACACCTTTCCTGAA 
+3342 
Nanog1 Forward 
Reverse 
GGAAGAACCACTCCTACCAATACTCA 
CGTAACATCTCCCATGTGAAGACTC 
-1081 
Nanog2 Forward 
Reverse 
TCTTTAGATCAGAGGATGCCCCCTAAG 
AAGCCTCCTACCCTACCCACCCCCTAT 
-219 
Nanog3 Forward 
Reverse 
TCAGCCCAGTACTCAGGCTTGT 
AGCCTAGCAGCCTCTTGGTTCT 
+929 
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Nanog4 Forward 
Reverse 
TAACTGGACCCTCTGACTGGCT 
CCCACCATCTTTTCTGCTAGTACAAG 
+1740 
Nanog5 Forward 
Reverse 
TGTAGATGCGGTCACGGTTC 
CCAATCCCTTCTCCCTGCT 
+2636 
β-actin Forward 
Reverse 
CGCCATGGATGACGATATCG 
CGAAGCCGGCTTTGCACATG 
 
MSat Forward 
Reverse 
GACGACTTGAAAAATGACGAAATC 
CATATTCCAGGTCCTTCAGTGTGC 
 
 
2.1.9 Antibodies 
Antibodies for IF (immune florescent)   
1st  
Antibody 
Cat  
Number 
Concentra
tion 
Specie
s 
2nd 
Antibody 
Cat  
Number 
Concentra
tion 
Colou
r 
Hmgn1 Homem
ade 
1/500 Rabbit Donkey 
anti-rabbit 
A21206 1/1000 Gree
n 488 
Hmgn2 Homem
ade 
1/500 Rabbit Donkey 
anti-rabbit 
A21206 1/1000 Gree
n 488 
Hmgn3 
(EP062146) 
Homem
ade 
1/5000 Rabbit Donkey 
anti-rabbit 
A21206 1/1000 Gree
n 488 
SSEA1 AB16285 1/200 MOUSE Donkey 
anti-mouse 
AB15011
1 
2ug/ml Red 
(647) 
Nanog AB80892 1/1000 RABBIT Donkey 
anti-rabbit 
A21206 1/1000 Gree
n 488 
Sox2 Ab97959 1/1000 Rabbit Donkey 
anti-rabbit 
A21206 1/1000 Gree
n 488 
Map2 Ab5392 1/1000 Chicke
n 
Goat anti-
chicken 
Ab15017
5 
1/500 Red 
647 
Oct3/4 santa SC8628 1/500 GOAT RABBIT 
ANTI-GOAT 
A11078 1/1000 Gree
n 488 
Oct4 AB AB19857 1/500 RABBIT Donkey 
anti-rabbit 
A21206 1/1000 Gree
n 488 
NeuroD1 Ab60704 1/1000 Mouse Donkey 
anti-mouse 
A21206 2ug/ml Red 
(647) 
TBP  1/400 Mouse Goat anti-
mouse 
A21206 1/200 Yello
w 
 
 
Antibodies for western blot on whole protein and chromatin 
 
1st 
Antibody 
Cat 
number 
Expected 
size 
Concentration Species 2nd  
Antibody 
Cat 
number 
Concentration 
Hmgn1 Homemade 14 kDa 1/1000 Rabbit  Goat 
anti 
rabbit 
HRP 
2346 1/2000 
Hmgn2 Homemade 17 kDa 1/2000 Rabbit Goat 
anti 
rabbit 
HRP 
2346 1/2000 
TBP Ab51841 34-40 
kDa 
1/3000 Mouse GOAT 
ANTI 
MOUSE 
HRP 
4567 1/5000 
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Oct4 Ab19857 50 KDa 1/500 Rabbit Goat 
anti 
rabbit 
HRP 
2346 1/2000 
H2AZ 
Millipore 
07-594 13 KDa 1/1000 RABBIT Goat 
anti 
rabbit 
HRP 
2346 1/2000 
P300 Sc584 300 KDa 1/1000 RABBIT Goat 
anti 
rabbit 
HRP 
2346 1/10,000 
P53 (SC) Sc-99 50 KDa 1/500 Mouse GOAT 
ANTI 
MOUSE 
HRP 
4567 1/2000 
Nanog Ab80892 35KDa 1/300 Rabbit Goat 
anti 
rabbit 
HRP 
2346 1/2000 
Sox2 Ab97959 34 KDa 1/1000 Rabbit Goat 
anti 
rabbit 
HRP 
2346 1/5000 
H3.3   17 KDa 1/100,000 RABBIT Goat 
anti 
rabbit 
HRP 
2346 1/2000 
B-tubulin 
(thermo) 
12430-1 43KDa 1/3000 Mouse  GOAT 
ANTI 
MOUSE 
HRP 
4567 1/10,000 
HMGN3b   1/3000 Rabbit Goat 
anti 
rabbit 
HRP 
2346 1/2000 
H3K4me3 
(Millipore) 
07-473 14 KDa 1/5000 Rabbit Goat 
anti 
rabbit 
HRP 
2346 1/2000 
 
 
2.1.10 Protein extraction and analysis  
SDS-PAGE using Invitrogen protocols:  
 
Reagents  and buffers Manufacture  Catalogue number  
Nupage 4-12% bis-tris gel Invitrogen (novex) NP0322BOX 
Nupage 12%  Invitrogen NP0321BOX 
Reducing agents 10% Invitrogen NP0004 
Antioxidant  Invitrogen NP0005 
Nupage Mops  Invitrogen NP0001 
Running buffer 20x Invitrogen  
Transferring buffer  10x Invitrogen NP0006 
Nupage LDS sample Buffer 
4X 
Invitrogen NP0007 
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Methanol  Thermo scientific  
Milk (SEMI-SKIMMED) Marvel  MARVEL 
TWEEN 20  Thermo scientific   
TRIS PH7.5   
NaCL 5M    
 
 
 BIO-RAD protocol  
 
Reagents and machine Catalogue number  
BLOTING TRANS-BLOT TURBO 
TRANFER SYSTEM PACK 
1704155 
MINI TRANSFER PACKS  1704156 
 
BUFFERS  
TBST buffer 1x (antibody blocking buffer) 
20mM tris ph 7.5       20ml       1M TRIPZ PH7.5 
150mM NaCl               30ml       5M NaCl  
Up to 1L of dH2O + TWEEN 20  
 
2.1.11 Chromatin immunoprecipitation reagents and buffers  
5% Formaldehyde Solution (can be stored at 4C for 1 week) 
(5% HCHO, 50 mM HEPES pH8.0, 0.1 M NaCl, 1 mM EDTA, 0.5 mM EGTA) 
 
Formaldehyde dilution buffer  
50 mls 
1M HEPES pH 8.0   2.5 ml 
5M NaCl    1.0 ml 
0.5M EDTA pH 8.0  0.1 ml 
0.5M EGTA pH 8.0 
Water       
 
 
Use single use vials of 16% (?)  formaldehyde.  
Dilute to 5% in formaldehyde dilution buffer.  
 
1 M Glycine Solution 
     50 ml  100 ml 
Glycine    3.76g               7.51g 
 
2x Cell lysis buffer 
(1x is 10 mM Tris pH8.0, 10 mM NaCl, 10 mM EDTA, 0.5 mM EGTA, 0.2%NP40 
and protease inhibitors) 
     25 mls   
1M Tris pH8.0   500 l   
5M NaCl     100 l   
10% NP40 or IPEGAL (w/v) 1 ml   
99 
 
 99 
0.5M EDTA 
0.5M EGTA 
Water       
 
10x stock of mini protease inhibitor tablet – 1 tab in 1 ml water. 
 
6 ml of 1x cell lysis buffer: 3 ml of 2x, 600 ul protease inhib stock, 2.4 ml 
water.  
 
2x Nuclei Lysis Buffer 
1x is 50 mM Tris pH8.0, 10 mM EDTA, 0.5% SDS 
     25 mls   
1M Tris pH8.0   2.5 ml   
0.5M EDTA pH8.0   1 ml   
10% SDS    2.5 ml   
 
3 ml 1x nuclei lysis buffer: 1.5 ml of 2x, 300 ul of protease inhibitor stock, 
1.2 ml water. 
 
IP Dilution Buffer 
(12.5 mM Tris pH8.0, 0.19 M NaCl, 0.01% SDS, 1.2% Triton X-100) 
     50 ml  100ml 
1M Tris pH8.0   625 l  1.25 ml 
5M NaCl    1.9 ml  3.8 ml 
10% SDS    50 l  100 l 
10% Triton X-100   6 ml  12 ml 
Water                                                 41.42 ml 
IP Wash I 
(20 mM Tris pH8.0, 0.15 M NaCl, 2 mM EDTA, 0.1% SDS, 1% Triton X-100) 
  50ml  
1M Tris pH8  1 ml  
5M NaCl  1.5 ml  
0.5M EDTA  0.2 ml  
10% SDS  0.5 ml  
10% Triton X-100 5 ml  
Water   41.8 ml 
 
High Salt Buffer 
(20 mM Tris pH8.0, 0.5 M NaCl, 2 mM EDTA, 0.1% SDS, 1% Triton X-100) 
  50 ml  
1M Tris pH8  1  ml  
5M NaCl  5  ml  
0.5M EDTA  0.2  ml  
10% SDS  0.5  ml  
10% Triton X-100 5  ml  
Water    38.3  ml 
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IP Wash II 
(10 mM Tris pH8.0, 0.25 M LiCl, 1 mM EDTA, 1% Nonidet P40, 0.5% sodium 
deoxycholate) 
  50 ml  
1M Tris pH8  0.5 ml  
5M LiCl  2.5 ml  
0.5M EDTA  0.1 ml  
10% Nonidet P40 5 ml  
10% sodium deoxycholate 2.5 ml  
Water  39.4 ml 
 
TE Buffer 
(10 mM Tris pH8.0, 1 mM EDTA) 
  50 ml  
1M Tris pH8  0.5 ml  
0.5M EDTA  0.1 ml  
Water  49.4 ml 
 
Elution Buffer:  prepare fresh (some recommend heating to 65C before use) 
(1% SDS, 0.1 M NaHCO3) 
  10ml  
1% SDS  10 ml  
NaHCO3  0.08 g  
 
 (Easiest: weigh an aliquot of NaHCo3 and add the correct amount of 1% SDS 
solution.) 
 
2.1.12 Co-Immunoprecipitation (Co-IP) for chromatin and whole protein 
cell extract  
Buffer1 
TBS 
0.5% NP40 
15mM MgCl2 
 
Buffer2 (benzonase buffer)  
50mM Tris pH 7.5  
300mM NaCl 
0.5% NP40 
2.5 mM MgCl2 
 
Buffer3 (Dilution buffer)  
50mM Tris pH 7.5  
300mM NaCL 
0.5% NP40 
15mM EDTA 
 
Buffer4 (wash buffer1) 
TBS (TBS has 150mM NaCl) 
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0.5% NP40 
5mM EDTA 
 
Buffer5 (wash buffer2) 
50mM Tris  
5mM EDTA 
0.5% NP40 
300mM Nacl  
 
2x sample Buffer  
4x sample buffer  
10x reducing agent  
Sterile dh2o 
 
2.2 Methods 
2.2.1 ShRNA commercial sequences   
siRNA triggers obtained from Qiagen. The manufacture had siRNA triggers 
for Hmgn1 and Hmgn2 and negative control. It was tested which triggers 
performed better in knockdown. Each trigger was identified by two points: 
the position in the genome and N-scramble (based on HMGN1_3 siRNA target 
sequence) targeted the Hmgn2. For selecting the shRNA we use a web tool 
developed by lab of Greg Hannon. The output was filtered selecting for 
sequence feature experimentally shown to increase the efficiency of RNAi 
processing (Mittal , 2004) as well as for any potential off-target effects using 
a BLAST search for the human genome leaving four putative targets shown 
in table .  
Names  siRNA targets  shRNA sequences  
HMGN1_2 5’CACTGGAACA
AGTTCAAAGAA 
3’ 
5’AGCGCACTGGAACAAGTTCAAAGAATGATATG
TGCATTCTTTGAACTTGTTCCAGTG -3’ 
3’GTGACCTTGTTCAAGTTTCTTACTATACACGT
AAGAAACTTGAACAAGGTCACACGG -5’ 
HMGN1_3 5’TTGTGATAAT
GTGCTGTGAAA 
3’ 
5’- 
AGCGTTGTGATAATGTGCTGTGAAATGATATGT
GCATTTCACAGCACATTATCACAA -3’  
3’AACACTATTACACGACACTTTACTATACACGTA
AAGTGTCGTGTAATAGTGTTACGG -5’ 
HMGN2_1 5’CAGATTGATA
ATTCTGCCTAA 
3’ 
5’AGCGCAGATTGATAATTCTGCCTAATGATATG
TGCATTAGGCAGAATTATCAATCTG -3’ 
3’GTCTAACTATTAAGACGGATTACTATACACGT
AATCCGTCTTAATAGTTAGACACGG -5’ 
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HMGN 
scramble  
5’GGTATAGTAC
GGTTTAGATAT 
3’ 
5’AGCGGGTATAGTACGGTTTAGATATTGATATG
TGCAATATCTAAACCGTACTATACC -3’   
3’CCATATCATGCCAAATCTATAACTATACACGTT
ATAGATTTGGCATGATATGGACGG -5’ 
Table  2.1 the list of selected target sequence 
The number of each target ID indicate the position of the first nucleotide 
with respect to the Hmgn1 and Hmgn2 coding sequence from Qiagen 
manufacture.  
Plasmid pGIPZ is constitutive Lentiviral system that can knockdown gene 
for long time (Figure 3.20A). Five Lentiviral pGIPZ plasmids: Three 
triggers for Hmgn2 gene, one negative control (non-silencing), and two 
positive control GAPDH and EG2 were performed in E14, P19 and Hepa 
cell lines (Figure 3.20 B). Moreover, the potential off target effect were 
performed using BLAST search of mouse RNA-seq database leaving 
putative targets of Hmgn2 and some pseudogenes. The selected RNA 
prediction gene targets were selected based on E value 0.039(the 
number of hits for particular size the lower E-value the more significant 
a match to the database sequence and very small probability to have 
match by chance) coverage 100%, and identification 100%.    
 
 
target ID                       shRNA
sequence 
(19 nt) 
RNA-seq targets TARGE
T 
shRNAmir 
type 
V3LMM_48038
1  
Mature 
Antisense 
TAGCAGAC
AACCTCGC
AGA 
predicted gene 10357 (Gm10357), 
misc_RNA 
predicted gene 6750 (Gm6750), 
misc_RNA 
predicted pseudogenes 7931 
(Gm7931), misc_RNA 
predicted gene 10357 (Gm10357), 
misc_RNA 
high mobility group nucleosomal 
binding domain 2 (Hmgn2), mRNA 
ORF 
 
GIPZ/TRI
PZ 
 
 
 
 
 
 
V3LMM_51696
8  
Mature 
Antisense 
GTTACTGA
CACATGAT
CCT 
 
predicted gene 10357 (Gm10357), 
misc_RNA 
predicted pseudogenes 7931 
(Gm7931), misc_RNA 
predicted gene 10357 (Gm10357), 
misc_RNA 
3’UTR  
 
GIPZ/TRI
PZ 
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high mobility group nucleosomal 
binding domain 2 (Hmgn2), mRNA 
V2LMM_55514  
Mature 
Antisense 
ACAATCAT
GGTATTTC
AGG 
predicted pseudogenes 7931 
(Gm7931), misc_RNA 
high mobility group nucleosomal 
binding domain 2 (Hmgn2), mRNA 
3’UTR GIPZ/TRI
PZ 
N2-1 mature 
antisense  
(Qiegen)1 
5’CAGATT
GATAATTC
TGCCTAA 
3’ 
Mus musculus predicted gene 
10357 (Gm10357) 
Mus musculus predicted 
pseudogene 7931 (Gm7931) 
Mus musculus predicted gene 
10357 (Gm10357) 
Mus musculus high mobility group 
nucleosomal binding domain 2 
(Hmgn2) 
3’UTR TRIPZ 
only 
Table  2.2 the list of selected target sequence 
The number of each target ID indicate the position of the first nucleotide 
with respect to mRNA of Hmgn2 coding sequence in pGIPZ and pTRIPZ  
 
 
 
2.2.2 Plasmids construct (pSLIK, pGIPZ and pTRIPZ) 
2.2.2.1 The construct of pEN-shRNA-Hmgn_(pSLIK-CD4)  
Schematic Construct of pEN-TGRmiRc3-Hmgn2-1-(pSLIK-CD4-expression 
vector) from pENTR-TGmiRC3 and pSLIK-CD4 after gateway system was 
performed to generate Lentiviral knockdown gene using RNAi system 
(shRNAmir30). pSLIK-CD4 vector is tet-regulatable expression system of 
shHmgn2miR-30. it  carries GFP and shRNAmir under the control of TRE 
promoter which can be activated under Doxycycline binding to rtTA3 (Tet-
on/off system). Ubi-C promoter regulates CD4 , rtTA3 , and IRES which 
allows multisictronic transcript and drive the constitutive expression of  the 
vector. Adding the human miR30 sequence between shHmgn ensured the 
expression specificity of Hmgn. pSLIK has another feature which can be 
constitutive system instead of inducible by changing the selection marker 
(CD4). 5=-long terminal repeat; FLAP, DNA flap region consisting of a central 
polypurine tract and a central termination sequence; TRE, tetracycline 
responsive element; Ubi-c, ubiquitin C promoter; rtTA3, reverse 
                                         
1
 Target ID N2-1 sequence trigger was designed by quiegen company  
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tetracycline transactivator 3; Hygromycin, hygromycin-resistance gene; 
WRE, woodchuck hepatitis virus response element; 3=SIN LTR, 3=-self-
inactivating long-terminal repeat. 
 
 
 
 
Vector Elements  Terminology  Function  References  
Expression elements 
TRE promoter  Tetracycline 
responsive 
element 
Inducible Promoter controls the 
tTA transactivator that 
mediates the transgene 
expression.  
(Pan et. al., 
2008 and 
Hioki et. 
al., 2009)  
GFP reporter 
gene  
Green fluorescent 
protein  
Reporter gene for visualized the 
transfected cells.  
(Hioki et al, 
2009)  
5’ and 3’ miR30 Micro-RNA 30  Increasing the RNAi knockdown 
efficiently at protein level  
(Stegmeier 
et al., 2005)  
shRNA  Short hairpin RNA  RNAi technology for gene 
silencing.  
(Song and 
Yang, 2010) 
UBC-I promoter  Ubiquitin C 
promoter 
Allow the high expression of 
transgene  
(Schorpp et 
al, 1996) 
rtTA3 Reverse 
tetracycline 
transactivator 
Fusion protein interacts with 
Dox deriving the gene 
expression.  
(Sisson et 
al., 2006) 
IRES  Internal ribosome 
entry site 
Translational initiation from an 
internal region of the mRNA 
(Ibrahimi et 
al, 2009) 
Delta CD4  Cell surface 
marker  
Cell surface protein able to 
detect the transfected cells 
without affecting the cell 
function  
(Cooray et 
al, 2012) 
Lentiviral elements 
WRE Woodchuck Post-transcriptional regulatory (Zufferey et 
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hepatitis virus 
response element 
element stimulates the 
expression of transgene via 
increase the nuclear export.  
al., 1998) 
SIN/LTR 3′-self-inactivating 
long-terminal 
repeat 
Help insertion mutagenesis, 
integration site selection, and 
the potency of transgene 
expression 
(Xu et al., 
2011)  
CMV/LTR 5′LTR, 5′-long 
terminal repeat 
Drive a high level of expression  (Miyoshi et 
al.,1998) 
PSI Retroviral Psi 
packaging element 
Serve as the site of initiation of 
positive-strand DNA synthesis 
during reverse transcription 
(Warnock et 
al.,2011) 
RRE HIV rev responsive 
elements 
Essential for viral replication 
and serve as RNA scaffold that 
help to assemble the RNP 
complex to regulate the nuclear 
export of viral massage  
(Fernandes 
et al., 2011) 
FLAP  FLAP, DNA flap 
region consisting 
of a central 
polypurine tract 
and a central 
termination 
sequence 
 
Enhance the HIV-1 infection by 
assessing nuclear import of 
proviral DNA and it can protect 
the viral DNA.  
(Kankia and 
Musier-
Forsyth, 
2006) 
Cloning elements 
Ori  Open reading 
frame  
Encode no more than 15 
proteins that involved in the 
viral life cycle including 
structural and regulatory 
proteins  
(Tiscornia et 
al.,2007) 
Amp  Drug resistance 
ampicillin  
Antibiotic bacterial selection  (shin et 
la.,2006) 
 
Figure  2.1 lentivirus plasmid map within PSLIK system as destination vector 
flanked by att recombination sites 
PSLIK as backbone contains CMV/LTR (polymerase II) promoter, GFP a 
reporter gene to mark shRNAmir expression, rtTA3 tetracycline antiduction 
(TET system) or tetracycline responsive gene expression to allow 
construction of stable helper cell lines that produce pseudotyping VSV-G. A. 
pSLIK-CD4/mmHmgn plasmid map the production of gateway cloning system 
between pSLIK and pEN vectors. B. table describe the elements and their 
function in pSLIK-CD4 plasmid map. Schematic Construct of pEN-TGRmiRc3-
Hmgn2-1-(pSLIK-Hygromycin-expression vector) from pENTR-TGmiRC3 and 
pSLIK-Hygromycin after gateway system was performed to generate 
Lentiviral knockdown gene using RNAi system (shRNAmir30). TRE, 
tetracycline responsive element; Ubi-c, ubiquitin C promoter; rtTA3, 
reverse tetracycline transactivator 3; Hygromycin, hygromycin-resistance 
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gene; WRE, woodchuck hepatitis virus response element; 3=SIN LTR, 3=-self-
inactivating long-terminal repeat. 
 
 
2.2.2.2 The construct of constitutive pGIPZ Hmgn2 knockdown in P19 and 
Hepa cells lines   
Experimental process to generate viral particles containing Hmgn2 miRNAs, 
were performed using open biosystem procedures protocols for pGIPZ viral 
production. The viral particles were generated in the packaging HEK293T 
clone 17 cell lines (Figure 3.21). The plasmids were received from Open-
biosystem and they were cloned into competent cells (DH5alpha); then midi 
DNA purification was performed.  
 
 
Figure  2.2 schematic diagram illustrating the expression cassette encoded by pGIPZ 
lentiviral vector 
Bi-cistronic element (IRES) transcript encoding green florescent proteins 
(GFP) and puromycin drug selection and shRNAmir driven by CMV promoter. 
Abbreviation: IRES, internal ribosome entry elements; WRE, woodchuck 
response element; LTR, long terminal repeats; puro, puromycin.  
 
 
2.2.2.3 Construction of inducible Hmgn2 knockdown in P19 and Hepa cell 
lines 
Based on preliminary studies, Hmgn2 knockout in mice embryo is lethal. This 
indicates that constitutive system could cause cell toxicity and high rate of 
cell death before and after drug selection. Therefore, it was thought that 
inducible system could reduce the cell toxicity and could gain high Hmgn2 
knockdown efficiency.  
This section describes the steps that undertaken in order to generate P19 
cell lines with Hmgn2 knockdown using inducible system called TRIPZ from 
open bio-system. Four TRIPZ inducible shRNAs sequence triggers in addition 
to two each negative and positive controls were used in this experiment. 
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The same sequence triggers were used in GIPZ and TRIPZ experiments 
except N2-1 was used on only TRIPZ system. GIPZ plasmids were received 
from Open-biosystem and they were cloned into competent cells 
(DH5alpha); then midi DNA purification was performed. shRNAmir sequence 
triggers of GIPZ were cloned into empty TRIPZ vector. TRIPZ empty vector 
was gifted from Dr. Peter Adam. Moreover, the same process was performed 
on pSLIK shRNAmir sequence triggers cloned into TRIPZ system.  
Experimental processes to generate viral particles were generated in the 
packaging HEK293T clone 17 cell lines (Figure 3.11).  
 
 
Figure  2.3 schematic diagram illustrating the expression cassette encoded by pTRIPZ 
lentiviral vector. 
TRIPZ inducible system contains two parts. First part is constitutive system 
derived by UBC promoter. This constitutive part consists of Bi-cistronic 
element (IRES) and rtTA3 element following Puromycin drug selection. The 
second part if inducible, which only can be activated by supplying the 
medium with Doxycycline, contains RFP and shRNAmir derived by TRE 
promoter.  Abbreviation: IRES, internal ribosome entry elements; WRE, 
woodchuck response element; LTR, long terminal repeats; puro, puromycin.  
 
 
 
The lentiviral miRNA constructs targeted against Hmgn2 and Hmgn1 were 
purchased from Open Biosystems in the constitutive pGIPZ vector system, 
and cloned into the inducible pTRIPZ vector system. (pTRPZ kindly provided 
by Dr. Peter Adams’ lab). in addition, the shRNAs that were used in previous 
vector pSLIK –CD4 were cloned into empty pTRIPZ vector. The control virus 
used was pGIPZ and pTRIPZ containing a shRNA toward turboGFP and 
turboRFP (open biosystems). 
 
 
 
 
 
108 
 
 108 
2.2.3 Cloning reagents and purification kits  
2.2.3.1 Gateway cloning technology for pSLIK  
2.2.3.1.1 Introduction to Gateway cloning technology 
 
In order to study the structure and the function of genes, having those gene 
cloned into expression vector is essential. Gateway cloning reactions are 
based on recombination reaction, which depends on the integration and 
excision of lambda bacteriophages. Integration is reversible reaction and it 
involves two enzymes: BP clonase and LR clonase. BP stands for attB (PCR 
product or expression clone) × attP (donor vector) recombination whereas 
LR stands for attL (entry clone) × attR (destination vector) recombination 
(Figure 3.2)  
 
 
Figure  2.4 the Invitrogen Gateway recombination cloning technology 
 
Briefly, BP clonase reaction is mediated by phage protein integrase (Int) and 
bacterial protein integration host factor (IHF) (Walhout et al., 2000). This 
reaction uses the lysogenic pathway of lambda bacteriophages to create the 
attL and attR reaction. On the other hand, LR clonase reaction, Invitrogen 
kit (cat no, 11828-029), uses the lytic pathway of lambda bacteriophages. 
They have been used for the cloning of recombinant DNA which can be 
activated using enzymes binding to specific sequence called ( att sites ) 
(Figure 3.1) .  The lytic pathway can be activated by recombination pathway 
of bacteriophage lambda Int, excisionase (Xis) protein, integration host 
factor (IHF) protein and protein integrase  (life technology manual sheet 
version 2011 and Walhout et al, 2000). 
The advantages of applying the Gateway technology is that it is very flexible 
due to the fast and easy way to transfer the gene of interest from one 
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vector to another. The reaction is Very fast reaction and under time 
management for less than an hour at room temperature. Moreover, this 
reaction does not required restriction enzyme, ligation, gel purification or 
re-sequencing. Furthermore, the reaction maintains the open reading frame 
of the E-coli genome. It uses site-specific recombinase to recombine the 
DNA plasmids. Gateway technology can clone multi-site to assemble many 
reporter transgenes (Walhout et al, 2000 and Spitzer et al, 2013).  
2.2.3.1.2 Gateway LR clonase reaction process 
 
LR ClonaseTM II enzyme (Cat. No. 11791-020) mix is supplied as a 5X 
solution and 100 ng (2 μl) of pENTRTM-gus was used as control for the 
reaction. (50-150 ng) from Entry clone and 150 ng/μl from destination 
vector were added to 1 μl of TE buffer under pH of 8.0. Then LR clonaseTM 
II enzyme was thawed and vortex on ice for two minutes. Next each mixture 
of destination and entry vector, a 2 μl of LR clonaseTM II enzyme was added 
and mixed with reaction by briefly vortexing or microcentrifuge for two 
times. After using LR clonaseTM II enzyme mix, turning the LR clonaseTM II 
enzyme mix to -20° or -80° degree would maintain the efficiency of the 
enzyme. The reaction should be incubated at 25° degree for 1 hour 
following an addition of 1 μl of the proteinase K solution to each sample to 
stop the reaction. Finally, vortex the reaction briefly would ensure the 
homogeneity of the reaction following an incubation sample for 10 minutes 
at 37°C.  
2.2.3.1.3 Transformation  
 
After LR clonase reaction occurs between entry and destination vectors, 
transforming 1 μl this reaction is applied through 50 μl of phage resistant 
cells (One Shot® OmniMAXTM 2 T1 Phage-Resistant Cells (Catalog no. C8540-
03)). The reaction with phage cells were Incubated on ice for 30 minutes; 
then, Heat-shock used for the cells by incubating at 42°C for 30 seconds. 
250 μl of S.O.C. Medium was added into the cells and they were incubate at 
37°C for 1 hour under shaking machine. 20 μl and 100 μl of each 
transformation were plated into selective plates.  
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It is important to note that any competent cells with a transformation 
efficiency of >1.0 × 108 transformants/μg may be used for clone screening.  
Moreover, 1 μl of pUC19 DNA (10 ng/ml) was transformed into 50 μl of One 
Shot® OmniMAXTM 2 T1 Phage-Resistant Cells as transformation control as 
described above. 20 μl and 100 μl were plated on LB plates containing 100 
μg/ml ampicillin. In order to generate pSLIK-shRNAmir30-CD4 and pSLIK-
shRNAmir30-hygromycin, the experimental strategy from life technology 
manufacture explained the process (Figure 3.6, B).  
 
 
 
Figure  2.5 Diagram shows from a-f the development of the expression clone system 
using LR reaction from gateway technology 
A. Is a portion of destination vector contains ccdB which required for LR 
gateway reaction. This destination vectors contains two genes ccdB and 
chloramphenicol (CmR) flanked by attL sequences.  Expression ccdB gene is 
lethal to cells that carry this vector. The reason is that ccdB gene encodes 
for a toxin targeting DNA gyrase. B is shRNA cloning into ccdB site using 
restriction enzyme Bsal. C is ligation and D. PCR amplification and check 
sequences are preformed to generate a destination vector contains shRNA 
and attL sequences for gateway cloning reaction. E. LR clonase reaction F. 
generating the entry vector with shRNA using LR clonase reaction.  
 
2.2.3.1.4 Bacterial transformation  
 
Transformation reactions use bacterial cells to amplify the DNA of interest 
and the competent cells (DH5alpha) which are able to take up foreign DNA 
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and acquire the new genetic information. DH5alpha is an ordinary E. coli but 
it requires treatment with calcium ions to be made into a competent cell. 
This cell has a very fragile cell wall and must be handled gently. During the 
transformation reaction the competent cells can be combined with ligation 
product and incubated on ice. DNA sticks to the outer cell walls, the heat 
shocked membranes become more porous and allow DNA to enter but not all 
the competent cells will take in the DNA, so the frequency will be 
determined. Then, the cells are incubated in LB broth at 37 degree 
centigrade overnight and this will allow transcription and translation of 
ampicillin resistance genes. PUC19, which is used as positive control, is a 
genetically engineered plasmid. It has a 2.7 kb and circular non-genomic 
DNA. The source of PUC19 plasmid is PBR322, but PUC19 differs from 
PBR322 by two point mutations. The chromosomal genotype of PUC19 is: 
fhua2Δ (argF-lacZ) U169phoAglnV44Q80Δ (lacZ) 
M15gyrA96recA1relA1endA1thi-1hsdR17 (figure 8). 
 
 
 
 
Figure  2.6 the PUC19 vector map 
Adapted from: 
http://www.atcc.org/ATCCAdvancedCatalogSearch/ProductDetails/tabid/4
52/Default.aspx?ATCCNum=37254&Template=vectors 
 
PUC19 contains: (1) PMB1 replicon responsible for replication of the 
plasmid. The high copy number of PUC plasmid is a result of the lack of the 
rop gene and a single point mutation in rep of PMB1; (2) bla gene, coding for 
beta lactamase that confers resistance to ampicillin; (3) region of E-coli 
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operon lac containing CAP protein binding site, promoter place, lac 
repressor binding site and 5’-terminal part of the lacZ gene encoding the N-
terminal fragment of beta-galactosidase. The LacZ gene is a part of the lac 
operon, which encodes the beta-galactosidase enzyme that breaks down 
lactose into glucose and galactose. The polylinker cloning site (MCS) within 
the lacz gene contains a recognition sequence for several restriction 
enzymes and inactivates the N-terminal fragments of beta-galactosidase and 
abolishes alpha-complementation. The genotype of PUC19 showed the most 
useful mutation. These mutations were: 
• EndA1 mutation which can inactivate an intracellular endonuclease 
that degrades plasmid of DNA in many miniprep methods (plasmid 
purification DNA). 
• HsdR17 mutation that can eliminate the restriction endonuclease of 
the ECOR1 restriction modification system so that methylated DNA 
from LacZ will not be degraded. 
• Δ(LacZ)M15 is an alpha-acceptor allele which means that proteins 
with the alpha acceptor inactived dimer are much less stable as 
measured by their ability to act as alpha acceptor after heat 
treatment. Therefore, it is needed for the blue-white screening for 
recombinant cells; 
• RecA1 can eliminate homologous recombination. This can make the 
strain sticky but reduces deletion formation and plasmid 
mutimerization; in other words, it reduces homologous recombination 
for a more stable insert; 
• GlnV44 is an amber suppressor. This means that tRNA suppressor is 
often caused by changes in the anti-codon loop of tRNA to allow 
recognition of a stop codon. Due to the wobble rules, the amber 
suppressor is specific for amber (UAG) codons.  
The possible products, which may result from the transformation reaction 
are: plasmid with insert but no functional LacZ; plasmid without insert but 
with functional LacZ, or no plasmid as well as no LacZ gene. After the plates 
were left overnight in a 37 degree Centigrade incubator, the calculation 
transformation efficiency was performed following this equation provided by 
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using the Subcloning efficiency DH5alpha kit: 
Transformation efficiency (# transformants/ug DNA) = # of colonies / pg 
PUC19 
DNA * 10(6) PG/ug * volume of transformants/ Xul plated * dilution 
factor 
 
2.2.3.1.5 Plasmid purification  
 
Plasmid DNA purification from E. coli is a core technique for molecular 
cloning.Small scale purification (Miniprep) from less than 5 ml of bacterial 
culture is a quick way for clone verification or DNA isolation, followed by 
further enzymatic reactions (polymerase chain reaction and restriction 
enzyme digestion). Here, we video recorded the general procedures of 
Miniprep through the QIAGEN QIAprep 8 Miniprep Kit, aiming to introducing 
this highly efficient technique to general beginners for molecular biology 
techniques. The whole procedure is based on alkaline lysis of E. coli cells 
followed by adsorption of DNA onto silica in the presence of high salt. It 
consists of three steps: 1) preparation and clearing of a bacterial lysate, 2) 
adsorption of DNA onto the QIAprep membrane and 3) washing and elution 
of plasmid DNA. All steps are performed without the use of phenol, 
chloroform, caesium chloride, ethidium bromide, and without alcohol 
precipitation. It usually takes less than 2 hours to finish the entire 
procedure, screening the purified DNA using restriction digest enzymes and 
using the plasmid editor to show the size of expected band for each 
plasmid. 
2.2.3.1.6 Checking the plasmid clone using Electrophoresis reagents and 
restriction enzymes  
 
Gel electrophoresis experiment is very important step to check the plasmid 
restriction site. The samples were prepared as following: First, the total 
digest each sample is 40 μl divided into: 1 μl of enzyme (Kpn1 and ECOR1), 4 
μl of the expected buffer, 1 μl BSA (depend on the enzyme reaction), 1-2 μg 
of DNA, and the rest of 40 μl amount was filled with distilled water. 1% gel 
in 120 ml buffer TAE 1x was used to prepare the gel (agarose gel 1.2 g in 
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TAE buffer 1x =120 ml). The gel was poured into 100 ml plate and 2 μl of 
dye was added to the gel to visuals the expected band. In addition, the 
sample was prepared by adding 4 μl of bromophenol (BPB), which can digest 
lower than 300 bp.. Loading the samples beside 1 kb and 100 bp of DNA 
ladder.  
Note:  
For restriction sites:  
Use APE plasmid editors to estimate the digest size.  
Then, you add buffer 1 = 4ul , BSA= 1ul , DNA x (1ug-2ug) , KpN1 or/ ECORI 
=1ul,  H2O= x in 40ul total amount.  
 
2.2.4 Lentivirus protocol  
2.2.4.1 The Production of lentivirus vectors for pSLIK  
For viral transfection, 293T/17 cell line was used and it was plated in 10cm 
dish. The transfection divided into three parts:  
The first part is that plating the 293T/17 cell line at passage 2 into 10cm 
dish as passage 0 before the day of transfection. Lipofectamine 2000 
(invitrogen; cat no, 11668-019) was used as transfection reagent, which is a 
Cationic lipid, and diluted in Opti-MEM® I Reduced Serum Medium (Cat. no. 
31985-062). Following the lipofectmine protocol and the amount of 
packaging vectors (pMCL/pRRE (7.5ug), pRSV-REV (7.5ug), and pCMV-VSV-g 
(5ug) from the literature (shin et al., 2006) as well as 10ug of recombinant 
vector pSLIK-shRNA-HMGN-miR30. Then the mixture of media, DNA and 
packaging vectors were added into 293T/17 cells with ultraculture media 
(Lonza cat no g1234) and it had been left for 48 hours as protocol 
recommend (figure: 4, part1).  
The second part is the freezing and transducing the target cells. The viral 
supernatant within the media was centrifuged for 10 minutes at 13,000 rpm 
to remove any cell from the media. Then, the supernatant was filtered via 
minisart syringe filter. Finally, aliquot 1ml of the lentivirus particles in 
eppendorf tube and apply a snap freezing by throwing the tubes into liquid 
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nitrogen and freeze them down in -80 or transduced target cells with fresh 
lentivirus particles.  
The third part of the lentivirus process is optimizing the viral particles 
dilution factor. Making a dilution of viral particles on 96 well plates then the 
viral particles diluted was transferred to 24 well plates. These 24 well plate 
contained target cells (P19 cell lines) and another 24 well plate with 
293T/17 cell to compare the viral particles amounts. The main purpose of 
making this step is to measure the MOI (multiplicity of infection) of the 
target cells. As it showed on the scheme after 4-hour incubation with only 
the virus particles the 24 wells was completed with normal DMEM for 
293T/17 cell lines and alpha-MEM for P19 cell lines media. Then after 24 
hr., the cells were observed under the florescent microscope to detect the 
transduced cells (green cells) from non-transduced cells.  
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Figure  2.7 generating the lentiviral particles 
Part1 shows the viral production preparation and the amount of packaging 
and recombinant vectors. Part2 shows the generating the viral particles and 
freezing down the viral particles.  
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2.2.4.2 The Production of Lentivirus vectors for pGIPZ and pTRIPZ  
2.2.4.2.1 Structure of the viral vectors 
 
pGIPZ: The short hairpin RNA constructs are expressed as human microRNA-
30 (miR30) primary transcripts. All vectors contain the turboGFP coding 
sequence located in the middle of the lentiviral vector. miRNA and tGFP 
sequences are driven by human cytomegalovirus (hCMV) promoter and 
terminates using the 5` long terminal repeat (5`LTR). Downstream of tGFP 
is woodchuck hepatitis virus regulatory element (WPRE) that enhances the 
expression of transgene. pGIPZ also expressed the gene for puromycin 
resistance. 
pTRIPZ: The human ubiquitin C promoter (UBC) drives constitutive 
expression of reverse tetracycline-transactivator 3 (rtTA3). Addition of 
doxycycline activates rtTA3, which activates the tetracycline-responsive 
element (TRE) promoter that drives miRNA and turboRFP expression. The 
puromycin resistance gene is consitutively expressed.  
2.2.4.2.2 Virus production  
 
The recombinant Lentivirus was produced by cotransfection of vectors and 
calcium phosphate (TLP5913) reagents in HEK293T/17 cells. The component 
of the translentiviral pGIPZ and pTRIPZ packaging systems was designed to 
enhance the biosafety and increase the level of shRNA expression. This 
packaging system contains pTLA1-Pak (packaging protein), pTLA1-enz (viral 
particles), pTLA1-Env (envelop protein), pTLA1-Rev (transporter protein) 
and pTLA1-TOFF (transactivator protein binds to TRE promoter). 
The first Lentivirus experiment was done on 9/05/2012 using open 
biosystems protocol on 6 well plates.  
2.2.4.2.3 Producing the Lentiviral particles in HEK293T/17 cells  
 
The experiment begins using the human embryonic kidney 293 cells from 
clone 17 (HEK293T/17). These cells contain the SV40 T antigen which is 
important for increasing the efficiency of Lentivirus production. When 
Calcium chloride combined with DNA and co-precipitated by adding the 
118 
 
 118 
phosphate buffer, it can increase the uptake of DNA in transformed, 
293T/17 cells.  
A. Cell plating:  
1.2*10(6) cell/well 293T/17 cells were prepared in one well of each 6-well 
plate with 2ml full media with serum for each transfer vector to be 
packaged into Lentiviral particles. Then, the cells were Incubated at 37°C 
with 5% CO2 overnight. 
B. Transfection 
 CaCl and 2X HBSS were brought into a room temperature after thawing 
them for transfection step.  
Each well of a 6-well plate was already indicated the quantity of DNA 
plasmid and Trans-Lentiviral packaging mix in 15 ml polystyrene tube. 
Sterile water was used to bring DNA mix to the indicated total volume as it 
showed in the table.  
 
 Lentivirus Transfer 
Vector DNA (shRNA or 
ORF) 
Trans-Lentiviral 
Packaging Mix 
Total Volume 
(With sterile 
water) 
One well of 
a 6-well 
plate 
8μg 4.3μL To 135μL 
 
The volume of CaCl was indicated for each 6 well plate by adding 15ul into 
the DNA assembled above. The tubes were vortexed at a speed sufficient to 
thoroughly mix reagents without spillover. While running the sample into 
the vortex, a drop wise of indicated 2X HBSS was added 150 μL in One well 
of a 6-well plate. The tubes were incubated at room temperature for 3 
minutes. A chalky precipitate should appear with time. The total volume is 
300 μL of transfection mix was added drop-wise into the cells and the cell 
was checked with medium once you add a drop of the Lentivirus mix.    
Cells were incubated at 37 C with 5% CO2 for 10-16 hours. After 16 hours of 
incubation, examine the cells microscopically for the presence of a 
fluorescent reporter protein, such as TurboGFP.  
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The media was changed to ultracultural- serum free media from lonza 
(BE12-725F). The cells with serum free media were left from 36-48 hrs.  The 
supernatant was collected to proceed the Lentivirus concentration using 
Millipore (Amicon ultra-15 centrifugal filter device). 
 
C. Viral Particle Collection and Concentration 
 After 48 hours incubation time with ultraculture medium the supernatant 
was taken from the host cell (293T/17). The supernatant was centrifuged at 
8000 rpm for 15 min. Then, the supernatant was filtered via 0.22 or 0.45 um 
ministrant filter (low protein binding). To obtain high transfection efficiency 
for the target cells (P19 EC cells) several experiments were performed:  
 
Amicon ultra-15 centrifugal filter device 
For concentration, the filtered supernatant was poured into an Amicon 
ultra-15 centrifugal filter device (Millipore).The device was centrifuged at 
40,000 rpm for 20min at 4 degree. 
 
Lenti-x Geostix  
Following the manufacture protocol, 20 μl was taken from prepared 
lentiviral supernatant and was applied to the sample well of the GoStix 
cassette. Next, 3 drops of Chase Buffer was added to the sample well. Then 
a few moments was spent in incubation for the bands to develop. a test 
band called (T) will start to appear within 5 min and reach maximum 
intensity at 10 min if the target sample contains sufficient lentivirus. 
 
Transdux and Polyberen  
To enhance the transfection reagents, transfection reagents called 
polyberen and transdux was used on P19, E14 and 293T/17 cells that will be 
transduced with the pGIPZ- GAPDH (positive control) lentivirus system and 
pSLIK-hygromicine (N-scramble) (negative control). Figure 2 showed a 
lentivirus serial dilution on P19, E14 and 293t/17 cells with set of polyberen 
and transdux on each well. Sadly there were no GFP expressed on neither 
293T/19 nor P19 and E14. Moreover, this experiments was used the pTRIPZ 
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(inducible system) after 72hrs doxycycline treatment but did not show any 
expression of RFP cells.  
Following the manufacture protocol from system bioscience after viral 
particle collection day and before the transduction day, 50,000 cells per 
well were plated in a 24 well plate in cell culture medium. The next day 
Cells should be between 50 to 70% confluent. 7*10(4) cell/well 293t/17 and 
8*10(4) cell/well p19. Medium was aspirated from cells. culture medium 
with TransDux or Polyberen were combined to a 1X final concentration.for 
example, 2.5 μl of TransDux was added to 500 μl culture medium and then 
transfer to each well. The virus was added to each well and swirl to 
mix.Optional step, increasing amounts of virus was added to different wells 
at varying MOIs (5, 10 and 20, etc.) to optimize the transduction. 
Applying the Transdux protocol from system bioscience on p19 and 293t/17 
failed to work using neither GIPZ nor TRIPZ with transfection reagents. 
However, 293t/17 worked well after 24 hr transfection using GIPZ (LV) in 
both transfection reagents whereas the TRIPZ (LV) with transfection 
reagents on 293t/17 did not work even after 72 hr with Dox 1ug/ml 
treatments.  
Lenti-X concentrator  
L.V containing supernatant pool similar stocks was harvested and 
Centrifuged briefly for 500x for 10 min or filter via 0.45 um filter. Then,   
clarified supernatant was transferred to a sterile container and combines 1 
volume of Lenti-x concentrator with 3 volumes of clarified supernatant. 
Next, these supernatant was gently mixed by inversion and larger volumes 
may be accommodated via the use of larger centrifuge tubes. the mix was 
incubated at 4 C for 1 hr ( but if the amount >100 ml make it O/N) and it 
was Centrifuged at 1500 X g for 45 min at 4 degree. After the 
centrifugation, the sample will be visible as an off white pellet. Then, 
supernatant was removed carefully without disruption the pellet. The 
supernatant can be removed by either pipette tip or by brief centrifugation 
at 1500x g. the pellet was re-suspended in 1/10 to 1/100 of the original 
volume using complete DMEM or PBS or TNE ( note: Recommended to be in 
ultraculture (serum free media).  Titre immediately the sample or store at -
121 
 
 121 
70 degree in single use aliquots.  pGIPZ and pTRIPZ are the target cells were 
plated into 12 well plate. A serial dilution 10x was made and was added into 
the 12 plates from column 2 to 4 the first column was added nude virus 
500ul for 24 hr and then adds to normal media with full serum. You add 
500ul normal media and 500ul from LV supernatant. 1/10 – 1/100 – 1/1000 – 
1/10,000.   
Lenti-X™ p24 Rapid Titer Kit 
To ensure that the lentivirus have a high titration and can be efficient for 
any cells types. A titration kit from clone tech was used to measure the 
titration of lentivirus particles using ELISA machine. Following the 
manufacture protocol, first step is to Preparing Dilutions for the p24 
Standard Curve: 
Samples were tested quantitatively and determined accurate virus titers, 
the test sample was needed  to prepare a p24 standard curve (0–200 pg/ml).  
A working strength p24 positive control stock solution was prepared by 
diluting 20 µl of the p24 Control (10 ng/1. ml) into 980 µl of fresh complete 
tissue culture medium (e.g. DMEM containing 10% FBS), for a 1:50 dilution.  
200 pg/ml was generated as stock solution. 200 pg/ml stock was used and 
tissue culture medium was completed as the diluent. A series of four addi-
tional standard dilutions of 100, 50, 25, and 12.5 pg/ml was made and 500 
µl of media was dispensed into each of four labelled tubes. 500 µl of the 200 
pg/ml stock was added into the 100 pg/ml tube, mix, and using a fresh 
pipet tip, 500 µl of this 100 pg/ml solution was transferred into the 50 
pg/ml tube and mix. Similar transfers were prepared similarly for the 25 
and 12.5 pg/ml tubes. 
 
 
Sample data for standard curve  
Standard 
(pg/ml) 
Absorbance 
(450nm) 
   
A B Mean 
value 
Standard dev. CV% 
12.5 0.082 0.061 0.072 0.015 20.6 
25 0.154 0.201 0.178 0.033 18.5 
50 0.395 0.354 0.374 0.030 7.9 
100 0.817 0.913 0.865 0.069 7.9 
200 1.429 2.146 1.787 0.507 28.4 
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Second step of the protocol is to Assaying the Lentiviral Supernatants:  
All reagents were allowed to reach room temperature (18–25°C). A 
sufficient number of 8-well strips were selected to accommodate all 
standards, test specimens, controls, and complete culture medium blanks 
(negative controls) in duplicate. 20 µl of lysis was dispensed buffer into 
each well. 200 µl of each standard curve dilution was dispensed with 
supernatant sample, and culture medium into appropriately labeled 
duplicate wells. The samples were 37(±1) °C for 60 (±5) minutes. sample 
contents of the wells was removed , and washed the microtiter  plate 100 µl 
of Anti-p24 (Biotin conjugate) detector antibody was distributed into each 
well. The sample was Incubated at 37(±1) °C for 60 (±5) minutes. The 
detector antibody was removed from the wells, and washed the microtiter 
plate. 100 µl of Streptavidin-HRP conjugate was added into each well. The 
samples was Incubated at room temperature (18–25°C) for 30 (±5) minutes. 
The conjugate was removed from the wells, and washed the microtiter 
plate. 100 µl of Substrate Solution was immediately distributed into each 
well with multichannel pipette. Plate was protected from direct sunlight, 
and incubated at room temperature (18–25°C) for 20 (±2) minutes. The 
reaction was stopped by adding 100 µl of Stop Solution to each well 
including the culture medium blanks. Solution color will change to a uniform 
yellow color without air bubbles and the content dry. After adding the Stop 
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Solution, the absorbance values were detected at 450 nm using a microtiter 
plate reader blanked on the negative control well. 
Table 1 showed lentivirus particles that were used and results of each 
sample at wavelength 450 as protocol suggested. Some of the samples were 
concentrated first before measuring the titration. The results, which were 
identified with ELISA machine, did not show any low titration values, but it 
gave no results because the values were higher than the wavelength level.  
 
pTRIPZ , pSLIK-hygromycine and pGIPZ titration kit 
Sample  Values Results Mean-
results 
Stand. 
Dev. 
CV% 
pTRIPZ-GAPDH 3.544 390.437 390.437 0 0 
pGIPZ-GAPDH 3.544 390.437 390.437 0 0 
pTRIPZ-N2-1 3.544 390.437 390.437 0 0 
pGIPZ-N2 3.544 390.437 390.437 0 0 
pTRIPZ-Nscram 0.419 54.505 54.505 0 0 
pTRIPZ-Non-sil 3.544 390.437 390.437 0 0 
pSLIK-HYGRO-Nscram 3.544 390.437 390.437 0 0 
pGIPZ-EG1 3.544 390.437 390.437 0 0 
Table  2.3 measuring the titration of Lentivirus virus using ELISA machine 
Some of The samples were concentrated using the concentrator from clone-
tech.  
 
 
D. Determining the titer of Lentivirus particles stocks and transduced target 
cells  
24-well tissue culture plate of HEK 293T cells at 5 x 104 cells per well in 
DMEM (10% FBS, 1% pen-strep) and another 24 well plate of P19 at 3*10(4) 
cells/well in full media with serum were seeded the day before the 
transduction under cell density from 40-50% confluent. 
124 
 
 124 
 
The dilutions of the viral stock in a round bottom 96-well plate using serum-
free media were made at the same time of viral collection. A series of 5-
fold dilutions was made  to reach to the  final dilution of 390625-fold. 
 
Each well an 80 μL was added with serum-free media. 20 μL of thawed viral 
particles stock was added to each corresponding well in column 1 (nude 
Lentivirus without dilution) the contents was mixed up and down 10-15 
times. Pipette tip was discarded. With new pipette tips, 20 μL was 
transferred from each well of column 2 to the corresponding well in column 
3 then from 3 to 4 . Mixed 10-15 times and discard pipette tips each time 
you move to new well. At the 24 well plate for P19 and 293T/17 Remove 
culture media from the cells in the 24-well plate. 225 μL was added with 
serum-free media to each well. The target cells P19 and 293T/17 cells were 
transduced by adding 25 μL of diluted viral particles from the original 96-
well plate to a well on the 24-well destination plate containing the cells. 
Transduced cultures were incubated at 37 °C for 4 hours. The transduction 
mix was removed from the culture and 1 mL of full serum media was added. 
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Cells were left in the incubation for 48 hours. Then the GFP was detecting 
using the florescent microscope.  
 
2.2.5 Cell lines, cell medium and reagents 
P19 cells were cultured in alpha-MEM with UltraGlutamine™ I, 
deoxyribonucleosides and ribonucleosides (Lonza BE02-002F), supplemented 
with 7.5% newborn calf serum (PAA B15-102) and 2.5% tetracycline-negative 
fetal bovine serum (A15-109) 293T/17 and Hepa cells were cultured in DMEM 
with glutamax and 10% fetal bovine serum. 
Cell lines used in this study were a mouse embryonic carcinoma cell line, 
P19 and a derivative from human embryonic kidney cell line, 293T/17. P19 
was maintained at 37°C in Minimum Essential Medium Eagle - Alpha 
Modification (Alpha MEM) with Nucleosides (Alpha MEM Eagle; w/o L-
Glutamine, Deoxyribonucleosides or Ribonucleosides; Quantity: 500mL) 
containing 2,5% Fetal Bovine Serum (FBS) from Sigma-Aldrich and 7,5% new 
born calf bovine serum (NBCBS) from Lonza in a 5% CO2 incubator. Another 
cell type, HEK293T/17, was maintained at 37°C in Dulbecco's Modified Eagle 
Medium (DMEM) containing 2 mM glutamine, 10% Fetal Bovine Serum (FBS) 
similarly at 5% CO2. 
 
2.2.6 Drug reagents  
2.2.6.1 Puromycin kill curve  
Puromycin (sigma cat number P7255) was added into wild type P19 EC cells 
for 5 days to detect the amount of puromycin needed to remove all the wild 
type cells. On day 0, P19 EC cells were plated around 5 - 8 x 104 cells per 
well in all 24-well plates which are sufficient for adding several 
concentration of puromycin in each well. Next days cell medium was 
prepared and added into falcon tube supplemented with various amount of 
puromycin ranging from 0 - 22 μg/ml of 10 mg/ml puromycin stock. Then 
from day 1 to day 5 a medium was changed with new puromycin supplement 
and some cells needs to split during these days.  
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Therefore, Monitor the cells daily and observe the percentage of surviving 
cells is critical to detect the right puromycin concentration. Thus, The 
minimum antibiotic concentration to use is the lowest concentration that 
kills 100% of the cells in 1 - 5 days from the start of antibiotic selection.  
 
2.2.6.2 Hygromycin B kill curve 
Hygromycin B (sigma cat number H3274) was used for pSLIK-hygro plasmids. 
The kill curve process is similar to puromycin. In day 0, 2 x 105 cells per well 
was plated in six 10-cm tissue culture dishes containing 10 ml of the 
appropriate complete medium. Next day the medium was changed and 
supplemented with hygromcyin B concentration (0, 50, 100, 200, 400, and 
800 μg/ml). Then. the cells Incubated for 10–14 days, replacing the 
selective medium every four days (or more often if necessary). During this 
period, the cells were examined for viable cells every two days. 
 
2.2.6.3 Toxilight bioassay kit from Lonza  
Doxycycline amount was examined for cell cytotoxicity in wild type cells 
although 1 μg/ml of Doxycycline is the optimal concentration for most of 
the cell lines and the doxycycline half-life in culture is 24 hours as previous 
studies suggest. Therefore, it is advisable to add doxycycline amount in the 
daily bases to maintain the doxycycline effects constant and avoid the 
fluctuation of shRNA expression during the knockdown process.  
Following the protocol from Lonza Vialight plus kit LT27-221 500 tests on 
P19 EC cells in wild type and knockdown cell lines. The protocol is for 
adherent cells Luminescence incompatible plate 96 well formats. To begin 
with, all reagents were prepared at the room temperature before using. 
Then, the Reconstitute the AMR plus in assay buffer was left for 15 minutes 
at room temperature to ensure complete rehydration. Next, the culture 
plate was removed from the incubator and allowed it to cool to room 
temperature for at least 5 minutes. The luminometer program took a 1 
second integrated reading of each appropriate well. Moreover, 50 μl of cell 
lysis reagent was added to each well and waiting for at least 10 minutes. 
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Furthermore, 100 μl of cell lysate was transferred to a white walled 
luminometer plate. 100 μl of AMR plus was added to each appropriate well 
and the plate was incubated for 2 minutes at room temperature. Finally, 
The Plate was placed in luminometer and initiate the program. (Luminoskan 
Ascent 2.5) 
 
 
2.2.7 Molecular biology reagents  
2.2.7.1 Trizol extraction 
Trizol reagent (cat number: 15596-018) from Ambion was used to extract 
the RNA. The cells were suspended and centrifuge, then the supernatant 
was removed. After that, a 1 ml of the Trizol reagent was added in each cell 
pellet (approximately 5x106 cell). To homogenize the cells with trizol 
reagent should be Pipetting up and down the mixture.  
A tube, which contained 1 ml of trizol, was used as negative control to 
ensure no contamination was detected during the extraction procedure. The 
samples were incubated at room temperature for 5 min then they were 
stored at -70 or -20 c for 1-2 hours. 100 μl BCP (Sigma B9673-200 mL) was 
added per ml of trizol reagent in each sample. The sample’s lid was held 
down and the tube was shaken for 30-40 second without vortex. The sample 
was incubated at room temperature for 5-15 min. Then it was centrifuged at 
12000 g for 15 min at 4°C. A fresh set of labelled eppendorf tubes were 
labelled and 500 μl of the isopropanol (19516-500 ml) from sigma were 
dispensed in each tube. The colourless solution was transferred to labelled 
tube with isopropanol. Next, The samples were vortex and were incubated 
at room temperature for 5-10 min and the samples were incubated at -20 c 
for 20 minute. Then the samples were centrifuged at 12,000 g for 15 min at 
4°C.  
The supernatant was completely removed and touched with clean tissue 
paper to clean the remaining supernatant. 1 ml of 75% of ethanol was added 
into each sample’s pellet and it was centrifuged for 5 min at 7500 g at 4°C. 
Then the supernatant was removed. This step was repeated twice. The 
sample was briefly centrifuged at 12,000 g to remove all the remaining 
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ethanol from the sample pellet without disrupting the pallet. The tubes 
were left the lid open and upside down to the tissue paper to allow the 
pellet to dry for 3-5 min and then it was heated at 30 °C on heat block for 3 
min. The pellet was suspended and in 50 μl of RNA free water and it was 
left at RT for 2 min. 
 
2.2.7.2 RNeasy extraction 
RNA was extracted using the Qiagen Rneasy kit with a QIAshredder column 
and on-column Dnase digestion, following the manufacturers’ instructions. 
RLT buffer was added to cells in a 60 mm dish and RNA sample was 
extracted from transduced cells using Qiagen RNase extraction. The cells 
were harvested from 60 mm dish, the media was removed and wash with 
DPBs. Next, Cells were disrupted by adding Buffer RLT and mixed properly 
to ensure the lysis homogenized with the cells. To homogenize the lysate, a 
step was followed using QIAshreddere spin Colom. Lysate was added directly 
into a QIAshreddere spin column, and it was centrifuged for 2 min at full 
speed. 1 volume of 70% ethanol was added to the homogenized lysate, and 
mixed well by pipetting only.  
Up to 700 μl of the sample was transferred including any precipitate that 
the sample may have formed, the sample then was placed to an RNeasy spin 
column in a 2 ml collection tube. The lid was closed gently, and centrifuged 
for 15 s at _8000 x g. The flow-through was discarded and the collection 
tubes were reused If the sample volume exceeds 700 μl. The successive 
aliquots were centrifuge in the same RNeasy spin column. The flow-through 
was discarded after each centrifugation. Furthermore, 700 μl Buffer RW1 
was added to the RNeasy spin column and the lid was closed gently, and 
centrifuged for 15 s at _8000 x g (_10,000 rpm) to wash the spin column 
membrane. The flow-through was discarded.  500 μl Buffer RPE was added 
to the RNeasy spin column and the lid was closed gently, and centrifuged for 
15 s at _8000 x g (_10,000 rpm) to wash the spin column membrane and the 
flow-through was discarded. The collection tube was reused if it is 
necessary. 500 μl of Buffer RPE was added to the RNeasy spin column and 
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the lid was closed gently, and centrifuged for 2 min at _8000 x g (_10,000 
rpm) to wash the spin column membrane.  
The long centrifugation dries the spin column membrane, ensuring that no 
ethanol was carried over during RNA elution because residual ethanol may 
interfere with downstream reactions. The RNeasy spin column was placed in 
a new 1.5 ml collection tube and 30–50 μl RNase-free water was added 
directly to the spin column membrane. The lid was closed gently, and 
centrifuged for 1 min at _8000 x g (_10,000 rpm) to elute the RNA. 
 
2.2.7.3 cDNA and Real time RT- PCR 
Total RNA was extracted using methods described in section 2.6.1. The RNA 
was used in a first strand cDNA synthesis reactions using SuperScript™ III kit 
(Invitrogen). cDNA synthesis was carried out using oligo(dT)20 primer in 
order to reverse transcribed polyadenylated transcripts only. The following 
steps were employed: 
 
Denaturation/ Annealing steps 
The following reaction was set up and incubated at 65⁰C for 5 minutes and 
then rapidly cooled on ice for 5 minutes.  
Reagents  Final volume 
(μl)  
RNA (300 ng in 10 ul 
dH20)  
10  
oligo(dT)20 (100 μM)  0.5  
dNTPs (50 μM)  0.5  
Total 11  
 
Reverse transcription  
cDNA synthesis master mix was prepared as below and added to the 
RNA/primer/dNTPs mix. The mix was incubated first at 25⁰C for 10 minutes 
and then at 50⁰C for 50 minutes. The reaction was heat inactivated at 85⁰C 
for 5 minutes.  
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RNA digestion 
The RT reaction was cooled on ice for 30 seconds. The RNA component was 
degraded by adding 1 ul of RNase H. The reaction were incubated at 37⁰C 
for 20 minutes and then either used for Real-time PCR amplification or 
stored at -20⁰C.  
 
2.2.7.4 Real-time PCR amplification  
The gene expression profiles studies shown in this project were conducted 
using SYBR®- green assays. This assay is based on detection of double 
stranded PCR products formed in the reaction using oligonucleotide primers. 
The primers for specific genes were design using either Primer Express or 
Primer 3 software. The basic criteria for primer design included designing 
primers over exon-intron-junctions, melting temperatures of 55-60º and an 
amplicon of 100-150 bp were applied. The primer pair sequences were 
compared against the entire mouse genome using BLAST alignment tool. The 
concentration of each primer was optimised, using dissociation curves to 
detect primer dimer formation and standard curves to check PCR efficiency. 
The list of primer sets used is shown in table 2.3  
The cDNA used in real-time PCR amplification was diluted 1:5, and 5 μl of 
this used in all PCR reactions. The PCR reactions was set up using 
transparent 96-well PCR plates (Abgene) in 25 μl reactions, typically in 
triplicates for each sample, by mixing all the reagents shown below. Fast 
start universal SYBR green master mix (Rox) from Roche was used (cat. no. 
04 913 914 001) 
 
 
Reagents  Final volume (μl)  
RNA (300 ng in 10 ul dH20)  10  
oligo(dT)20 (100 μM)  0.5  
dNTPs (50 μM)  0.5  
Total  11  
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SYBR®-green assay  Final volume (μl)  
SYBR PCR mix  12  
Forward primer (2.5-7.5 
μM)  
3  
Reverse primer (2.5-7.5 μM)  3  
dH20  1.5  
Template DNA  5  
 
PCR was performed on an MxPro 3000P (4 filter set plate) (Stratagene) using 
the thermal cycling conditions shown below. All SYBR green readings were 
normalised to Rox dye fluorescence. A dissociation curve (double stranded 
PCR product melting curve) was carried out to allow screening for non-
specific products amplified. 
 
Segment Number of cycles  Thermal cycling 
condition  
1  1  10 minutes  95⁰C  
2  40  15 seconds  95⁰C  
1 minute  60⁰C  
3  1  1 minute  95⁰C  
30 seconds  55⁰C  
30 seconds  95⁰C  
 
The data was analysed using excel file and the statistical analysis was 
summarize as following:  
CT (cycle threshold) average is used to detect the accumulation of a 
fluorescent signal. Then, STDEVP (CT) the standard deviation of delta Ct 
value measures the technical triplicates. The triplicates are valid when the 
SD is smaller than 0.25. Subtract the Sample average from housekeeping 
average (avct-hk avct) is applied to Compare the Ct difference for calibrator 
(GOI minus HK). Then calculate the error is important ERROR1 =SQRT (power 
(SD-SAMPLE, 2)+power (SD-HK,2)) to check for errors and variation among the 
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triplicate sample. Delta-delta CT value of ((SAMPLEAVCT-HKAVCT) DDCT-
internal (wt)) is used to measure the amplification efficiencies of the 
reference control gene and the target gene of interest between treated and 
untreated sample.  
Measuring the error bar (ERROR 2 (SQRT (power (ERROR$1,2)+power 
(ERROR1,2))) represent the range of possible relative of expression (delta-
delta CT values) and it defined by the standard error of the delta Ct's. the 
fold change (POWER(2,-DDCT)) represent the difference in gene expression 
which means  gene expression normalized to an endogenous reference of 
the gene and relative to the untreated control. Finally ERROR UP (POWER 
(2, -(DDCT-ERROR1)-FOLD CHANGE)) and ERROR DOWN (FOLD CHANGE-
POWER (2, -(DDCT+ERROR1))) are measured to the standard error of delta-
delta CTs values.   
 
2.2.8 Protein analysis reagents and kits  
2.2.8.1 Protein extraction  
2.2.8.1.1 Whole cell extraction  
 
Cells were collected from 10 cm dish and washed twice with cold PBS. 3 ml 
of cell lysis buffer (CLB) was added and scraped off cells with plastic 
scraper. The solution was mixed by pipetting into 15 cm tube. cells were 
freezed and thawed  from -20°C. the lysate cells were Heated at  65 °C for 
20 min or pass through 25 gaug needle 10 times or sonicate to beak up the 
chromatin and Spin for 15 min . finally  supernatant was added into new 
tube.  
 
 
Cell lysis buffer (CLB)  
 
Ingredients  Concentration  
4.5ml of 0.5M Tris-HCL pH 7.5 or 8    45mM 
100ul of 0.5M EDTA 1mM  
5ml of 10% SDS 1% 
5ml glycerol  10% 
Tiny bit of bromophenol blue 0.01%  
Water up to  50ml  
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10 ml of the following reagents was added to the cells and lysis solution was 
Freeze at -20°C for 3 month. Adding the 10 ml CLB from 2 mM stock 20 ul of 
1M DTT and 400 ul of protease inhibitor cocktail.  
 
2.2.8.1.2 Nuclear cell extraction  
 
Two buffers are used in the nuclear cell extraction  
Buffer A  
10mM HEPES PH 7.9 
10mM KCL  
0.1mM EDTA 
0.1mM EGTA 
1mM DTT 
0.5mM AE-BSF 
Total distal water 50ml   
Buffer C 
20mM HEPES PH7.9 
0.4M NaCL 
1mM EDTA 
1mM EGTA 
1mM DTT 
1mM AE-BSF 
Total distal water 50ml   
 
One million cells should yield about 100 ug of protein at about 2 ug/ul at 
the end of following process:  
To begin with cells were washed once with TBS and resuspended in 1 ml of 
TBS and transfer to eppendorf tube; pellet by quick-spin. Supernatant was 
aspirated and 400 ul of cold Buffer A was added to the solution and 
resuspend gently. Supernatant was left on ice for 15 minute to allow cells to 
swell. And 25 ul of 10% NP-40 was added to the cells. Vortex for 10 second 
was applied and supernatant used the Centrifugation in the cold at top 
speed for 30 second. Then supernatant (cytoplasm + RNA) was removed and 
the pellet (nucleus) was separated and resuspended in 50 ul of ice-cold 
Buffer C. then the supernatant was on tube for rock or shake in the cold for 
15 minutes to solubilize pellet. The supernatant was Centrifuge for 5 
minutes in the cold at top speed and removed the supernatant that contain 
nuclear extract at about 2ug/ul to freeze aliquots at -70 degree.   
 
2.2.8.1.3 Cytoplasmic cell extraction  
 
The Extraction of monolayer cells:  
Culture medium was removed from the cells. As an Optional step, If 
components of the culture media (i.e. phenol red) are inhibitory to protein 
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analysis, cells should be washed once with PBS (PBS; 43 mM Na2HPO4, 15 
mM KH2PO4, 137 mM NaCl, 27 mM KCl, pH 7.4) or Hanks’ Buffered Salts 
Solution (HBSS) prior to Cyto-Buster addition. The recommended amount of 
Cyto-Buster (from Table 1) was added and allowed to extract at room 
temperature for 5 min. cell debris were removed using a cell scraper or 
rubber policeman and the plate was oriented so all debris is pooled in the 
Cyto-Buster Protein Extraction Reagent. the extraction was removed to a 
suitably sized tube and centrifuge for 5 min at 16,000 Å~ g (4°C). it is 
important to note that the Longer centrifugation at higher speeds may be 
desired for certain applications. Then, the supernatant was removed to a 
new tube and proceed with analysis. It is important to note that the 
Extracts prepared with Cyto-Buster can be used immediately or may be 
stored for extended periods of time at –20 °C or –80 °C.  
 
2.2.8.2 Protein quantification  
2.2.8.2.1 Protein quantification using commassie stain  
 
SimplyBlueTM SafeStain  
 • 1 L (Cat. no. LC6060) 
The microwave procedure is fast, takes just 12 minutes, and yields results 
with sensitivity as low as 5 ng with an additional incubation with a salt 
solution. The procedure is for 1.0 mm mini-gels. For 1.5 mm mini-gels, use 
the values in parentheses. 
Caution: Use caution while using the stain in a microwave oven. Do not 
overheat the staining solutions. 
After electrophoresis, place the gel in 100 mL of ultrapure water in a 
loosely covered container and microwave on High (950 to 1,100 watts) for 1 
minute until the solution almost boils. Then the gel was on an orbital shaker 
for 1 minute (2 minutes). The water was discarded and their previous steps 
were repeated for 2 more times.  
After the last wash, 20 mL (30 mL) of SimplyBlueTM SafeStain was added 
and microwave was applied on High for 45 seconds to 1 minute (1.5 
minutes) until the solution almost boils. The gel was an orbital shaker for 5 
minutes (10 minutes). Detection limit: 20 ng BSA. The gel was washed in 100 
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mL of ultrapure water for 10 minutes on a shaker. And the Detection limit: 
10 ng BSA. 20 mL of 20% NaCl was added for at least 5 minutes. Detection 
limit: 5 ng BSA. The gel can be stored for several weeks in the salt solution. 
 
2.2.8.2.2 Protein quantification using using Nano-orang kit from Invitrogen 
 
Protein preparation:  
Protein was harvested from the cell culture using lysis buffer as following :  
4.5 ml tris-base 0.5M 
5ml glycerol  
5ml SDS 10%  
100ul EDTA 0.5M  
0.01% tiny from bromophenol blue  
Up to 50 ml d.H2O  
400 ul of protease inhibitors cocktail (diluted one tables in 1 ml H2O) and 1 
M  of DTT were added Into 10 ml of the lysis buffer . Then 3 ml of the 
mixture was added into each sample. The protein was sonicated at 4.5 W 
for 3 times in 5 second each and it Quantified using the Nano Orange kit 
from Invitrogen cat number N6666.  
Following the manufacturers’ instructions, the standard curve was made 
Figure 1.5 page 19 beside the samples at each run. Then the qRT-PCR 
detects the fluorescence when the sample was dropped to the room 
temperature after heated for 10 min at 95 c.  
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Figure  2.8 Standard curve of the P19 cells transduced with pTRIPZ Lentivirus 
The standard curve was made by bovine serum albumin (BSA) as reference 
standard. The chart showed that BSA at different concentration and it 
showed the equation of the line and R square amount.   
 
2.2.8.3 Western blot assay  
2.2.8.3.1 Western blot assay using manual SDS page from Invitrogen  
 
After protein quantification was assessed, the blotting assay can be 
performed.  
Following the manufacture instruction of  NuPAGE electrophoresis system 
from Invitrogen. The manufacture explained the PVDF transfer membrane 
method.  
To begin with, load the protein after quantification and heated at 70 c for 
10 min.  
then add reducing agent , antioxidant and loading buffer.  run the gel 
(NuPage 4-12% Bis-triz gel) at 55minute at 120 v and mA 115. During the 
electrophoresis run prepare the antibody blocking assay buffer (TBST).  
 
Tbs-TEEN 1X. 
20 Mm, Triz PH 7.5               20ml 1M Tris ph 7.5 
150 Mm. Nacl                        30ml 5M Nacl 
In 1L WATER + 1ml TWEEN20 
 
The antibody that was used mHmgn2 1/2000 and actin 1/2000 as a control 
the membrane, and watman paper were cut and socked into the methanol 
then to DH2O and lastly to the transfer buffer set up the gel with membrane 
into the following order  
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Then the gel with membrans was run at 1:30min on 25V.  After the 
transfering the gel into the membarn, blocking the membrane was made 
with TBST and 5% milk and left it for 1 hr into orbital shaker.  
First antibody Hmgn2 was added into the new TBST +5% MILK at dilution 
1:2000 in boch bag over night. At 4c. The next day the member was washed 
4 times with TBST. 15 minute each washing.  Then the secondary antibody 
was added which is IgG 1:4000 dilution within TBST AND 5% buffer.  
And left in orbital shaker for 1hr at RT.  Finaly the membran was washed 4 
times for 15min with TBST.  
The illumino peroxidase was added into the membrane for viewing the 
target band using 3000pixl picture programme.  
 
2.2.8.3.2 Western blot assay using Bio-Rad assay kit  
 
The precast gel was used 12% non-gradient gel from Novex Invitrogen and 
the buffer was used MOPS 20X. the transferring membrane was from Bio-rad 
and the transferring membrane was used called TRUBO cat number 21703. 
The blocking buffer was 1X PBS with 1ml tween 20 and 5% non-fat Milk and 
the washing step was with 1x PBS with tween 20 for 3 times in 5 min each.  
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2.2.9 Flow cytometry analysis  
2.2.9.1 Cell cycle analysis (propidium iodide)  
In the First day 106 of the cells (quantity of DNA same number of cells) was 
used to apply propidium iodide experiment. The cells were washed with 
PBS. Then the cell Pellet was in the 2.5ml PBS solution and 5 ml of 100% ice 
cold ethanol  
The cell pellet was vortex 7.5ml in 50ml falcon tube. Immediately, the 
solution was added in -20°C overnight  
The Next day, the cells were centrifuge to removed the alcohol and the rest 
of solution was removed by flipping the tube on tissues and leave it to dry 
out. (50ug/ml) of propidium iodide was used with Rnase A (0.5 mg/ml) in 
fresh 1 ml of PBS.  500 ul was taken from the mixture and mixed with 
pellet. The cells were incubated at RT. Then the cell will be ready to read 
out through Attune.  
 
22.9.2 Cell compensation using FACS analysis 
Cell compensation experiment was performed on FACS analysis. Before 
applying the target sample, P19 EC wild type controls need for setting the 
experiment. In this protocol, three controls were used: negative wild type 
P19 EC cells, P19 stained with green fluorescents antibody and P19 stained 
with red fluorescent antibody. Then experiment will be performed using 
another control for the staining and transfection beside the target sample.  
To begin with, Cell compensation was optimized using wild type P19 EC cells 
as control. GFP (green) P19 EC cells control was performed using transient 
transfection for GFP plasmid in wild type P19 EC cells in 48 hours incubation 
period. Non-stained P19 EC cells were used to gate the four quadrants. Red 
fluorescent SSEA1 was stained in wild type P19 EC cells for 2 hours without 
cell fixation. The analysis was collected twice live cells with no fixation on 
the last day (day 25).  
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2.2.10 Immunofluoresent reagents  
Immunofluoresent assay was developed by Dr. Torstein Stain lab at the 
University of Glasgow. To being with, 4% paraformaldehyde was prepared in 
warm smaller volume of PBS to 60°C ;then PFA was added to warm PBS and 
mixed . 1M of NaOH was added as dropwise until the PBS+PFA dissolved. 
Similar volume of 1 M HCl was added to neutralise the solution using pH 
paper to check pH. Take volume up to final volume with H2O, filter sterilise. 
4% PFA solutions mix needs to be warmed up every time there is 
immunoflorecent application. Therefore, this solution can be used either as 
fresh or as frozen.  
To Fix cells, the medium was removed from the plate (wells) and 100 μl 4% 
PFA drop-wise was added to each well. All the volumes in 24 wells are 100 
μl, although it can use 200 μl to be sure. The plate or well were Incubated 
for 20 min at RT. During this incubation period, methanol was chilled at -
20°C. PFA was removed and 100ul of chilled methanol was added per well. 
Then the plate was Incubated at -20 degree for 1 min. the plate was 
Aspirated and the cells were washed for one time in PBS (slides can be 
stored in PBS at 4C  at this stage). To Permeabilise cells, PBS was added 
with 0.1% triton x-100 and Incubated at room temperature for 10 min. then, 
Washing once with PBS and 20 mM glycine for 10 minutes to remove any cell 
debris. IF buffer was prepared as following: 100 ul per well (PBS+ 0.3% 
triton x-100 , 2.5% horse serum).  
Then, the cells were blocked with IF buffer for 45 mins - 1hr at RT. (NB: 
prepare excess block to dilute primary Ab). The Primary Ab was used as the 
following: dilute primary Ab (1:200-1:1000) in IF buffer and  Add 100ul/ well 
and incubate at 1 hr at RT. It is important to note that, it is possible to 
combine several 1’ antibodies together. The Best way is actually to  place 
30 ul of solution on nescofilm and place coverslip up side down on the 
droplet. Cover to prevent evaporation. Then, primary Ab was removed and 
rinsed for 3 times for 10 min washes with PBS and 0.3% triton.  
Secondary Ab was used as following step: (NB. Keep slides in the dark after 
secondary is added) Dilute the Ab (1:500-1:1000) in IF buffer for 1 hr at RT. 
It is important to note that it can combine several 2nd antibodies at this 
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step. The plate was protected from light and covered to prevent 
evaporation. The Best way is to place 30 μl solution on nescofilm and place 
coverslip up side down on the droplet. Next, 3 times of washing step with 
PBS for the plates in 10 minutes happened after blotting with first and 
second antibodies; then Washing one time with dH2O.  
The plate was Mounted with prolong gold mounting medium with contain 
DAPI to counterstain the nuclei. If prolong gold doesn’t contain DAPI 
already, add DAPI to 1 ug/ml final concentration just before use. The slides 
were left to set for 24 hours in the dark, covered. The slide was stored at 
RT short tem, or -20 degree for long term and thaw before you use. For 
chamber slides, cover with PBS and leave at 4°C. Allow reaching RT before 
imaging. 
 
 
2.2.11 Chromatin Immunoprecipitation reagents and buffers  
Protein and DNA cross-linked with formaldehyde:  
P19 cells were cultured under advanced DMEM/F12, 1X glutamine and 10% 
NBCS . the culture was expanded in 10X of 15 mm dish. Each plate should be 
50-60% confluent. Each chromatin prep use 7.5*107 cells. 7.5*107 cells were 
collected from P19 cells and 6*107 cells were collected from E14 cells.  
Count one plate of cells and collect the total number of the cell and how 
many plates is needed to reach to 7.5*107 .The cells were trypsinized and 
collected under the same medium but without serum (the serum reduce the 
formaldehyde efficiency).  
Reagents preparation:  
Before DNA pre-clearing step PBS , 2X cell lysis buffer, 2X nuclei buffer were 
pre-chilled in ice. In addition 1 ml of 10x nuclei buffer, 5% formaldehyde, 
and 1.5 ml of 1M of glycine were prepared for ready use.  
5% Formaldehyde was added into the final concentration of 0.5% (20 ml of 
medium so 2.2 ml from 5% formaldehyde added into cells with medium).The 
plates were rotated into orbital shaker for 5 min each plate at room 
temperature. Then 1M of glycine to stop cross link reaction. The cells were 
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washed, scrapped from the plate using cold PBS. And centrifuged for 5 min. 
Cell lysis buffer with protease inhibitor were added into the cell pellet to 
remove the cell membrane. Then the nuclei lysis buffer was added into the 
cell pellet at the end DNA and protein was only left in the solution. The 
chromatin (DNA+ protein) was sonicated using Ultrasonic energy to disrupt 
the chromatin into smaller fragments. the process was done using machine 
SONICATOR 3000 at amplitude 3 for 5 min 10 sec on and 30 sec off. Then the 
sonicated chromatin was run in electrophoresis to check the size of the 
sample.  
Pre-clearing chromatin 
To eliminate the Chip background, pre-clearing was performed to ensure 
that almost no signal was obtained with the IgG control precipitation, which 
was done with each experimental set. Each IP has amount of chromatin, 
which range from 5-20 ug. Chromatin amount is equal to 1*106 - 6*106 cells. 
In P19 the total cells in 1 ml was 3.75*107 whereas E14 a 1 ml from 
chromatin 3*107 cells. The total cell was used in each IP was 1*10(6) 
cell/900ul IP with IgG antibody. Using protein A sepharose beads is 
necessary for chip to reduce the background level that caused by IgG 
antibody.  
Immune-precipitation of chromatin 
After pre-clearing different antibodies of the interest were added into each 
900 ul of pre-clearing chromatin include one IgG antibody as positive control 
and 260 ul was for input control.   
 
The antibodies was used as following  
Antibody Cat number (Millipore) Concentration  
H3 CT PAN 07690 2ul 
H3K4me3 07473 2ul 
H3K14ac 07353 2ul 
Hmgn2 Homemade rabbit 2ul 
Hmgn1 Homemade rabbit 1ul  
H3K27ac  2ul  
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Another sephorose beads were added into chromatin with antibodies 
solution after centrifugation and washing steps. After several washes, wash 
with buffer I twice, then wash with high salt buffer to increase the chance 
that chromatin will be prevented from interacting with the beads. Next 
wash with IP wash buffer II, finally with 50-degree pre warm TE buffer. To 
elute the chromatin with elution buffer; then to maintain the protein-DNA 
crosslinked 17 ul from 5M NaCl and 1ul of Rnase A in the input only. Finally 
the sample was kept in at 65 degree overnight.  
Recover the DNA: 
To remove the DNA, Qiagen minlute column using PB buffer was obtained. 
The chromatin was eluted in 50 ul Qiagen elution buffer. 
Western blot for chromatin extraction  
This is the procedure for the benzonase digest for chromatin western 
preparation 100 ul of prepared chromatin was applied in this experiment. 
Then 10 ul of 10X TBS (200 mM Tris 7.5 PH and 1.5 M NaCl) was added into 
chromatin. in addition, 10 ul of 10% Triton X-100 was and 1.2 ul of MgCl2 
100 mM were added into chromatin. It is important to note that this mixture 
is to give a final concentration of 1X of MgCl2, which is required for 
benzonase activation.  
Make aliquots of 60 ul of the digest mixture. For example, 2 aliquots of the 
same sample was needed for the experiment. Benzonase (25 Unites) enzyme 
was measured to detect the amount of benzonase is needed in 100 ul of 
chromatin. it is important to note that The benzonase is highly 
concentrated. Therefore, ~250 U/ul is needed to dilute it at least 1 in 10 
and then take 30 unites. 3 ul of diluted benzonase was used to obtain 1 in 
10 of digested chromatin and it kept for further use. Benzonase with 
chromatin was left to digest for 15 minutes at room temperature.  After 
digestion step, samples was prepared for western blotting assay as 
following: 14 ul chromatin + 5 ul of 4X Nupage loading buffer (LDS) + 1 ul of 
sample reducing reagent DTT. Then the sample mix was heated at 75 C for 
10 minutes and loaded on pre-cast gel.  
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NOTE: if chromatin were not highly concentrated, a start up with a bigger 
amount of chromatin rather than 100 ul would be feasible. For example, 300 
ul starting chromatin amount and the volumes of 10X TBS (30 ul), Triton X-
100 (30 ul) and MgCl2 (3.5 ul) was adjusted based on chromatin amount.  
 
2.2.12 Co-Immunoprecipitation (Co-IP) for chromatin and whole protein 
cell extract  
Cell harvesting/prep (for T75/20 mL, 80-95% confluence, 200000000 cells 
approximately) were collected in falcon tube and centrifuge 500 g/5 
minutes at RT . Supernatants were removed and the cells were washed one 
time with PBS following centrifuge 500 g/5 minutes. Cell lysis and 
benzonase digested the resuspended cells in 1 of 2 ml buffer to 4 of dH2O 
(1:4) + protease inhibitors.  The cells were incubated on ice for 10 minutes 
and resuspend occasionally; Then the cells were Centrifuge 300 g/3 minutes 
at 4°C to collect nuclei and to save aliquots of supernatant for checking the 
fractionation efficiency. Resuspend the pellet was applied in 500 μl 
benzonase buffer and protease inhibitors; next,  25u/100 μl benzonase was 
added in to the pellet and incubated on ice for 30 minutes following 
resuspention occasionally. Then, the pellet Centrifuged in speed 300 g for 3 
minutes at 4°C. to Recover the supernatant, the pellet was dissolved in 
sample buffer to check chromatin prep and solubilisation efficiency. Adding 
500 μl dilution buffer and inhibitors diluted 2 fold of supernatant. This step 
is important to deactivates benzonase with (EDTA). The process is continue 
as following to prepare the sample for western blot essay using CO-IP.  
Bead preparation begins with, 400 μl protein G (should be A for rabbit Ab) 
beads was prepared by washing twice with 1ml PBS and 0.5% BSA (adjust 
volumes according to requirements); then suspend beads step started by 
centrifuge the beads at speed 800 g for 1 minutes at RT, and supernatant 
was removed. This Resuspend pelleted beads became 1 to 1 with buffer 1. 
Pre-clear step started by Adding 50 μl beads and 10 μl rabbit IgG to lysate 
and Incubate with rotation 30 minutes at 4 degree C. then, the beads were 
Centrifuge at 800 g for 5 minutes under 4 degree c. Dilution step used dilute 
lysate ¼ in dilution buffer and protease inhibitors for approximately 5x106 
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cells/ml and save 1-2 aliquots of 5% input (i.e 5% volume to be used in each 
sample).  
IP step started with sample was in 1.5 ml eppendorf and 1 ml pre-cleared 
lysate and Ab (30ug Hmgn2 or 10mg of IgG – 10ul) were added. This step was 
repeated three times; then the sample was incubated under rotation from 2 
hours to overnight at 4 degree. The final step used 50 ul of prepared 
proteins A/G beads was added to the samples and incubated under rotation 
for 3 hours at 4 degree. The sample was washed two times with buffer 4 and 
2 times with buffer 5. Then the supernatant was removed for final wash and 
two times of 30 ul of sample buffer was added to the sample. The sample 
was heated for 10 minutes at 68-70°C. finally, the samples were ready to be 
run on western blot.  
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Chapter 3  The characterisation of lentiviral-
mediated gene silencing of Hmgn2 in embryonic 
carcinoma EC P19 stem cells  
3.1 Introduction  
From previous study on Xenopus laevis the expression and the location of 
Hmgn1 and Hmgn2 are parallel. These two proteins found to be 
developmentally regulated such as down regulation of Hmgn1 and Hmgn2 
affect the development of mouse embryo at pre-implantation stage. These 
results showed that losing the expression of Hmgn1 and Hmgn2 could 
terminate mouse embryo development (Postnikov and Bustin, 2009). 
Moreover, a study on Xenopus laevis in Hmgn1 and Hmgn2 found to be highly 
expressed in mesoderm and neuroectoderm region (Korner et. al., 2003). In 
addition, Hmgn1 and Hmgn2 expression showed at the early stage of embryo 
development and Hmgn2 downregulation in bovine embryo showed the 
embryo failing to develop to blastocysts due to the change in chromatin 
remodeling in histone H3 hyperacetylation at lysine 14 (Furusawa and 
Cherukuri, 2010).  From these previous studies, it indicates that Hmgn1 and 
Hmgn2 may involve in maintaining pluripotency.  
To confirm this hypothesis, loss of function experiment was carried out by 
siRNA and shRNA against Hmgn1 AND Hmgn2 in mouse teratocarcinoma stem 
cells  (P19 EC cells). Lentiviral system is the best system because shRNA 
based on microRNA encoded to DNA vector to facilitate the ectopic mRNA 
expression. Moreover, lentiviral system can be constitutive or inducible to 
derive the expression and each shRNA based on microRNA gave arise to 
single siRNA for more gene target specificity (Hannon and Rossi, 2004).  
In this chapter pSLIK-CD4 and pTRIPZ inducible lentivirus knockdown were 
used in P19 EC cells. both systems are tet-inducible TRE2 and they are only 
inducible systems. However, the reporter genes that track shRNA expression 
in pSLIK is GFP whereas pTRIPZ the reporter gene is turboRFP. PSLIK-CD4 
design has TRE to encode GFP and miR-shRNA and it has separate Ubc 
promoter to express the reverse tetracycline transactivator (rtTA). 
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Moreover, this promoter express the drug resistance marker by IRES and it 
can silence many genes (Figure 3.1).  
 
 
  
 
Figure  3.1 Schematic showing the insertion of miR-shRNA and GFP transgene in 
pSLIK-CD4 
lentivirus encoding the Hmgn2 miR-shRNA. The schematic was adapted from 
(Shin et al., 2006). pSLIK-CD4 and pSLIK-hygro is the destination vector, 
which consists of four parts. First part is attR sequence elements are 
required for LR gateway reaction to flanked ccdB gene from destination 
vector. The insert TRE-GFP-shRNAmir is performing with rtTA3 to generate 
inducible knockdown system. The second part is the constitutive system of 
pSLIK using FLAP recognitions sites derived by CMV promoter. This part is 
optional to choose the constitutive or inducible system.  The third part is 
for activating the Lentiviral recombination system (SIN/LTR, WRE, and 
SV40). The forth part is for cloning the vector into the competent cells (Ori 
and amp) adapted from (shin et. al., 2006).  
 
 
 
Similar to pSLIK-CD4, pTRIPZ has TRE promoter, which can derive the 
expression of turbo RFP besides miRNA-shRNA. Furthermore, it had UBC 
promoter to derive the expression of rtTA, IRES, and Puromycine. PTRIPZ 
consider being more tightly regulated shRNA expression in many cell lines 
(Hu and Luo, 2012).  Therefore, these lentiviral systems were optimizing to 
knockdown Hmgn1 and Hmgn2 in P19 EC cells (Figure 3.2) 
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Figure  3.2 schematic diagram illustrating the expression cassette encoded by pTRIPZ 
lentiviral vector 
TRIPZ inducible system contains two parts. First part is constitutive system 
derived by UBC promoter. This constitutive part consists of Bi-cistronic 
element (IRES) and rtTA3 element following Puromycin drug selection. The 
second part if inducible, which only can be activated by supplying the 
medium with Doxycycline, contains RFP and shRNAmir derived by TRE 
promoter.  Abbreviation: IRES, internal ribosome entry elements; WRE, 
woodchuck response element; LTR, long terminal repeats; puro, puromycin 
(adapted from open-biosystem) 
 
3.2 Aims and objectives  
The aim of this part of the work was to investigate whether lentiviral 
shRNAmir systems could be used in P19 cells for the inducible knockdown of 
Hmgn1 and/or Hmgn2. 
The specific objectives of the experimental work described in this chapter 
were: 
1. To test for detrimental effects of doxycycline on P19 cells 
2. To optimise conditions for generating P19 cells stably transduced with 
pSLIK or pTRIPZ lentiviral particles.   
3. To investigate whether P19 cells transduced with pSLIK or pTRIPZ 
shRNAmir viral particles have reduced expression of Hmgn2.  
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3.3 Results  
3.3.1 Testing for detrimental effects of doxycycline on P19 EC cells 
Doxycycline is a common reagent used for regulating inducible expression, 
and it is typically used at 1-2 μg/ml. In order to investigate whether growing 
P19 cells in doxycycline could be detrimental (Chang et. al., 2014 and Souza 
et. al., 2015), several different tests were carried out. The effect on cell 
proliferation was assayed using a luminescent 96-well plate assay for 
cellular ATP (Figure 3.3).  
 
Figure  3.3 The effect of Doxycycline treatment on the growth and viability of  P19 cells. 
Cells were incubated with the indicated concentrations of doxycycline 
(µg/ml) and grown for four days. Cell viability was assayed using the Vialight 
assay according to the manufacturer’s instructions (Lonza). Error bars were 
calculated based on the concentration to the number of repeat.  
 
 
In order to test whether doxycycline causes gross defects in cell 
morphology, cells were assayed by FACS after 3 and 5 days of treatment 
with different concentrations of doxycycline (Figure 3.4). The forward and 
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side scatter measurements would reveal whether cells are significantly 
altered in terms of their size, shape or granularity, which might indicate 
changes in cell health or identity. No significant changes were observed in 
any of the samples.  
 
 
 
 
A) 
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Figure  3.4 The Effects of doxycycline on P19 EC cells 
Flow cytometer analyses (FACS) of wild type EC P19 cells after 3 (A) and 5 
(B) days of Dox treatment with the indicated concentration of doxycycline 
(0.5, 1, 2, 4, 6, 8, 10, and 12 µg/ml). Media was replaced every 24 hours, 
and cells were passaged every 48 hours. The gate for healthy cells was 
drawn based on wild type P19 cells without Dox treatment. FSC-A (forward 
scatter) corresponds to a relative size for the cell whereas SSC-A (side 
scatter) corresponds to granularity. The percentage of cells falling within 
the gate is indicated.  
 
 
 
 
In a further attempt to investigate whether doxycycline might have a major 
impact on this investigation, the mRNA expression level of Hmgn2 and Oct4 
were assayed following five days of treatment with varying levels of 
doxycycline (Figure 3.5). It can be seen that there is quite wide variability 
in the expression levels between samples, and there is no consistent trend 
with increasing doxycycline concentration.  In particular, at 1 µg/ml 
B) 
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doxycycline, the levels of Hmgn2 and Oct4 mRNA are very similar to those of 
untreated cells.  
These investigations indicated that 1 µg/ml of doxycycline treatment for up 
to 5 days does not have a major detrimental on P19 cells. However, 
doxycycline may be causing other changes in gene expression, so it is 
important to include dox-treated control cells with each experiment.  
Figure  3.5 the influence of doxycycline on Hmgn2 and Oct4 expression in P19 EC cells 
Cells were incubated with the indicated concentration of doxycycline for 
five days. Medium was replaced every 24 hours. RNA was prepared, and 
qRT-PCR carried out to quantify the relative expression of Hmgn2 and Oct4. 
Gene expression was normalised to β-Actin as housekeeping gene and is 
calculated relative to expression in untreated wt P19 EC cells. Error bars 
represent the standard deviation from QPCR triplicates.  
 
 
3.3.2 The Construction of pSLIK-CD4-shRNAmir30  
The pSLIK lentiviral system was initially chosen for expression of shRNA. This 
system enables doxycycline-induced expression of miRNA containing the 
shRNA for RNA-interference. The Ubi-C promoter drives constitutive 
expression of rtTA3 and delta CD4, which are separated by an internal 
ribosome entry site (IRES). Doxycycline causes rtTA3 to bind the TRE 
promoter, driving expression of shRNAmir and GFP. Mohan (2012) had 
previously used siRNA for successful knockdown of HMGN1 and HMGN2 in P19 
cells, so the same trigger sequences were used in the design of the lentiviral 
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shRNAs: N1-2 and N1-3 target Hmgn1,  N2-1 targets Hmgn2, and sc is a 
negative control containing a scrambled version of the N2-1 trigger 
sequence. 
The cloning strategy is shown in Figure 3.6. shRNA sequences were 
synthesised and cloned into the entry vector pENTR-TGmiRC3 by the 
company Shinegene (Figure 3.7).  
 
 
Figure  3.6 Diagram shows from a-f the construction of the pSLIK lentiviral shRNA 
expression vector 
Part a: the entry vector (pENTR-TGmiRC3) for receiving the shRNA contains 
the ccdB gene, which is toxic when expressed in standard E.coli strains. 
Insertion of the shRNA into BsaI sites removes the ccdB gene, to generate 
the vector in part d. Gateway recombination is used to move the shRNA 
from the entry vector into the destination vector shown in part e (pSLIK-
CD4). The final vector is shown in part f (pSLIK-shHmgn-CD4).  
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Figure  3.7 : Elements in the pSLIK-shHmgn-CD4 lentiviral vector Plasmid map of the 
final lentiviral expression vector 
 
3.3.2.1 Cloning of pSLIK-shHmgn-CD4 vectors  
Gateway recombination technology was used to insert the shRNAmir30 
sequences from the entry vectors into the pSLIK-CD4 destination vector. The 
final vectors were checked by restriction enzyme digestion using EcoRI 
(Figure 3.8) and Kpn1 (not shown), and then confirmed by DNA sequencing.  
 
 
 
 
 
Figure  3.8 Example restriction digest of plasmid clones resulting from the LR-
recombination reaction 
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LR recombination reactions were performed using pSLIK-CD4 and the entry 
vectors containing N1-3 or N2-1. Colonies were grown in culture and DNA 
extracted using a miniprep kit (Qiagen). DNA (1.5 ug) was digested with 
EcoRI-high fidelity and run on a 0.8% agarose gel in TAE buffer. D. The 
expected bands for unrecombined pSLIK-CD4 are 10.18 kb, 2054 bp, 780 bp. 
The expected bands of recombined pSLIK-shHmgn-CD4 plasmids are 10.18 
kb, 1.5 kb, 780 bp. In this gel, clone N1-3B is not correct, but N1-3A, N1-3C, 
N1-3D and N2-1 show the expected bands.  
 
 
3.3.2.2 The Production of pSLIK-shHmgn-CD4 viral particles 
PSLIK-shHmgn-CD4 vectors were transfected into the cell line Hek293/T17 
along with three third generation packaging vectors (see chapter 2; 
materials packaging vectors) (Shin and et al., 2006).  
Supernatant containing viral particles was harvested as described in chapter 
2, diluted to varying degrees with serum-free ultracultural medium, and 
then added to exponentially growing P19 cells. After three days, 1 µg/ml 
doxycycline was added, and the induction of GFP expression was assayed by 
microscopy three days later (Figure 3.9).   
Figure 3.9 shows the results from a typical experiment. Strong GFP 
expression can be seen in many cells transduced with undiluted virus, or 
with virus diluted by 2 or 4 fold.  Fewer cells express GFP following 
transduction with virus used at the highest dilution (16x). However, even at 
the high viral concentration, less than 50% of cells are expressing GFP.  
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Figure  3.9  Fluorescent microscopy shows serial dilution of pSLIK-Hmgn1-2-
CD4 viral particles 
The green cells indicate the transduced cell with viral particles. These cells 
derived by TRE promoter, which is activated by rtTA3 gene under three days 
doxycycline presences. The image divided into three parts: the bright field, 
the GFP and transduced cells (merge). Each image contains 2 fold dilutions 
the first image is undiluted Lentiviral particles.  
 
3.3.2.3 The Optimisation of pSLIK-shHmgn-CD4 viral transduction 
In order to optimise viral transduction of P19 cells, several parameters were 
tested: A range of doxycycline concentrations was tested to ensure 
maximum induction. There was little difference between 1 µg/ml and 8 
µg/ml doxycycline, and it was decided to use 2 µg/ml in all further 
experiments.  
Several batches of fetal bovine serum were tested to ensure there were no 
trace levels of tetracycline that could induce GFP expression in the absence 
of exogenous doxycycline. Finally, a range of viral supernatant dilutions in 
different culture vessels was tested, and it was decided to use 3 ml of nude 
viral supernatant in a 25 cm2 flask for 24 hrs.  
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3.3.2.4 The Analysis of pSLIK-transduced P19 cells 
Given that it was not possible to transduce more than 50% of P19 cells with 
the lentiviral particles, we attempted to use magnetic cell sorting (MACS) to 
enrich for transduced cells. However, this was not successful in our hands, 
and colleagues using the same system in our department also found this was 
unsuccessful. It appears that the CD4 fragment is not expressed from this 
vector as expected. Therefore, we used FACS sorting for GFP following 
doxycycline treatment to enrich for transduced cells.  
To determine the Hmgn1 and Hmgn2 expression in transduced P19 cell lines 
before and after FACS sorting, we used real-time quantitative RT-PCR. 
Expression of Hmgn1 and Hmgn2 in unsorted cells is shown in Figure 3.10.  
with and without DOX (Figure 3.10). None of the transduced cell lines 
showed a reduction in Hmgn2 or Hmgn1 expression below the levels in wt 
cells. The N1-2 cells did show a reduction in Hmgn1 expression in dox-
treated cells compared to no-dox cells. However, a similar reduction in 
Hmgn2 expression was observed in these same samples, so the effect on 
Hmgn1 expression was not specific.   In Knockdown P19 cell lines did not 
show reduction neither Hmgn2 nor Hmgn1. We concluded that knockdown 
P19 cell lines still a mixture population of transduced and normal cells 
(Figure 3.10).  
Expression of Hmgn1 and Hmgn2 in sorted cells is shown in Figure 3.11. In 
the N1-2 cells, the expression of Hmgn1 was reduced in dox-treated cells 
compared to wt cells. In N2-1 cells, expression of Hmgn2 was reduced in 
dox-treated cells compared to untreated cells, but the level was not 
significantly reduced compared to wt cells. Furthermore, a similar reduction 
in Hmgn1 expression was observed in dox-treated cells compared to 
untreated cells. 
Western blotting was used to investigate whether the protein levels of 
Hmgn1 or Hmgn2 were reduced in the transduced cells. No reduction in 
either protein compared to the wt P19 cells was observed (data not shown – 
western not good enough).  
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Figure  3.10 A. Hmgn1 and B.  Hmgn2 RNA level in pSLIK-transduced P19 
polyclonal cell lines 
These cell lines were grown with or without 2 ug/ml Dox for five days. The 
expression level are normalized against control gene and expressed as 
fraction of expression in wtP19 cells. Error bars reflect standard deviation 
between technical PCR replicates. Knockdown P19 polyclonal cell lines: sc 
(Hmgn-scramble), N1-2 (Hmgn1-2), N1-3 (Hmgn1-3) and N2-1 (Hmgn2-1). 
 
 
 
 
0
0.5
1
1.5
2
2.5
WT WT SC
DOX
SC
NO
DOX
N1-2
DOX
N1-2
NO
DOX
N1-3
DOX
N1-3
NO
DOX
N2-1
DOX
N2-1
NO
DOX
H
m
g
n
1
 f
o
ld
 c
h
a
n
g
e
  
knockdown P19 cell lines 
0
0.5
1
1.5
2
2.5
WT WT SC
DOX
SC
NO
DOX
N1-2
DOX
N1-2
NO
DOX
N1-3
DOX
N1-3
NO
DOX
N2-1
DOX
N2-1
NO
DOX
H
m
g
n
2
 f
o
ld
 c
h
a
n
g
e
 
P19 knockdown cell lines 
158 
 
 158 
A. 
 
B. 
 
Figure  3.11 A. Hmgn1 and B. Hmgn2 gene expression in pSLIK-transduced P19 cells 
enriched for high GFP expression using FACS sorting 
The sorted cells were cultured with or without 2 ug/ml Dox treatment for 
30 days. Expression level was normalized against selected control gene and 
is plotted as a fraction of wt P19 levels. Error bars reflect the standard 
deviation between technical PCR triplicates. Knockdown P19 monoclonal 
cell lines: sc (Hmgn-scramble), N1-2 (Hmgn1-2), N1-3 (Hmgn1-3) and N2-1 
(Hmgn2-1). 
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3.3.2.5 The Conclusions from pSLIK experiments 
From these experiments, we concluded that the performance of the pSLIK 
system was not good enough for our requirements. Levels of P19 cell 
transduction were low, and the absence of a drug-selection marker or CD4 
expression meant that FACS sorting of dox-treated cells is the only way to 
enrich for transduced cells. Even following sorting, evidence for knockdown 
of Hmgn1 or Hmgn2 was inconclusive. For these reasons, we decided to try a 
different inducible lentiviral vector: pTRIPZ.  
 
3.3.3 pTRIPZ as an inducible lentiviral vector system 
The pTRIPZ lentiviral vector (Thermo-scientific) is an alternative system for 
the production of lentivirus particles that express shRNAs in response to 
doxycycline. Greg Hannon reference A schematic of the expression cassette 
is shown in Figure 3.12. The UBC promoter drives constitutive expression of 
rtTA3 and the puromycin resistance gene, separated by an IRES element. In 
the presence of doxycycline, the rtTA3 transactivator binds the TRE 
promoter and drives expression of turboRFP and the shRNAmir. (Rytlewski 
and Beronja, 2014; Dull et. al., 1998).  
 
 
Figure  3.12 Schematic diagram illustrating the expression cassette encoded by pTRIPZ 
lentiviral vector 
Abbreviation: IRES, internal ribosome entry elements; WRE, woodchuck 
response element; LTR, long terminal repeats; puro, puromycin. TRE, RRE, 
tRFP, amp, ori 
 
The main advantage of pTRIPZ over pSLIK is that it carries the gene for 
puromycin resistance, so that transduced cells can be selected. A puromycin 
kill curve was carried out with each new puromycin vial in order to 
determine the optimum puromycin concentration to use for P19 cells. The 
160 
 
 160 
optimum concentration was typically 1.5 µg/ml. No difference in sensitivity 
was observed whether the cells were grown in DMEM/F12 or alpha-MEM 
media. 
3.3.3.1 The Experimental design of Inducible pTRIPZ for Hmgn2 in EC P19 
cells 
Various shRNAmir triggers were cloned from pSLIK and pGIPZ vectors (see 
chapter 4) into pTRIPZ (provided by K. West): 
shHMGN2-381:   targets Hmgn2 
shHMGN2-514:   targets Hmgn2 
shHMGN2-968:   targets Hmgn2 
shHMGN2-N2-1:   targets Hmgn2 
shGAPDH:    targets Gapdh 
shN-scramble  negative control 
sh-346:    non-silencing 
 
3.3.3.2 Transfection of packaging cell line 293T/17 with inducible lentiviral 
vector  
Viral particles were produced by transfecting HEK293T/17 cells with the 
pTRIPZ vector and packaging mix (Thermo Scientific), as described in 
chapter 2. 
Media supernatant containing the viral particles was collected. P19 cells 
were cultured in ultracultural medium for 24 hours, then the medium was 
changed to alpha-MEM supplemented with 10% serum. Cells were selected 
with 1.6 ug/ml puromycin, and then 1 ug/ml doxycycline added for four 
days. FACS was performed to quantify the percentage of cell expressing 
RFP: 
shHMGN2-381:   6% 
shHMGN2-514:   2% 
shHMGN2-968:   35% 
shHMGN2-N2-1:   43% 
shGAPDH:    2% 
sh-346:    59% 
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It can be seen that the percentage of cells carrying the vector varied from 
2% - 59%, despite all the cells being resistant to puromycin. Fluorescent 
microscopy confirmed the general trend of these results (Figure 3.13). 
However, there was concern that the cells did not appear to be healthy 
when cultured in the presence of both puromycin and doxycycline. 
Specifically, cell morphology was altered (Figure 3.13) and the proliferation 
rate was decreased, even when only a small percentage of cells were 
expressing RFP.  
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Figure  3.13 Fluorescent microscopy of P19 cell lines transduced with pTRIPZ (1:1) 
lentiviral particles 
Non-concentrated particles were diluted 1:1 with ultracultural serum free 
media and added to P19 cells. After 24 hours, the medium was changed to 
alpha-MEM plus 10% serum. Cells were selected with 1.6 ug/ml puromycin, 
then 1 ug/ml doxycycline added for five days.  
 
 
RT-PCR expression of Hmgn2 knockdown P19 cells was performed to 
determine the knockdown efficiency (Figure 3.14). It was found that only 
shHMGN2-968 cells showed a modest knockdown of Hmgn2 in the presence 
of doxycycline compared to wt P19 cells by 20%.  
 
 
 
Figure  3.14 RT-PCR of Hmgn2 knockdown in P19 cell lines transduced with TRIPZ 
lentiviral vectors 
Cells were selected with puromycin and induced with 1ug/ml Doxycycline 
daily for five days. Two controls are 16.1(364) (negative control), and GAPD 
(positive controls) and four shRNAmir-Hmgn2 sequence triggers are 
4.1(381),8.1 (968), 2.1 (514) and N2-1. The y-axis presents the fold change 
from delta CT value.  
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3.3.3.3 The Optimisation of pTRIPZ transduction of P19 cells 
The above experiments demonstrated that it is possible to transduce P19 
cells with pTRIPZ lentiviral particles and detect RFP. However, the 
percentage of transduced cells was low, the cells did not look healthy, and 
it was unclear whether knockdown of Hmgn2 was occurring. Further 
experiments revealed that transduced cells were much healthier when 
grown in advanced DMEM-F12 instead of alpha-MEM (data not shown), and 
from this point onwards, P19 cells were always grown in advanced DMEM-
F12. 
To increase the lentivirus titer, two different methods of concentrating viral 
particles were tested. A polyethylene glycol precipitation method was 
unsuccessful, but concentration by centrifugation through a filter unit 
increased the efficiency of transduction significantly (kit – as described in 
Chapter 2- section 2.2.4.2.3: PART C PAGE 121). The multiplicity of 
infection was also increased by reducing the density of P19 cells to 5x105 
cells per well of a six-well plate.  
 
3.3.3.4 The Generation of pTRIPZ-transduced P19 lines 
The concentrated viral particles were diluted 1:10, 1:50, 1:100 and 1:500 in 
ultracultural media in four separate transductions for each pTRIPZ vector, in 
order to determine the best dilution ratio.   
Transduced cells were selected with puromycin for one week as described 
earlier, and treated with doxycycline for up to 12 days to induce expression 
of RFP and shRNA. FACS for RFP was performed at 0, 2, 4, 5, 8 and 12 days 
of doxycycline treatment. Fluorescent microscopy was performed at day 4, 
and RNA samples and protein extracts were collected at the same time 
point (Figure 3.15).  
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Figure  3.15 Experimental design for transducing P19 cells with pTRIPZ lentivirus 
P19 cells were transduced with concentrated pTRIPZ viral particles and 
selected with 1.5 µg/ml puromycin for five to eight days. Doxycycline (1 
µg/ml) was added at day 0 and samples collected for FACS at 0, 2, 4, 6 and 
8 days.  
 
 
Figure 3.16a and b show the FACS data from the experiments using 1:10 and 
1:500 viral dilutions, respectively.  It can be seen transduction efficiency 
correlates with viral titre, as transduction with 1:10 dilution of virus (Figure 
3.16a) yielded up to 50% of RFP positive cells, whereas transduction with a 
1:500 dilution of virus yielded a maximum of 5% RFP positive cells.  Not all 
pTRIPZ vectors were equally effective. For example, shHMGN2-968 yielded 
45% and 4.5% RFP-positive cells with the 1:10 and 1:500 viral dilutions 
respectively, whereas shHMGN2-514 yielded 3% and 0.5% RFP-positive cells 
in the same experiments.  After day 6, the level of RFP in the 1:10 
experiment gradually declined, and the experiment was terminated after 
day 8 due to the loss of RFP Given the significant difference in the 
percentage of cells expressing RFP, only cells from the 1:10 dilution 
experiment were analysed in subsequent assays.  
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A) 
 
B) 
 
 
Figure  3.16 Flow cytometer (FACS) of RFP expression in P19 EC cells transduced with 
pTRIPZ lentivirus 
There are four shHMGN2 (shHMGN2-968, shHMGN2-N2-1, shHMGN2-381 and 
shHMGN2-514) and four controls, WT P19, sh-346 (non-silencing) and shN-
scramble (negative controls) and shGAPDH (positive control). A) 1:10 diluted 
viral particles B) 1:500 diluted viral particles. Cells were selected with 1.5 
μg/ml of puromycin for 8 days, then treated with 1 μg/ml doxycycline for 
the indicated times. Media was canged every 24 hours.   
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Fluorescent microscopy was performed at day 4 to check the cell 
morphology and health and RFP level (Figure 3.17). The results were similar 
to FACS analysis in that approximately 50% of cells transduced with the 
shHMGN2-381 vector were RFP0% of cells. On the other hand, the shHMGN2-
N2-1 cell line had less than 10% RFP-positive cells, whereas it was 30% in 
FACS analysis.    Negative control shN-scramble had around 50% RFP-positive 
cells by fluorescent microscopy, while it was 10% in FACS analysis (Figure 
3.17).  
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Figure  3.17 Fluorescent microscopy of P19 cells transduced with 1:10 diluted pTRIPZ 
after 4 days doxycycline treatment 
P19 EC cells were transduced with 1:10 diluted viral particles, selected with 
puromycin and treated with doxycycline for four days. Shown are the 
TurboRFP (fluorescent) image and the merge between brightfield and 
fluorescent field for each shHmgn2 (shHMGN2-381, shHMGN2-N2-1 and 
shHMGN2-968) and controls (shGAPDH, sh-346 and shN-scramble), using the 
10x objective.  
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3.3.3.5 Examine Hmgn2 expression using reverse transcriptase-coupled 
quantitative real-time (PCR) and western blot assay  
QRT-PCR was employed to detect the changes in Hmgn2 mRNA expression 
after four days of doxycycline treatment (Figure 3.18a). The results showed 
that Hmgn2 expression in shHMGN2-968 and shHMGN2-381 cells induced with 
Dox was downregulated by 80% and 30% respectively compared with wild 
type P19 EC cells. In contrast, shHMGN2-N2-1 cells failed to show any 
knockdown of Hmgn2, even though this same siRNA sequence was previously 
used successfully in transient siRNA transfections (Mohan, 2012). These 
observations may be related to the percentage of cells expressing RFP: 
shHMGN2-968  and shHMGN2-381 cells were around 45% RFP-positive at day 
4, whereas shHMGN2-2-1 cells were 25% RFP-positive at this time point 
(Figure 3.16A).  
Negative Controls (shN-scramble and shNon-silencing) with Dox showed a 
slight reduction in Hmgn2 expression. None of the cell lines showed a 
reduction in Hmgn2 expression in the absence of doxycycline. However, in 
two of the lines, Hmgn2 expression was more than two fold higher than wt 
in the absence of doxycycline.  
Hmgn1 expression was assayed in these cell lines in order to check for non-
specific knockdown by the shRNA, and to look for possible upregulation of 
Hmgn1 to compensate for a loss of Hmgn2 (Figure 4.18B). Hmgn1 expression 
was not significantly altered in shHMGN2-968 cells with or without doxycycline. 
However, Hmgn1 expression was reduced by 80% in shHMGN2-2-1 cells 
following doxycycline treatment. Furthermore, four of the samples showed 
Hmgn1 expression more than two-fold higher than wt cells. Without further 
replicates, it is not possible to conclude whether this wide variability in Hmgn1 
expression is due to the pTRIPZ transductions, or is due to other factors such as 
cell confluency or genetic drift due to time in culture.  
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A) 
 
 
B) 
 
Figure  3.18 Expression of Hmgn2 and Hmgn1 in EC P19 cells transduced with pTRIPZ 
viral particles 
EC P19 cells were transduced with a 1/10 dilution of concentrated pTRIPZ 
viral particles, selected with puromycin, and treated with doxycycline for 
four days. RNA was prepared and Hmgn2 (A) and Hmgn1 (B) expression 
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quantified using qRT-PCR. Data was normalized to GAPDH, and is plotted 
relative to expression in wt P19 cells. Mean and s.d from PCR triplicates are 
shown.  
 
Western blotting was performed in order to investigate whether Hmgn2 
protein levels were reduced in pTRIPZ-transduced cells (Figure 3.19). 
Coomassie blue staining of the gel prior to transfer, and western blotting 
using an antibody against -actin were used as loading controls. Hmgn2 
expression was significantly reduced in shHMGN2-381 and shHMGN2-N2-1 
cells (lanes 9 and 10 respectively) compared to WT P19 cells (lane 1). 
shHMGN2-968 cell lines did not show any loss of Hmgn2 protein, in contrast 
to the qRT-PCR analysis.  
 
Figure  3.19 Western blot analysis of Hmgn2 protein levels 
EC P19 cells were transduced with a 1/10 dilution of concentrated pTRIPZ 
viral particles, selected with puromycin, and treated with doxycycline for 
four days. A: coomassie blue-stained protein gel. B: western blot cut in half 
and probed with antibodies against actin (upper blot) or Hmgn2 (lower 
blot). Wild type (Lane 1); shN-scramble (lanes 2 and 7); shNon-silencing 
(lanes 3 and 8);  shHMGN2-381 (Lanes 4 and 9); shHMGN2-N2-1 (lanes 5 and 
10); shHMGN2-968 (lanes 6 and 11) respectively. No dox: lanes 1-6. 4 days 
dox: lanes 7-11.  
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3.3.3.6 Checking the expression of HMGN2 in knockdown EC P19 cells using 
fluorescent immunostaining  
The FACS analysis in Figure 3.16 shows that less than 50% of cells were 
transduced with pTRIPZ lentivirus. This means that methods such as western 
blotting and QRT-PCR are less accurate for reporting whether the different  
vectors are capable of knocking down Hmgn2 expression. 
Immunofluorescence was therefore used in order to analyse knockdown on a 
cell-by-cell basis (Figure 3.20).  
The top row of images in Figure 3.20 shows RFP expression in red, which 
represents cells transduced by the virus. The second row shows Hmgn2 
immunofluorescence in green. The third row shows a merge of the DAPI 
signal and Hmgn2 signal for the two lines with shRNAmir against Hmgn2 – 
N2-1 and 381. This shows the total number of cells in the field.  The bottom 
row shows a  merge between the red and green fields.  
In the shGAPDH and shN-scramble controls, it is clear that the intensity of 
green Hmgn2 staining is similar in all cells, whether they are expressing RFP 
or not. In shNon-silencing cells, the overall level of Hmgn3 expression is 
similar to the shGAPDH and shNscramble controls. However, some shNon-
silencing cells with high RFP expression appeared to have low Hmgn2 
expression (Figure 3.20).    
In doxycycline-treated shHMGN2-381 and shHMGN2-N2-1 cells, the overall 
level of green Hmgn2 staining appears to be reduced in over 80% and 60% of 
cells respectively (compared to the controls). This is particularly clear in 
the cells highlighted by arrows – these express high levels of RFP and have 
lower Hmgn2 than other cells in the same field.  Cells not treated with 
doxycycline expressed Hmgn2 at similar levels to the controls (Figure 3.17).  
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Figure  3.20 Immunofluorescence of Hmgn2 knockdown P19 EC cells 
Immunofluorescence analysis of Hmgn2 expression in P19 cells transduced 
with pTRIPZ lentiviral particles. Cells were treated with 1 ug/ml dox for five 
days(× 1000 magnification). A. RFP expression from the pTRIPZ vector. B. 
Hmgn2 immunofluorescence staining. C. DAPI and Hmgn2 merge image D. 
Merge image between RFP (red) and Hmgn2 (green).  
 
 
 
3.3.3.7 Investigating the influence of HMGN2 knockdown in the expression of 
stem cells pluripotent markers 
Previously, knockdown of Hmgn2 in P19 EC cells using siRNA was shown to 
reduce the expression level of Oct4, Sox2 and Nanog, as shown by qRT-PCR 
and western blot analysis (Mohan, 2012). In order to investigate whether a 
similar phenomenon was observed in cells transduced with Hmgn2-
knockdown pTRIPZ vectors, Oct4, Sox2 and Nanog levels were quantified by 
qRT-PCR. The results showed the expression levels of Oct4 and Nanog were 
relatively unchanged compared to wild type P19 EC cells after 4 days 
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(Figure 3.21a and c) or 6 days (not shown) of Dox induction. Sox2 expression 
was reduced to 50% of wt in shHMGN2-968 cells, and reduced to 20% of wt in 
shHMGN2-381 cells (Figure 3.21B).  
 
A. Oct4 expression in Hmgn2 knockdown P19 EC cells with pTRIPZ under 
doxycycline for 4 days.  
 
 
 
 
 
 
 
 
B.   
 
 
 
B. Sox2 expression in Hmgn2 knockdown P19 EC cells with pTRIPZ under 
Doxycycline for 4 days  
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C. Nanog expression in Hmgn2 knockdown P19 EC cells with pTRIPZ under 
doxycycline for 4 days  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  3.21 Expression of Oct4, Nanog and Sox2 in pTRIPZ-transduced cells 
EC P19 cells were transduced with pTRIPZ virus, selected with puromycin 
and treated with doxycycline for 4 days. RNA was harvested and qRT-PCR 
analysis for Oct4 (A), Sox2 (B) and Nanog (c) expression was carried out. 
Data was normalized to Gapdh and relative expression in wt EC P19 cells 
was set to 1.  Mean and s.d from PCR triplicates are shown. 
 
 
3.4 Discussion 
The aim of this chapter was to test two different doxycycline-inducible 
lentiviral systems for the ability to knock down Hmgn2 in mouse epiblast 
carcinoma stem cells (P19 EC cells). The pSLIK vector system was used 
initially. However, the lack of a constitutively expressed selection marker 
on this vector made it hard to select transduced cells. FACS sorting for the 
doxycycline-induced expression of GFP was not particularly helpful, and 
although a dox-induced reduction in Hmgn2 expression was observed in cells 
expressing the N2-1 shRNA, a comparable reduction in Hmgn1 expression 
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was also observed. This suggests that the Hmgn2 knockdown was not 
specific in this system. 
In an attempt to improve on the pSLIK system, the pTRIPZ lentiviral vector 
was tested. The key difference is that pTRIPZ constitutively expresses the 
gene for puromycin resistance, so transduced cells can be selected. Three 
constructs containing different shRNAmirs were chosen to knockdown 
Hmgn2: shHMGN2-381, shHMGN2-968 and shHMGN2-N2-1. It was found that 
concentration of the viral supernatant using a centrifugal filter unit enabled 
more efficient transduction. Selection of transduced cells with puromycin 
followed by 4 – 6 days of doxycycline treatment resulted in up to 50% of 
cells expressing the RFP lentiviral marker. However, there was considerable 
variation in transduction efficiency between vectors, which reduces the 
utility of this system. It is possible that the puromycin selection was not 
strong enough, or that transduction with a higher viral MOI would improve 
efficiency. Attempts to repeat these transductions, both by this researcher 
and by others, were not successful.  
It was observed that expression of RFP was maximal with 4 – 6 days of 
doxycycline treatment, but decreased significantly by day 8. Furthermore, 
freezing transduced cells and subsequent recovery resulted in much lower 
levels of RFP expression, further reducing the utility of this system. Several 
studies have demonstrated epigenetic silencing of lentiviral transgenes in 
P19 cells. Specifically, DNA methylation has been shown to silence CMV, 
EF1α and SFFV promoters in less than 17 days, whereas the A2UCOE 
promoter was not epigenetically silenced, even after 44 days (He at al, 
2005, Zhang et al, 2010).  The doxycycline-responsive TRE promoter found 
in pTRIPZ and pSLIK includes the CMV promoter, so it is possible that 
epigenetic silencing caused the reduction in RFP expression observed after 8 
days of doxycycline treatment, and the loss of RFP expression following 
cryopreservation.  
Hmgn2 expression was assayed at the mRNA and protein level to determine 
whether shRNA-driven knockdown was apparent in pTRIPZ-transduced cells. 
QRT-PCR indicated some reduction in Hmgn2 expression in dox-treated 
shHMGN2-381 and shHMGN2-986 cells. Western blotting suggested 
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knockdown of Hmgn2 protein in dox-treated shHMGN2-381 and shHMGN2-N2-
1 cells but not shHMGN2-968 cells. Immunofluorescence indicated 
downregulation of Hmgn2 protein in RFP-positive shHMGN2-381 and 
shHMGN2-N2-1 cells.   
Previous work has suggested that knockdown of Hmgn2 in P19 cells using 
siRNA leads to a reduction in the expression of the pluripotent markers, 
Oct4, Sox2 and Nanog (Mohan, 2012). In order to explore this further, 
expression of these three genes was assayed in the pTRIPZ cells. The data 
revealed that Oct4 and Nanog expression was not affected in the different 
cell lines, but that expression of Sox2 was downregulated in dox-treated 
shHMGN2-968 and shHMGN2-381 cells.  
 
3.5 Conclusions  
In summary, although the pTRIPZ system is superior to the pSLIK system in 
that transduced cells can be selected more easily, the overall percentage of 
pTRIPZ cells expressing the RFP marker did not exceed 50%. Western blots 
and immunofluorescence indicated significant knockdown of Hmgn2 in 
shHMGN-N2-1 and shHMGN2-381 cells, but this was not consistent with 
mRNA expression data from qRT-PCR assays. The inability to freeze and 
recover pTRIPZ-transduced cells proved to be a major obstacle to further 
analyses of these cells. In the next chapter, I present data using an 
alternative lentiviral vector, pGIPZ, which constitutively expresses 
shRNAmir and GFP.  
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Chapter 4 The optimization of pGIPZ 
constitutive lentiviral knockdown Hmgn2 in P19 
EC and Hepa cells  
4.1 Introduction: the pGIPZ lentiviral vector 
In parallel with the pTRIPZ work described in the previous chapter, pGIPZ 
plasmids that constitutively express shRNAmir were also tested. PGIPZ 
expresses the reporter gene GFP, the puromycin resistance gene, and 
shRNAmir from a constitutive CMV promoter (Figure 4.1). PGIPZ used 
lentivirus shRNA vector have high transduction effciency and it can 
transduced non-dividing cells such as neurons besides other primary cells 
(Hu and Luo, 2011).  
 
 
Figure  4.1 schematic diagram illustrating the expression cassette encoded by pGIPZ 
lentiviral vector 
Bi-cistronic element (IRES) transcript encoding green florescent proteins 
(GFP) and puromycin drug selection and shRNAmir driven by CMV promoter. 
Abbreviation: IRES, internal ribosome entry elements; WRE, woodchuck 
response element; LTR, long terminal repeats; puro, puromycin.  
 
 
From previous results, pTRIPZ and pSLIK showed to have a lack of stability 
under doxycycline influence and FACS and mRNA detected low transduction 
efficiency. Another issue was reported that UBC promoter is a type of Pol III 
promoter that showed to have less lentiviral transduction efficiency over 
CMV promoter (Hu and Luo, 2011 and Shin et. al., 2006). Therefore, due to 
the difficulties in knockdown P19 EC cells, a decision was made to 
knockdown P19 EC cells using constitutive system pGIPZ as this may provide 
better knockdown over pTRIPZ and pSLIK.  
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4.2 aims  
The principle aims of this chapter are to:   
1. Applying constitutive lentiviral system to knockdown Hmgn2 in P19 EC 
and Hepa cells.  
2. Comparing the pGIPZ performance between cancer stem cells (P19 EC 
cells) and hepatoma cells (Hepa cells)   
3. Identify the quick silenced transgene after the transduction due to 
the methylated promoter  
 
4.3 Results 
PGIPZ vectors used Five Lentiviral pGIPZ plasmids were obtained from Open 
Biosystems/Thermo Fisher Scientific. They were transformed into 
competent cells (DH5alpha), and then midi DNA purification was performed. 
shHMGN2-381   targets Hmgn2 
shHMGN2-514   targets Hmgn2 
shHMGN2-968  targets Hmgn2 
shGAPDH-391   targets Gapdh, positive control 
shEG2-480   targets EG2, positive control 
sh-346    non-silencing, control 
 
 
4.3.1 pGIPZ transduction of Hepa cells 
PGIPZ plasmids were transfected into HEK293T/17 cells along with 
packaging mix in order to generate viral particles. Cell supernatant 
containing viral particles was harvested after 2 days and added to P19 cells 
in various dilutions. Puromycin was then added in order to select for 
transduced cells.  
However, initial attempts to transduce pGIPZ lentiviral particles into P19 
cells had a very low success rate, with no cells surviving after puromycin 
selection. In order to investigate whether the problem was due to poor 
lentiviral production, or if P19 cells are particularly hard to transduce, the 
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same lentiviral supernatant was used to transduce the murine Hepa cell 
line.  
Transduction of Hepa cells by pGIPZ was much more efficient than the P19 
cells. Constitutive GFP expression from the pGIPZ vector was monitored by 
fluorescence microscopy (not shown) and FACS analysis (Figure 4.2 and 4.3).  
Even before puromycin selection was applied, five out of the six vectors 
tested showed transduction of more than 60% of cells (Figure 4.2). After 2 – 
4 days of selection, the percentage of cells expressing GFP increased to 
more than 80%.  
 
 
 
Figure  4.2 Percentage of Hepa cells expressing green fluorescent protein (GFP) 
following pGIPZ transduction and selection 
Hepa cells were transduced with viral supernatant, expanded, then 
puromycin added at 8 µg/ml for 0, 2, 4 or 6 days. The percentage of cells 
expressing GFP was quantified by FACS analysis. 346 is negative control, 391 
and 480 is positive control and shRNAmir-Hmgn2 sequence triggers are 968, 
381 and 514.  
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Figure  4.3 FACS analysis of pGIPZ-transduced Hepa cells 
Transduced cells were selected with 8 µg/ml puromycin for two days prior 
to analysis. Each pair of graphs corresponds to a different pGIPZ vector.  
ShRNAmir-Hmgn2 vectors are 381, 968 and 514, whereas 391 and 480 are 
positive controls and 346 is the negative control. The dot plots on the left of 
each pair represent the health and size of the transduced cells (black dots) 
comparing with wt Hepa cell lines (blue dots). The x axis shows the forward 
scatter (shape) of the cells and the y-axis shows the side scatter (size) of 
the cells. The histogram plot on the right shows GFP expression in 
transduced cells (red line) comparing with WT P19 cells (purple line) in the 
R1 gate. The x axis represents the green channel from 102 to 106 and the y 
axis represents the number of cells.   
 
 
4.3.2 pGIPZ transduction of P19 cells 
The observation that the pGIPZ lentiviral particles could transduce Hepa 
cells efficiently implied that a much higher multiplicity of infection is 
required to transducer P19 cells. Consequently, and as described in Chapter 
3 for the pTRIPZ particles, 12ml of pGIPZ viral particles from 10 cm dish 
were concentrated with a centrifugal filter by 350ul. 
P19 cells were transduced with concentrated virus, expanded, and selected 
for up to 6 days with 2.5 µg/ml puromycin. GFP expression was assayed 
every two days (Figure 4.4 and 4.5) FACS results showed 30-90% GFP 
expression for all vectors except for pGIPZ-shHMGN2-514. Indeed, pGIPZ-
shHMGN2-514 cells showed low survival and low GFP expression in both 
Hepa and P19 cells (Figures 4.2, 4.3, 4.4 and 4.5), so these cells were not 
analysed further.  
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Figure  4.4 Percentage of P19 cells expressing green fluorescent protein (GFP) 
following pGIPZ transduction and selection 
P19 cells were transduced with viral supernatant, expanded, then 
puromycin added at 2.5 µg/ml for 0, 2, 4 or 6 days. The percentage of cells 
expressing GFP was quantified by FACS analysis. 346 is negative control, 391 
and 480 is positive control and shRNAmir-Hmgn2 sequence triggers are 968, 
381 and 514.  
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Figure  4.5 FACS analysis of pGIPZ-transduced P19 cells 
Transduced cells were selected with 2.5 µg/ml puromycin for four days prior 
to analysis. Each pair of graphs corresponds to a different pGIPZ vector.  
shRNAmir-Hmgn2 vectors are 381, 968 and 514, whereas 391 and 480 are 
positive controls and 346 is the negative control. The dot plots on the left of 
each pair represent the health and size of the transduced cells (black dots) 
comparing with wt Hepa cell lines (blue dots). The x axis shows the forward 
scatter (shape) of the cells and the y-axis shows the side scatter (size) of 
the cells. The histogram plot on the right shows GFP expression in 
transduced cells (red line) comparing with WT P19 cells (purple line) in the 
R1 gate. The x axis represents the green channel from 102 to 106 and the y 
axis represents the number of cells.   
 
 
The ability of the different pGIPZ vectors to knockdown Hmgn2 expression 
was assayed using qRT-PCR (Figure 4.6). It can be seen that expression of 
Hmgn2 in shHMGN2-381 cells was reduced by over 70%, whereas expression 
in the positive and negative controls was unaltered. shHMGN2-968 did not 
cause a knockdown of Hmgn2 expression.  
 
Figure  4.6 Hmgn2 expressions in transduced P19 cell lines with PGIPZ lentiviral 
constitutive system 
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The transduced cells were normalized based on WT P19 cells. Three controls 
are 346 (negative control), 391 and 480 (positive controls) and three 
shRNAmir-Hmgn2 sequence triggers are 381, 968 and 514. The y-axis 
presents the fold change from delta CT value. Each RT-analysis represents 
the day of Collection after the Puromycin selection. Day 2 (A) shows no 
knockdown in Hmgn2 in P19 cells whereas Day4 (B) and Day6 (C) shows 
knockdown in 318 around 60% to 65%. For 968 the knockdown did not appear 
until day 6 for around 90% whereas 514 shows 60% knockdown in day 4 but it 
failed to survive until day 6.  
 
 
 
Figure 4.6 Hmgn2 expressions in P19 cell lines transduced with PGIPZ 
lentiviral vectors. Cells were selected for four days with 2.5 µg/ml 
puromycin. Hmgn2 expression was assayed using real time RT-PCR and 
normalised to actin. Relative expression compared to wt cells is plotted on 
the y-axis. Data represent the mean and standard deviations of PCR 
triplicate reactions.  Controls are 346 (negative control), 391 and 480 
(positive controls) and three shRNAmir-Hmgn2 sequence triggers are 381, 
968 and 514.  
We observed on several occasions that when P19 cells carrying pTRIPZ or 
pGIPZ vectors were frozen then thawed; expression of the reporter gene 
was greatly reduced. This is illustrated in Figure 4.7 Before the 
cryopreservation, FACS analysis showed greater than 50% GFP-positive cells 
in various pGIPZ cell lines. After thawing and puromycin selection for four 
days, the fraction of GFP positive cells was less than 2%. To investigate 
whether the GFP reduction was due to promoter silencing, we treated the 
cells with 5-Aza-2’-deoycytidine.  We found that two days of treatment with 
this drug increased the percentage of GFP-positive cells to 15-20%, and five 
days of treatment further increased the percentage to 20-50%  (Figure 4.7). 
This suggests that the CMV promoter at pGIPZ expression vector can be 
silenced by DNA methylation during cryopreservation.  
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Figure  4.7 The effect of 5-Aza-2-deoxycytidine on the percentage of GFP-positive cells 
following cryopreservation. 
pGIPZ-transduced cells were grown in 2.5 μg/ml puromycin for 15 days, 
then cryopreserved. After thawing, cells were grown for 3 days, before 
addition of 2.5 μg/ml puromycin for 4 days.  5-aza-2-deoxycytidine (8 μM) 
(Hofmann et. al., 2005) was added for 2 days (red) and 5 days (green), or 
not at all (blue).   
 
4.4 Discussion 
In this chapter, the lentiviral vector system pGIPZ was tested. After 
optimization of media, transfection conditions, drug selection and 
concentration of viral particles, high efficiencies of P19 cell transduction 
were obtained. In contrast, Hepa cells were much more easily transduced, 
and did not require concentrated viral particles.   
 
Cribbs and his colleagues (2013) compared the concentrated with 
unconcentrated Lentiviral particles. They demonstrated that concentrated 
Lentiviral particles decreased 10 fold in viral collection. This is indicated 
that there was a loss of virus during the ultracentrifugation process. 
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However, they found increase of target gene called NGFP (nerve growth 
factor receptor) expression when they transduced their primary T cells 
under concentrated lentivirus. They suggested that concentrator eliminates 
several conditions from the viral particles supernatant. Consequently the 
ultracentrifugation with a reduction of centrifuge speeds from 90,000 g to 
20,000 g  can increase the transduction efficiency and stability. Therefore, 
optimizing the centrifugation speed is critical to produce high viral titer 
with high transfection stability (2013). 
 
Comparison of the pSLIK, pTRIPZ and pGIPZ vector systems in chapter 3 and 
4 highlights the importance of choosing an appropriate lentiviral system for 
the cell type being studied. Key properties include:: (i) shRNA expressed in 
the form of shRNAmir, so a polymerase II promoter can be used to drive 
expression (ii) a strong, or regulatable, polymerase promoter to drive 
shRNAmir expression (iii) a single vector containing all doxycycline-
regulatory machinery, with no need for specific cell line (iv) a reporter gene 
(GFP or RFP) to be used as an indication of transduced cells (Meerbrey et. 
al., 2011) (v) a selectable marker such as the puromycin resistance gene.  
 
In chapter 3, it was discussed how epigenetic silencing of the TRE promoter 
in pSLIK and pTRIPZ vectors might be contributing to the loss of reporter 
gene expression over time and during cryopreservation.  Loss of reporter 
gene expression was also observed during cryopreservation of cells 
transduced with pGIPZ. Treatment of these cells with 5-Aza-2’-deoycytidine 
reactivated GFP expression, suggesting that the loss of GFP expression was 
due to DNA methylation of the CMV promoter, as has been previously 
observed in P19 cells (He et al 2005, Zhang et al 2010). One way to address 
this problem in future would be to replace the CMV promoter in the pGIPZ 
vector with a promoter that is resistant to epigenetic silencing, such as 
A2UCOE or CAG (Zhang et al 2010) 
 
Both pTRIPZ and pGIPZ use an IRES (internal ribosomal element) to allow 
bicistronic expression of the puromycin resistance gene. In pTRIPZ, the 
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construct is rtTA3-IRES-puro and in pGIPZ, the construct is GFP-IRES-puro.  
Ibrahimi and his colleagues (2009) found that IRES is less efficient and more 
cell type-dependent than the self cleaving peptides T2A and P2A at allowing 
production of two proteins from one transcript. Poor functioning of the IRES 
element in P19 cells could result in low expression of the puromycin 
resistance gene. This would mean the multiple copies of the viral vector per 
cell are required to generate resistance, and so a higher concentration of 
virus is needed to obtain efficient transduction. Changing the IRES element 
to P2A or T2A in the pTRIPZ and pGIPZ vectors could improve transduction 
efficiency in future experiments.  
 
4.5 Conclusion remark  
The purpose of this chapter was to optimize the lentivirus system and to 
address the difficulties in transduced P19 cell lines. Due to the difficulties 
to transduced stem cells, Choosing the efficient Lentiviral system for stem 
cells depend on the following properties: (i) the backbone of the vector is 
miR-30 and these miRNA expressed from strong promoter such as 
polymerase II promoter  (ii) using single vector with no need for specific cell 
line (iii) in inducible Lentiviral system, the basal transcription profiles of 
shRNA should be high in polyclonal population (iv) the reporter gene (GFP or 
RFP) is used as an indication of transduced cells (Meerbrey et. al., 2011) (v) 
puromycin consistency depend on bicistronic vectors from IRES can be 
problematic with a replacement of  T2A or P2A can increases the gene 
expression efficiency (Ibrahimi et. al.,2009). However, creating a stable 
robust transduced cell with lentivirus can be challenging for many reasons: 
(i) constitutive system can generate gene silencing during cell culture for 
more than one month (ii) inducible system can cause leaking expression due 
to the rtTA random positions in the cell lines (iii) freezing and thawing the 
transduced cell in constitutive system pGIPZ can cause the gene silencing. 
Therefore, a further experiment need to preform to modify the plasmids 
and transduced P19 EC cells.   
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Chapter 5 The functional role of Hmgn2 in 
embryonic carcinoma stem cells using a 
constitutive knockdown  
5.1 Introduction 
Chapters 3 and 4 have described the testing of pSLIK, pGIPZ and pTRIPZ 
lentiviral vectors for the knockdown of Hmgn1 and/or Hmgn2 in P19 
embryonal carcinoma cells. To summarise: we were unable to get high 
levels of pSLIK transduction, mainly due to the lack of a selection marker on 
the lentiviral vector. Although pTRIPZ carries a puromycin selectable 
marker, we were again unable to obtain cell populations with more than 
50% of cells expressing the RFP reporter. In contrast, with pGIPZ we were 
able to obtain 80-90% of cells expressing the GFP reporter. Knockdown of 
Hmgn2 was observed with vectors carrying shRNAmir against Hmgn2 in 
several instances. However, the data was not always consistent, possibly 
due to variable infection levels. The difference between pGIPZ and pTRIPZ 
is likely to be the strength of the promoter driving the reporter-shRNAmir 
construct: in pGIPZ, the promoter is CMV, whereas in pTRIPZ it is the 
doxycycline-regulated TRE promoter.  
With both pTRIPZ and pGIPZ, we found that expression of the reporter was 
greatly reduced by freezing and recovering the cells. This expression could 
be rescued to certain extent by treating the cells with the DNA methylation 
inhibitor, 5-azacytidine, indicating that the lentiviral vectors may be 
epigenetically silenced during the freeze-thaw process. This phenomenon 
significantly impacted on our ability to analyse the phenotype of the 
knockdown cells, as we could not go back to previous cultures to collect 
more samples.  
At this stage, a decision was made to focus on the pGIPZ system, as this was 
giving the highest levels of transduction. This chapter describes how viral 
particles were made from control and experimental vectors in parallel, and 
P19 cells were transduced, selected and expanded to allow the collection of 
FACS data, RNA, protein and chromatin samples at different time points. 
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5.2 Aims  
 
1. To establish a constitutive microRNA-mediated Hmgn2 knockdown 
system in EC P19 cells using the pGIPZ lentiviral approach.  
2. Investigate the cell surface marker expression in knockdown Hmgn2  
3. Investigate the expression of putative Hmgn2 target genes upon 
knockdown Hmgn2.  
4. Further examine other pluripotent marker in Hmgn2 knockdown cells.   
 
 
5.3 Results  
5.3.1 Generation of P19 EC cells transduced with pGIPZ lentiviral 
vectors 
Figure 5.1 shows the experimental timeline for generating P19 EC cells 
transduced with the pGIPZ constitutive shRNAmir30 system. The plan is 
divided into five parts: transfection, transduction, expansion, puromycin 
selection and sample collection. Each stage was optimised to achieve a high 
transduction level.  
Transfection: Five pGIPZ vectors were used for constitutive expression of 
GFP-shRNAmir.  
 
shHMGN2-381:   targets Hmgn2 
shHMGN2-514:   targets Hmgn2 
shHMGN2-968:   targets Hmgn2 
shGAPDH:    targets Gapdh, positive control 
sh-346:    non-silencing, negative control 
 
Lentiviral expression vectors (pGIPZ) and packaging vector mix were 
transfected into HEK293/17 cells, and medium containing viral particles was 
collected 48 hours later.   
Viral particles were concentrated 30 fold using centrifugal concentrators. 
P19 EC cells were transduced with these lentiviral particles for 36 hours in 
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ultracultural media without serum, before transferring to standard P19 
media with serum. Cultures were then expanded for seven days to generate 
enough cells for the selection process.   
Puromycin was added at 1.5 µg/ml on day 0. On day 5, the puromycin 
concentration was increased to 2 µg/ml, and on day 15 it was increased to 
2.5 µg/ml. This gradual increase in selection pressure is intended to 
eliminate cells with low levels of lentiviral gene expression, thus enriching 
for cells with high expression. GFP expression was monitored by FACS every 
five days, and protein and RNA samples were collected at the same time 
points. At the final time point, day 25, chromatin was prepared from the 
cells (Figure 5.1) 
 
 
 
Figure  5.1 Experimental model for generating the P19 knockdown cell lines using the 
pGIPZ lentiviral constitutive system 
Lentiviral particles were generated and collected from host HEK293T/17 cell 
lines. Concentrated viral particles were transduced into P19 cells, and the 
culture expanded for 7 days. Puromycin was added at 1.5 µg/ml on day 0. 
On day 5, the puromycin concentration was increased to 2 µg/ml, and on 
day 15 it was increased to 2.5 µg/ml. Every five days a FACS analysis, 
protein and RNA were extracted and collected for further analysis.  
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5.3.2 FACS analysis on transduced P19 EC cell line 
FACS was used to assay for GFP expression over the time course of the 
experiments (Figure 5.2). It can be seen that the percentage of cells 
expressing GFP rises as selection pressure is increased, leading to a 
maximum of 97% GFP in the GAPDH and 381 cells. 968 and 381 had 72% and 
53% GFP respectively, whereas the 514 cells failed to survive.  
Healthy cells were gated based on their forward and side scatter, in order 
to distinguish them from dying or dead cells (Figure 5.2). It can be seen that 
after day 2, the percentage of healthy cells was greater than 60% in most 
samples. This indicates that increasing the selection pressure did not have a 
detrimental effect on the overall health of the cell cultures.   
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Figure  5.2 Flow cytometer analysis of pGIPZ-transduced cells 
A: Percentage of healthy cells within the population, and the percentage of 
GFP-positive cells within the healthy cell population.  B: GFP percentage 
from part A is plotted against time for each cell line.  
 
 
5.3.3 Screening the positive transduced knockdown cells using 
fluorescent microscopy  
Transduced P19 EC cell lines were analyzed at day 27 for any changes in 
gross morphology due to loss of Hmgn2. Fluorescent microscope pictures 
were taken on live cells on the same day of performing FACs analysis for the 
cell surface marker SSEA1. Figure 5.3 shows the GFP expression and cell 
morphology of the transduced cell lines. Cell morphology was not 
significantly altered in the Hmgn2 knockdown P19 EC cell lines (381 and 
968) compared with control shRNA-non-silencing or shGAPDH P19 EC cell 
lines.    
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B.  
 
 
Figure  5.3 Microscopy examination of HMGN2 knockdown P19 cell lines 
GAPDH (positive control), non-silencing (negative control), HMGN2 (968) and 
(381) at x20 magnification. A: White and yellow arrows point to regions of 
high and low GFP, respectively. B: The regions within orange boxes on the 
bright field are shown magnified in the lower panels to illustrate cell 
morphology.  
 
 
5.3.4 Screening the Hmgn2 knockdown P19 cell lines for possible 
spontaneous cell differentiation  
The pluripotent status of pGIPZ-transduced P19 EC cell lines was assessed 
using FACS analysis for SSEA-1 pluripotency marker, which is located on the 
cell surface.  
As expected, the majority of GAPDH, non-silencing and shHMGN2-381 cells 
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expressed GFP. This is shown by most of the cells lying in the right half of 
each plot, compared with the untreated wt P19 control, where all the cells 
are in the left half of the plot. Interestingly, the GFP-expressing cells fall 
into two discrete groups, of cells with low and high GFP. It can be seen that 
the high intensity green signal of the second group appears to “leak” into 
the red channel, giving some red signal even in the absence of a red 
fluorescent antibody (middle column). 
 
The negative control IgG antibody did not change the overall pattern of red 
and green staining for the shNon-silencing and shHMGN2-381 - transduced 
cells (compare the left with the middle column). However, most of the 
shGAPDH cells in the lower left quadrant of the middle plot are absent from 
the IgG control and the SSEA-1 plot. This phenomenon occurred in both 
replicates. It could be due to non-specific staining by the IgG and SSEA-1 
antibodies giving signal in the green channel, or it could be due to loss of 
these cells during the washing steps (Figure 5.4A).   
 
Figure 5.4B shows that 74% of wt P19 cells are SSEA-1 positive. Strikingly, in 
pGIPZ-shNon-silencing and pGIPZ-shHMGN-381 cells that express GFP (ie are 
carrying the lentivirus), the proportion of SSEA-1-expressing cells is very 
similar, at 73% and 76% respectively. This suggests that the pluripotency of 
these cells has not be significantly affected by the lentiviral vector. 
In contrast, cells carrying the pGIPZ-shGAPDH vector and expressing GFP are 
only 4% SSEA-1 positive. This could represent a loss of pluripotency in cells 
that have a knockdown in GAPDH expression. However, given the concerns 
about the IgG control in the shGAPDH cells, it is not possible to draw any 
firm conclusions.  
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A.  
 
B. 
Sample name  %SSEA1 
positive 
cells 
%GFP cells %GFP cells that are SSEA1 
positive  
WT-P19 (CONTROL) 74% n.a n.a 
GAPDH(Positive 
control) 
5% 99% 4% 
Non-silencing 
(Negative control) 
78% 79% 73% 
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shHMGN2-381 88% 59% 76% 
Figure  5.4  FACS analysis for GFP and SSEA-1 expression in pGIPZ-knockdown P19 
cells 
A: Dot plots, where the x-axis represents the (BL1) green channel and 
corresponds to GFP expression. The y-axis represents the (BL2) red channel 
and corresponds to SSEA-1 expression. Each horizontal row corresponds one 
cell type: WT-P19, GAPDH , Non-silencing and shHMGN2-381. In the top row, 
the left hand plot is unstained cells, the middle plot is cells transiently 
transfected with a plasmid expressing GFP, and the right plot is cells 
incubated with anti-SSEA-1. These plots were used to set the gates for the 
four quadrants. In the other three rows, plots on the left column show cells 
incubated with the IgG control. The middle plots are unstained cells, and 
the right plots are cells incubated with anti-SSEA-1.  The analysis was 
performed twice on unfixed, live cells on the day 25. B: the left column is 
the total percentage of SSEA-1-positive cells, the middle column is the total 
percentage of GFP-positive cells, and the right column is the percentage of 
GFP cells that are also SSEA-1 positive.   
 
 
5.3.5 HMGN2 knockdown in undifferentiated mouse embryonic 
carcinoma EC P19 cells   
Western blotting (Figure 5.5A and B) and real time RT-PCR (Figure 5.5C) 
were performed to examine HMGN1 and HMGN2 expression in pGIPZ-
transduced P19 EC cells. Using whole cell extracts, western blotting was 
performed and normalized based on histone H3 (Figure 5.5A and B). In cells 
carrying pGIPZ-shHMGN2-381, expression of Hmgn2 was reduced at both the 
RNA and the protein level, indicating successful knockdown. Expression of 
Hmgn1 in this line was similar to wt. levels. 
Hmgn2 expression was not reduced in pGIPZ-shHMGN2-968 cells, even 
though this vector also targets Hmgn2. Hmgn1 protein levels were reduced 
in these cells, although Hmgn1 mRNA was unaffected.  
In pGIPZ-shNon-silencing cells, Hmgn1 and Hmgn2 mRNA was reduced, but 
protein levels were unaffected. Similarly, in pGIPZ-shGAPDH cells, Hmgn2 
mRNA was reduced but HMGN2 protein was unaffected.  
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C.  
 
 
 
 
 
 
 
 
Figure  5.5 Hmgn1 and Hmgn2 expression in pGIPZ-transduced P19 cells after 20 days 
of selection 
A. Western blotting was performed for Hmgn1 and Hmgn2, with H3 as the 
loading control. B. Coomassie blue gel of normalised whole cell extracts. C. 
Hmgn1 and Hmgn2 mRNA expression as quantified using real time rt-PCR, 
with α-tubulin as the control and normalised to the shNon-silencing cells. 
The error bars represent standard deviations from three qPCR reaction 
replicates.  
 
 
5.3.6 HMGN2 knockdown influence the expression of key pluripotency 
genes 
Previous data from the lab had indicated that expression of Nanog, Oct4 and 
Sox2 was reduced in Hmgn2-knockdown cells. Figure 5.6A and B show gene 
expression and protein analysis were performed in Hmgn2 knockdown P19 
EC cells for Nanog, Oct4 and Sox2.  
It can be seen that Oct4 protein and mRNA is reduced in the shNon-silencing 
cells, as well as in shHMGN2-381 and shHMGN2-968 cells. 
Nanog mRNA and protein is reduced in shGAPDH, shHMGN2-381 and 
shHMGN2-968 cells, and the mRNA is also reduced in shNon-silencing cells.  
Sox2 mRNA and protein is reduced in shNon-silencing and shHMGN2-968 
cells, and the proteins are also reduced in shGAPDH cells.  
0
1
2
3
4
5
6
H
m
g
n
2
 f
o
ld
 c
h
a
n
g
e
 
sample ID  
Hmgn2 expression in hmgn2 knockdown EC P19 
cells 
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
5
H
m
gn
1
 f
o
ld
 c
h
an
ge
 
Sample ID 
hmgn1 expression in hmgn2 knockdown P19 cells day 
20 
202 
 
 202 
A. 
B.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0
0.5
1
1.5
2
2.5
Sox2 expression in hmgn2 knockdown EC P19 cells 
0
1
2
3
4
5
6
7
Oct4 expression in hmgn2 knockdown EC P19 cells  
0
1
2
3
4
5
6
7
Nanog expression in knockdown P19 cells  
203 
 
 203 
 
Figure  5.6 Nanog, Oct4 and Sox2 expression in pGIPZ-transduced P19 cells after 20 
days of selection 
A. Western blotting was performed for Nanog, Oct4 and Sox2, with H3 as the 
loading control. B. Coomassie blue gel of normalised whole cell extracts. C. 
Nanog, Oct4 and Sox2 mRNA expression as quantified using real time rt-PCR, 
with α-tubulin as the control and normalised to the shNon-silencing cells. 
The error bars represent standard deviations from three qPCR reaction 
replicates. 
 
 
5.3.7 Knockdown HMGN2 in EC P19 cells influence other genes 
expressions that involved in induce pluripotent stem cells formation.  
Two additional pluripotency markers were also studied: c-myc and KLF4. 
Both genes showed increased protein levels in shNon-silencing and 
shHMGN2-381 cells compared to the other lines. However, levels of c-myc 
mRNA were not significantly altered, and Klf4 mRNA was increased in 
shGAPDH and shNon-silencing samples (FIGURE 5.7A and B).  
 
A.  
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Figure  5.7 Klf4 and c-myc expression in pGIPZ-transduced P19 cells after 20 days of 
selection 
A. Western blotting was performed for Klf4 and c-myc, with H3 as the 
loading control. B. Coomassie blue gel of normalised whole cell extracts. C. 
Klf4 and c-myc mRNA expression as quantified using real time rt-PCR, with 
α-tubulin as the control and normalised to the shNon-silencing cells. The 
error bars represent standard deviations from three qPCR reaction 
replicates. 
 
The above data do not indicate specific changes in the expression of Oct4, 
Sox2, Nanog, c-myc or Klf4 that correlate with the loss of Hmgn2 
expression. Changes in gene expression that occur in both Hmgn2-
knockdown and control cells may be a result of non-specific effects of 
shRNA expression, either through off target miRNA-like effects on protein 
translation, or through activation of the interferon pathway.  
Interpretation of the data is complicated by the fact that the mRNA and 
protein results are not always consistent. This could be due to biological 
effects on protein translation or stability that are not seen at the RNA level. 
The differences could also be technical artefacts arising from variable 
protein extraction efficiency, RNA contamination, or protein extract 
degradation.  
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5.4 Discussion   
The aim of this chapter was to gain further insight into the effect of Hmgn2 
loss in pluripotent and induce pluripotent markers in epiblast P19 EC cells. 
This was accomplished by applying a constitutive knockdown lentiviral 
shRNA based on microRNA system.  
Constitutive long period of Hmgn2 knockdown in undifferentiated epiblast 
P19 EC cells revealed three findings: i) long term knockdown for Hmgn2 in 
epiblast P19 EC cell protocol process, ii) two population bright green and 
less green of Hmgn2 knockdown P19 EC cells using fluorescent microscope 
and SSEA1 cell surface staining, iii) the loss of Oct4 and Nanog and gain of 
Sox2, Klf4, C-myc and Hmgn1 expression using western blot and qRT-PCR. 
Several experiments attempted to generate Hmgn2 knockdown P19 cell lines 
(Chapter 3 and Chapter 4). Three stages used to process to achieve the 
knockdown of Hmgn2 in EC P19 cells: generating viral particles by host cells 
(HEK293/17 cell lines), P19 EC cell transduced with lentiviral particles and 
puromycin selection. These three stages depend on four factors: lentiviral 
plasmid promoters, the health of the HEK293T/17 and EC P19 cell lines, 
lentiviral efficiency, and puromycin concentration influence. However, after 
short period of puromycin selection (day 2 and 5), Hmgn2 did not show any 
evidence of GFP cells. PGIPZ plasmid expression represents by the 
expression of GFP report gene in transduced cells (green or GFP cells) . GFP 
cells were observed in day 10, 15 and 20 under increase of puromycin 
selection start from 1.5, 2 and 2.5 ug/ml. The last day of collection (day25) 
GFP cells showed a slight reduction in GFP cells in transduced P19 EC cells. 
This result suggests two points: one is the chance of gaining high Hmgn2 
knockdown P19 cell population by increasing the puromycin concentration 
and one CMV promoter silencing in pGIPZ lentiviral plasmid due to 
methylation on promoter site in constitutive knockdown system.  
Hmgn2 knockdown process revealed two populations after purimycine 
selection using Cell compensation and fluorescent microscope. Bright and 
light GFP population can be seen clearly on cell compensation using SSEA1 
staining for cell pluripotency. This polyclonal population may affect on the 
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level of Hmgn2 knockdown and other affected gene expressions. These 
results suggest that although using puromycin drug selection for increasing 
the chance for collecting high positive Hmgn2 knockdown, the level of 
Hmgn2 knockdown still variant due to the differences of viral particles 
concentration in some cells.  
The Knockdown of Hmgn2 may affect significantly by overexpression the 
Hmgn1 in RNA and protein. However, still unclear if the knockdown of 
Hmgn1 will gain the same effect on Hmgn2 expression using the same 
constitutive system. In addition, the knockdown of Hmgn2 did not change 
the expression of Hmgn3a RNA (data did not shown). These results suggest 
that the loss of Hmgn2 may be compensated by increase expression of 
Hmgn1.  
The knockdown of Hmgn2 may leads to reduction in the expression of some 
pluripotent genes Oct4 and Nanog whereas Sox2 was over expressed in 
Hmgn2 knockdown P19 EC cells in RNA and Proteins. In the induce 
pluripotent markers, Hmgn2 knockdown P19 EC cells leads to expression of 
C-myc and Klf4. In protein analysis, it showed that there is slight reduction 
of Klf4 comparing with negative control non-silencing while in C-myc, it 
showed that more reduction. In gene expression, it revealed that C-myc and 
Klf4 had a significant down regulated. Interestingly, wild type P19 EC cells 
showed less or no expression of C-myc and Klf4 in protein and RNA which 
can bring skeptical thoughts that wild type epiblast P19 EC cells may not 
have high expression of Klf4 and C-myc comparing with embryonic stem 
cells. However, there were some contradictions in the data from western 
blot and gene expression analysis due to variability levels of protease 
activity in protein extract (the protein lysis buffer was lab made) and 
variability level of transduced cells in RNA extract (see appendix Figure S1). 
on the other hand, These results may recommend two points: i) Hmgn2 may 
be act as mediator of key pluripotent genes and ii) Hmgn2 can possibly 
induce the epiblast stem cells to be more embryonic stem cells  
In earlier study shows that Furusawa and colleagues (2006) found that 
Hmgn1 expression was high in epiblast mouse embryogenesis from day E7.5-
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E9.5 and fairly strong on E10.5 unlike ectoderm embryonic region. they 
found that knockdown Hmgn1 in mice enhance the expression of Hmgn2 
expression due to the lack of phenotype raising the possibility of 
homeostatic mechanisms. The level of hmgn2 in knockout Hmgn1 was the 
same as the level of Hmgn1 over expression mice. In siRNA study Knockdown 
Hmgn2 in EC P19 cells did not affect the expression of Hmgn family 
members (Mohan, 2012). On the other side, Furusawa and colleagues finding 
was match with the presented results here, Hmgn1 was more expressed 
than Hmgn2 in P19 EC cells in protein analysis. However, in gene expression 
both Hmgn1 and Hmgn2 wild type P19 EC cells give high level of expression. 
in Hmgn2 knockdown P19 EC cells the normalization was accomplished by 
using negative control (non-silencing). In this case non-silencing protein 
analysis in Hmgn1 and Hmgn2 were relatively high, but it seems that there 
is more expression of Hmgn1 than Hmgn2 whereas Hmgn2 knockdown in 
shHMGN2-381 clearly showed over expression of Hmgn1. Two possible 
hypotheses can be used to explain the data. First, P19 EC cell lines have 
endogenous high amount of Hmgn1 than Hmgn2 which may affect on the 
Hmgn2 knockdown P19 EC cells. Second, Hmgn1 compensate for the loss of 
Hmgn2 to either drive the cells to become more specific or pluripotent cells 
using novel pathway. Third, technical difficulties by using constitutive 
lentiviral system based on drug selection may affect on the P19 cells.   
to investigate whether the Hmgn2 knockdown cells that have lost the key 
pluripotent markers ,Oct4 and Nanog, may maintain the cell pluripotency. 
In presented study here, Protein and RNA analysis showed that knockdown 
of Hmgn2 affect the Oct4 and Nanog expression while Sox2 expression were 
up regulated in the same cells by 2 fold change. Moreover, cell cycle 
analysis was performed on thawed Hmgn2 knockdown P19 EC cell lines using 
pripeidoum iodide (PI)  showed more cell arrested in G1 and cell 
proliferation rate was higher than wild type P19 EC cells (data did not 
show). These results suggested two hypothetical questions: one if more cells 
arrested in the S-G2 phase of the cell cycle, and one whether the Hmgn2 
Knockdown lead to cells (epiblast cells are on late blastocysts) commitment 
to next (early post-implantation) or previous cell state (early blastocysts). 
208 
 
 208 
To investigate the first hypothesis, SSEA1 (CD15) were expressed in Hmgn2 
knockdown P19 EC cells by almost half of expression comparing with non-
silencing  
During culturing Hmgn2 knockdown P19 EC cells, there were several points 
were raised from observing Hmgn2 knockdown cell under the cell 
microscope and noticing cell proliferation rate. First, the knockdown P19 EC 
cells seems to grow as colonies but not as monolayers as P19 EC cells. 
second, the cells were growing very fast as wild type P19 EC cells. these 
two observation gain indication that the knockdown cells may reserve its 
pluripotency instead of committed to differentiation state. Klf4 and C-myc 
are common transcriptional factors to be used in induced pluripotent stem 
cells beside Oct4 and Sox2. In this study here, Hmgn2 knockdown showed 
downregulation of C-myc and Klf4 normalized either negative control (non-
silencing) or wild type P19 EC cells. in western blot, Klf4 and C-myc have 
slight reduction comparing with non-silencing.  
Nevertheless, these results showed four issues: i) pGIPZ a constitutive 
plasmid contain CMV promoter, which can be methylated less than a month, 
ii) western blot data from whole protein extract may have experienced 
some proteinase activity which showed some degradation in the quality of 
protein, iii) RNA was extracted from polyclonal population that had 
variability in GFP level, and iv) from public mouse RNA sequences data 
showed that shRNA sequences for Hmgn2, 381, 968, and 514 contain 
pseudogenes which may also explain the variability in gene expression. 
Therefore, it will be challenging to repeat just the protein extract without 
repeating the whole experiment. Consequently, analysing the protein 
content of crosslinked chromatins preparation may be very useful for this 
scenario.   
 
 
 
 
 
209 
 
 209 
5.5 Conclusion remark  
 
The results of this chapter show that Hmgn2 may play novel roles in 
pluripotency and reprogramming of epiblast P19 EC cells. Hmgn2 long 
knockdown specifically affect the expression of pluripotent and induce 
pluripotent markers. Further experiments need to carry out before deriving 
any further conclusion.  
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Chapter 6 Profiling the endogenous Hmgn2 and 
Hmgn2 knockdown events across the Oct4 and 
Nanog region in mouse epiblast P19 EC 
6.1 Introduction 
Hmgn proteins act by binding to nucleosomes and modulating chromatin 
structure. They have been shown to alter histone modifications, compete 
with linker histones and influence enhancer structure (Deng et. Al. 2015 and 
Subramanian et. al., 2009). A major aim of this project was to investigate 
whether chromatin structure was altered in P19 cells that have a knockdown 
in Hmgn2.  
 
Previous work in the lab had indicated that the expression of Oct4, Sox2 and 
Nanog was decreased in cells with a transient knockdown of Hmgn2 (Mohan 
2012). ChIP assays had shown that histone H3 lysine 4 methylation was 
reduced and H3K27me3 was increased, at the Oct4 and Nanog loci in 
Hmgn2-knockdown cells (K. West, unpublished). H3K4me3 is typically 
associated with active promoters, and H3K27me3 is often associated with 
genes that become silenced, for example during development (Bernstein et. 
Al., 2006).  
 
The first aim of this chapter was to investigate whether the pattern of 
histone modifications at the Oct4 and Nanog loci is similar in P19 cells 
compared to mouse embryonic stem cells. Embryonic stem cells (E14) were 
chosen as a control, as ENCODE research teams have characterised histone 
modifications, chromatin features and the binding profiles of many 
transcription factors across the mouse E14 genome. These ChIP assays 
should indicate whether the chromatin features in the teratocarcinoma P19 
cells are significantly different to the normal mouse ES cells.  
 
Before performing ChIP at the Oct4 and Nanog loci in Hmgn2 knockdown 
cells, it is important to know whether the expression of these genes is 
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actually altered. The data presented in Chapter 5 were inconclusive as to 
whether the expression of these genes was altered in Hmgn2 knockdown 
cells. There was concern as to whether the whole cell extract method 
adequately extracts chromatin-bound factors, or whether proteolytic 
activity had degraded the protein samples. The fact that frozen stocks of 
these cells cannot be regrown meant that new protein extracts could not be 
obtained from these cells. In an alternative approach, this chapter presents 
western blotting of chromatin in which cross links have been reversed. This 
method reveals the levels of several chromatin-bound proteins in pGIPZ-
transduced P19 cells. 
 
Following on from the western blotting of chromatin, ChIP assays were 
performed to investigate Hmgn binding and histone modifications at the 
Oct4 and Nanog loci in Hmgn2 knockdown cells.  
 
6.2 Aims   
 
5. Compare the global levels of histone modifications and chromatin-bound 
Hmgn1 and Hmgn2 in P19 and mES E14 cells using western blotting of 
crosslinked chromatin. 
6. Compare the histone modifications at the Oct4 and Nanog loci in EC P19 
cells and ES E14 cells using crosslinking ChIP assay. Examine the global 
changes in chromatin-bound factors in Hmgn2 knockdown P19 EC cells 
using western blot.  
7. Investigate changes in histone modifications at the Oct4 and Nanog genes 
in Hmgn2 knockdown cells using ChIP. 
8. Investigate the migration of TATA-binding protein using CO-IP in 
chromatin and whole cell protein extract.  
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6.3 Results  
6.3.1 Preparation of cross-linked chromatin from wild type P19 and E14 
cell lines.  
An optimised ChIP protocol routinely used in the lab was followed for all 
ChIP experiments (Barkass et. al., 2012). Crosslinked chromatin was 
prepared from P19 EC and mES E14 cells, and sonicated to an average 
fragment size of 300-100 bp ready for immunoprecipitation (Figure 6.1).  
 
  
Figure  6.1 Shearing of wild type P19 and E14 chromatin. 
Agarose gel electrophoresis of sonicated P19 and E14 chromatin after 
reversal of crosslinks and purification of DNA.  
 
6.3.2 ChIP primer design 
ChIP real time PCR primers were designed against the promoter and 
transcribed region of the Oct4 and Nanog genes, using ENCODE data as a 
guide (Figure 6.2) . This data revealed the enrichment of the active 
promoter mark H3K4me3  active over the  transcription starting sites (TSS) 
of the Oct4 and Nanog genes.  On the other hand, the same promoter 
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regions have no enrichment of the repressive mark H3K27me3 (Figure 6.3 A 
and B).  
A.  
 
B. 
 
Figure  6.2 UCSC genome browser view of mouse Oct4 (A) and Nanog (B) genes on 
chromosome 17 and 6. 
The data includes the primer sets that were used in QPCR-ChIP experiment. 
Moreover, the data presents E14 ChIP-seq data for histone (H3K4me3 and 
H3K27me3) at Oct4 and Nanog regions. Oct4 and Nanog both contain 
enrichment of H3k4me3 at the transcription starting sites (TSS).  
(https://www.encodeproject.org). 
 
 
Primers were designed to encompass the H3K4me3 peak and surrounding 
region (Table 6.1). A primer set that detects the major satellite (Msat) 
repeat served as a control for heterochromatin, and a primer for the 
housekeeping gene (β-actin ) was also used.  
Oct4 primer set Distance from 
Oct4 TSS 
Nanog primer 
set 
Distance from 
Nanog TSS 
Oct1 -1781bp N1 -1081bp 
Oct2 -399bp N2 –219bp 
Oct3 +410 N3 +929bp 
Oct4 +2070 N4 +1740 bp 
Oct5 +3342 N5 +2636bp 
Table  6.1 Location of Oct4 and Nanog loci primer sets 
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6.3.3 HMGN proteins in E14 and P19 cells 
After the chromatin extraction step, western blotting can be performed to 
ensure the quality of chromatin and detect the bound proteins. Benzonase 
digestion was used to digest native or heat-denatured DNA and RNA 
followed by reversal of crosslinks to separate any conjugated proteins. Then 
samples were ready for western blot application. Figure 6.3 shows western 
blotting for Hmgn1 and Hmgn2 proteins in wt P19 and E14 cells. The results 
show that more Hmgn2 is bound to chromatin in E14 cells than in P19 cells, 
whereas Hmgn1 is present at similar levels in both cell types.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  6.3 Western blotting for Hmgn2 and Hmgn1 in chromatin isolated from P19 EC 
and E14 cells 
The chromatin was treated with benzonase enzyme to remove the DNA, 
then crosslinks were reversed prior to electrophoresis. H3 is the loading 
control.  
 
 
ChIP assays were performed as described previously (Barkess et al 2012) . 
ChIPs were performed in duplicate and the final samples were combined 
before analysis.  Real time PCR was used to quantify DNA that was 
immunoprecipitated. Ct values were normalised to input and then to the 
MSat primer set using the Ct method. 
ChIP was performed using an antibody to histone H3 as a control (Figure 
6.4). This antibody should detect all modified forms of H3, as it recognises 
an epitope in the C-terminus. In Figure 6.4 it can be seen that enrichment 
HMGN2 
HMGN1 
H3 CT PAN 
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of H3 is very even across both the Oct4 and Nanog loci in P19 cells. In E14 
cells, the enrichment of H3 is slightly lower over the Nanog gene 
 
 
 
Figure  6.4 H3 enrichment at the Oct4 and Nanog gene loci in P19 and E14 cells 
CHIP-QPCR analysis of H3 enrichment at the Oct4 and Nanog loci. Data was 
normalised to input and the MSat primer set. Error bars represent the errors 
from PCR triplicates. 
 
 
Hmgn1 and Hmgn2 binding at the Oct4 and Nanog pluripotent genes is shown 
in Figure 6.5. On the Nanog gene, Hmgn2 binding is enriched by up to 6-fold 
compare to the MSat control. In both P19 and E14 cells, the highest level of 
Hmgn2 binding is at the N2 primer set, which is the one nearest to the TSS 
(-291 bp).  
Similar levels of Hmgn2 binding are seen at the Oct4 locus. Binding is 
slightly higher at the two primer sets nearest the TSS: OCT2 (-399 bp) and 
OCT3 (+410bp), but the trend is less clear than it is at the Nanog locus.   
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Figure  6.5 Hmgn2 binding at the Oct4 and Nanog gene loci in P19 and E14 cells. 
CHIP-QPCR analysis of Hmgn2 enrichment at the Oct4 and Nanog loci. Data 
was normalised to input and the MSat primer set. Error bars represent the 
errors from PCR triplicates. 
 
Figure  6.6 Hmgn1 binding at the Oct4 and Nanog gene loci in P19 and E14 cells. 
CHIP-QPCR analysis of Hmgn1 enrichment at the Oct4 and Nanog loci. Data 
was normalised to input and the MSat primer set. Error bars represent the 
errors from PCR triplicates. 
 
Hmgn1 binding at the Oct4 and Nanog loci also showed up to 7 fold 
enrichment compared to the MSat control (Figure 6.6). However, there did 
not appear to be increased enrichment near the TSS of either gene in either 
P19 or E14 cells.  
0
1
2
3
4
5
6
7
8
OCT1. OCT2. OCT3. OCT4. OCT5. N1 N2 N3 N4 N5 ACTIN MSAT
re
p
la
ti
ve
 e
n
ri
ch
m
e
n
t 
 
P19 EC cells WT E14 cells
0
1
2
3
4
5
6
7
8
OCT1. OCT2. OCT3. OCT4. OCT5. N1 N2 N3 N4 N5 ACTIN MSAT
re
la
ti
ve
 e
n
ri
ch
m
e
n
t 
 
WT P19 EC cells WT E14 cells
217 
 
 217 
 
6.3.4 Active and repressive Histone modifications in P19 and E14 cells 
H3K4me3 and H3K27me3 are key histone modifications that often mark 
active promoters and repressed genes, respectively (Bernstein et. al., 
2006). In order to investigate whether the global levels of these 
modifications are different in P19 and E14 cells, western blotting on 
chromatin samples was performed (Figure 6.7).  TBP was used as a loading 
control. The levels of both H3K4me3 and H3K27me3 were similar in P19 
cells compared to E14 cells (Figure 6.7). 
 
 
 
 
 
 
 
 
Figure  6.7 Western blotting for H3K4me3 and H3K27me3 chromatin from EC P19 and 
E14 ES cells 
Chromatin was treated with Benzonase enzyme to remove the DNA, then 
crosslinks were reversed prior to electrophoresis. TBP is the loading control. 
 
 
 
 
In E14 cells. H3K4me3 was enriched by 30 -35 fold at Oct4 primer sets 2, 3 
and 4 (Figure 6.8). These primer sets correspond to the regions of highest 
H3K4me3 enrichment observed in the publically available ChIP-seq data 
from the ENCODE project (Figure 6.2).  H3K4me3 was also highly enriched 
(20-40 fold) at Nanog primers sets 3, 4 and 5 (Figure 6.8), again 
corresponding to regions with high H3K4me3 in Figure 6.2.  
H3K4me3 
H3K27me3 
TBP 
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In P19 cells, relative levels of H3K4me3 at the Oct4 and Nanog genes were 
only up to six fold higher than those observed at MSat (Figure 6.9).  
 
Figure  6.8 H3K4me3 enrichment at the Oct4 and Nanog gene loci in P19 and E14 cells. 
CHIP-QPCR analysis of H3K4me3 enrichment at the Oct4 and Nanog loci. 
Data was normalised to input and the MSat primer set. Error bars represent 
the errors from PCR triplicates. 
 
ChIP for H3K27me3 is shown in Figure 6.9. As expected, H3K27me3 levels at 
the Oct4 and Nanog genes were low, as these genes are not repressed in P19 
or E14 cells.  
 
Figure  6.9 H3K27me3 enrichment at the Oct4 and Nanog gene loci in P19 and E14 cells 
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CHIP-QPCR analysis of H3K27me3 enrichment at the Oct4 and Nanog loci. 
Data was normalised to input and the MSat primer set. Error bars represent 
the errors from PCR triplicates. 
 
 
6.3.5 Genome-wide analysis of Hmgn2 binding  
The ChIP data presented above suggests that Hmgn1 and Hmgn2 do not bind 
specifically at promoters, but are instead bound at fairly similar levels at all 
the genomic loci tested. Similar conclusions have been reached from other 
studies in the lab (Barkess et. al., 2012). However, it is possible that peaks 
of Hmgn binding have been missed due to the locations of the PCR primer 
sets. To gain a clearer understanding of where Hmgn2 is bound across the 
genome, ChIP-seq was used to profile the binding of HMGN2 across the 
mouse P19 genome (performed by Dr. K. West).   
Figure 6.10 shows the ChIP-seq data of Hmgn2 binding at the Nanog gene 
locus in P19 cells. In addition, ChIP-seq data from ENCODE project 
representing the histone modification (H3K4me3 and H3k4me1) from mouse 
embryonic stem cells. are shown. The Hmgn2 ChIP-seq track shows well-
defined peaks of enrichment.  These peaks are not present in the Histone 
H3 control track, showing that these genomic sequence elements might be 
specifically enriched by immunoprecipitation of HMGN2 protein. Moreover, 
histones H3K4me1 ChIP-seq from ENCODE project showed a peak of 
enrichment that correlates with one of the Hmgn2 peaks, upstream of the 
Nanog gene. These peaks seem to be located at the enhancer region of 
Nanog genes marked by red arrows, whereas histone H3K4me3 is enriched at 
the 5’ end of transcription starting sites (TSS).  
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Figure  6.10 ChIP-seq of HMGN2 and H3 in undifferentiated EC cells 
ChIP-seq localization of Hmgn2 and H3 in P19 EC cells, and ENCODE project 
views of H3K4me3 and H3K4me1 ChIP-seq profiles from ES cells. ChIP-seq 
peaks and summits identified by Sicer analysis with H3 as control are shown 
in black below the ChIP-seq track. UCSC annotated genes are shown in blue 
and the direction of the transcription is indicated by arrows (above track). 
The enriched location is identified by black track for Hmgn2 comparing with 
H3 as control and histone modifications (H3K4me3 and H3K4me1) in ES cells. 
The enriched location between HMGN2 and histone H3K4me1 are shown in 
red arrow.  
 
6.3.6 Preparation of cross-linked chromatin from Hmgn2 knockdown P19 
cell lines.  
As described in Chapter 5, Hmgn2 knockdown cells were generated using 
shRNAmir expressed using the pGIPZ constitutive lentiviral system. These 
cell lines were analyzed using FACS, RT-PCR, and western blotting (Chapter 
5). Chromatin was prepared as described in Chapter 2 (Barkess et. al., 
2012), and sonicated to reach to an average fragment length of 500-100bp 
ready for immunoprecipitation (Figure 6.11).  
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Figure  6.11 Shearing of wild type P19 and E14 and HMGN2 KNOCKDOWN P19 
chromatin. 
Agarose gel electrophoresis of P19 EC and E14 chromatin after sonication to 
an average fragment size of 200 – 1000 bp for use in ChIP.   
 
 
 
6.3.7 Hmgn2 is undetectable in chromatin from pGIPZ-shHMGN2-381 – 
transduced P19 cells.   
In order to investigate the level of chromatin-bound Hmgn1 and Hmgn2 in 
pGIPZ-transduced P19 cells, western blotting was used (Figure 6.12). As 
described for Figure 6.3 chromatin was treated with Benzonase to digest the 
nucleic acid, and crosslinks were reversed prior to electrophoresis. H3 was 
used as the loading control. Strikingly, Hmgn2 protein was undetectable in 
chromatin from shHMGNG-381 cells, whereas it was present in cells carrying 
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the negative control, shNon-silencing, vector. No reduction in Hmgn2 
protein was observed in cells carrying the shHMGN2-968 vector, even though 
this is intended to target Hmgn2. Conversely, the amount of chromatin-
bound Hmgn1 was increased in shHMGN2-381 cells, compared to wt P19 cells 
(Figure 6.12).  
These results are similar to those observed using whole cell extracts (WCE) 
(Figure 5.5). In shHMGN2-381 cells, both WCE and chromatin show a large 
reduction in Hmgn2 levels, and an increase in Hmgn1 levels. In shHMGN2-
968 cells, no reduction in Hmgn2 expression is observed in either WCE or 
chromatin, indicating that this shRNA trigger is unsuccessful in knocking 
down Hmgn2. There are some inconsistencies between the WCE and 
chromatin data, however. For example, the WCE blots show reduced Hmgn2 
levels in the wt P19 sample, and Hmgn1 is absent from the shHMGN2-968 
sample (Figure 5.5). 
 
 
Figure  6.12  Analysis of Hmgn2 knockdown in pGIPZ-transduced P19 cells 
The chromatin was treated with benzonase enzyme to remove the DNA, and 
then crosslinks were reversed prior to electrophoresis. H3 is the loading 
control.  
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6.3.8 Analysis of chromatin-bound factors in pGIPZ-transduced cells 
Western blotting was unable to detect Oct4 in chromatin from shHMGN2-381 
cells (Figure 6.13), whereas there was no reduction in shHMGN2-968 cells. 
Oct4 was significantly reduced, but not absent, in shNon-silencing cells.   
TBP was assayed initially as a loading control. However, in shHMGN2-381 
and shNon-silencing cells, the normal TBP is absent or reduced, and a higher 
mobility band was detected by the antibody (Figure 6.13).  
 
 
 
 
 
Figure  6.13 Oct4, Nanog and TBP immunoblot from chromatin (input) after 25 days of 
HMGN2 knockdown in EC P19 cells. 
 
 
Other pluripotent and induce pluripotent factors were conducted using 
western blot for Input. Sox2 and C-myc was lost in Input of shHMGN2-381 
comparing with non-silencing while Klf4 showed a gain of expression in 
shHMGN2-381 comparing with non-silencing (Figure 6.16). These results 
contradict with western blot for whole protein extract which showed UP-
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regulation in Sox2 and slight down regulation in C-myc and Klf4 for the same 
shHMGN2-381 cell line (Chapter 5).  
 
 
 
 
 
Figure  6.14 C-myc, Klf4 and Sox2 Immunoblot from chromatin (input) after 25 days of 
HMGN2 knockdown in EC P19 cells 
 
 
6.3.9 Chromatin immunoprecipitation of Hmgn proteins in Hmgn2 
knockdown cells 
As shown above, western blotting revealed that Hmgn2 and Oct4 were 
undetectable in chromatin from shHMGN2 cells. To investigate whether the 
binding of Hmgn2 to the Oct4 gene locus was reduced, ChIP assays were 
performed using chromatin from shHMGN2-381 cells, and the control, 
shNon-silencing cells.  
Control ChIPs using non-immune IgG and histone H3 were performed in order 
to compare the chromatin from the two cell lines (Figures 6.15 and 6.16). 
IgG is a control for background levels of non-specific immunoprecipitation, 
and reveals primer sets that might have abnormal results. H3 controls for 
differences in the ability of the chromatin preparations to be 
immunoprecipitated. For example, significant differences in crosslinking 
efficiency, size differences due to varying sonication efficiency, or loss of 
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protein epitopes due to over-sonication could alter the profile of chromatin-
bound proteins or modifications. All enrichments are calculated relative to 
that for the Msat primer set, which normalizes for differences in the total 
amount of chromatin that is immunoprecipitated. 
Similar levels of IgG immunoprecipitation were observed in chromatin from 
shNon-silencing and shHMGN2-381 cells (Figure 6.15). Enrichment was higher 
at the actin promoter compared with the Oct4 and Nanog primers, 
particularly with the shNon-silencing chromatin (9 fold higher than Msat), 
indicating that care must be taken when interpreting data from this primer 
set.   
Levels of H3 enrichment were similar in both cell types, although slightly 
higher in chromatin from shNon-silencing cells (Figure 6.16). Enrichment at 
the actin promoter was up to 2.5 fold higher than Msat in shNon-silencing 
cells, which is less than the 9 fold observed with the IgG control.  
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Figure  6.15 ChIP using non-immune IgG in Hmgn2 knockdown cells. 
Chromatin was prepared from P19 cells transduced with pGIPZ-ShNon-
silencing (negative control) or pGIPZ-shHMGN2-381 (Hmgn2 knockdown). 
ChIP was performed using rabbit IgG, and qPCR carried out with primers to 
the Oct4 and Nanog gene loci. Data was normalised to input and the Msat 
primer set. Error bars represent the errors from PCR triplicates.  
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Figure  6.16 Enrichment of H3 around the Oct4 and Nanog TSS in knockdown P19 EC 
cells 
Chromatin was prepared from P19 cells transduced with pGIPZ-ShNon-
silencing (negative control) or pGIPZ- shHMGN2-381 (Hmgn2 knockdown). 
ChIP was performed using an antibody to the C-terminal region of H3, and 
qPCR carried out with primers to the Oct4 and Nanog gene loci. Data was 
normalised to input and the Msat primer set. Error bars represent the errors 
from PCR triplicates.  
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ChIP for Hmgn2 showed that most of the Hmgn2 binding at the Oct4, Nanog 
and Actin loci is absent in shHMGN-381 cells, in contrast with up to 7 fold 
enrichment at these sites in shNon-silencing cells (Figure 6.17). This is 
consistent with the global loss of Hmgn2 protein observed in the western 
blots of the chromatin (Figure 6.12).   
Notably, binding of Hmgn1 is increased at the Oct4, Nanog and Actin loci in 
shHMGN2-381 cells compared to shNon-silencing cells (Figure 6.18) This is 
consistent with the increase in chromatin-bound Hmgn1 observed by 
western blotting in Figure 6.12.  
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Figure  6.17 Global loss of Hmgn2 around Oct4 and Nanog TSS regions in knockdown 
P19 EC cell lines. 
Chromatin was prepared from P19 cells transduced with pGIPZ-ShNon-
silencing (negative control) or pGIPZ- shHMGN2-381 (Hmgn2 knockdown). 
ChIP was performed using an antibody to the C-terminal region of Hmgn2, 
and qPCR carried out with primers to the Oct4 and Nanog gene loci. Data 
was normalised to input and the Msat primer set. Error bars represent the 
errors from PCR triplicates.  
 
0
1
2
3
4
5
6
N1 N2 N3 N4 N5 ACTIN MSAT
re
la
ti
ve
 e
n
ri
ch
m
e
n
t 
 
Nanog promoter sites  
Non-silencing
shHMGN2-381
230 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  6.18 The enrichment of Hmgn1 around Oct4 and Nanog TSS in knockdown EC P19 
cells. 
Chromatin was prepared from P19 cells transduced with pGIPZ-ShNon-silencing 
(negative control) or pGIPZ- shHMGN2-381 (Hmgn2 knockdown). ChIP was 
performed using an antibody to the C-terminal region of Hmgn1, and qPCR 
carried out with primers to the Oct4 and Nanog gene loci. Data was normalised 
to input and the Msat primer set. Error bars represent the errors from PCR 
triplicates. 
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6.3.10 Changes in histone modifications at the Oct4 and Nanog genes in 
Hmgn2 knockdown cells 
 
Western blotting of chromatin was performed to investigate if there were any 
global changes in the levels of H3K4me3 or H3K27me3 in Hmng2 knockdown cells 
(Figure 6.19). The results showed no significant changes in the levels of these 
modifications. The histone variant H2A.Z was also assayed, but this did not 
change in shHMGN”-381 cells either (Figure 6.19).  
 
 
Figure  6.19 analysis of HMGN2 knockdown cells EC P19 cells. 
Western blot from chromatin INPUT on knockdown cells comparing with WT EC 
P19 and ES E14 cells shows the histones variants. The knockdown binding sites of 
HMGN2 (shHMGN2-381 and shHMGN2-968), a negative control region (shNon-
silencing), and positive control region (shGAPDH).  
 
 
 
 
Chromatin immunoprecipitation was performed to investigate whether level of 
histone modifications at the Oct4 and Nanog loci were altered in Hmgn2 
knockdown cells (Figure 6.20 and 6.21). The results show that H3K4me4 was 
significantly reduced at most Oct4, Nanog and Actin primer sets in Hmgn2 
knockdown P19 cells (shHMGN2-381) compared to control (shNon-silencing) cells 
(Figure 6.20).Levels of H3K27me3 across these loci were also reduced in Hmgn2 
knockdown cells (Figure 6.21) 
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Figure  6.20 The enrichment of H3K4me3 around Oct4 and Nanog TSS in knockdown EC P19 
cells 
Chromatin was prepared from P19 cells transduced with pGIPZ-ShNon-silencing 
(negative control) or pGIPZ- shHMGN2-381 (Hmgn2 knockdown). ChIP was 
performed using an antibody to H3K4me3, and qPCR carried out with primers to 
the Oct4 and Nanog gene loci. Data was normalised to input and the Msat primer 
set. Error bars represent the errors from PCR triplicates. 
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Figure  6.21  The enrichment of H3K27me3 around Oct4 and Nanog TSS in knockdown EC 
P19 cells 
Chromatin was prepared from P19 cells transduced with pGIPZ-ShNon-silencing 
(negative control) or pGIPZ- shHMGN2-381 (Hmgn2 knockdown). ChIP was 
performed using an antibody to H3K27me3, and qPCR carried out with primers to 
the Oct4 and Nanog gene loci. Data was normalised to input and the Msat primer 
set. Error bars represent the errors from PCR triplicates. 
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6.3.11 The investigation of TBP migration using CO-IP against ubiquitination 
and/or acetylation  
As previously shown in Figure 6.13, anti-TBP recognised a protein approximately 
10-15 kDa larger than typical TBP in chromatin from some of the GIPZ-
transduced cell lines. In order to investigate these further, westerns for TBP in 
whole cell extracts (WCE) were also carried out (Figure 6.22). The higher Mw 
band was also observed in WCE for some pGIPZ_transduced cell lines, although 
this phenomenon was not specific to the Hmgn2 knockdown cells (ShHMGN2-381) 
(Figure 6.22) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  6.22 TBP migration immunoblot after 25 days HMGN2 knockdown whole-cell extract 
and chromatin 
 
 
We reasoned that the higher Mw band could be an alternative splice form of 
TBP, a phosphorylated form, or an ubiquitinated form. Multiple phosphorylation 
and ubiquination sites on TBP have been demonstrated (follow from 
www.phosphosite.org). In order to test whether ubiquitination was involved, a 
co-immunoprecipitation assay was performed.    
Co-immunoprecipitation (CO-IP) was carried out using an antibody for ubiquitin 
(Figure 6.23A) or non-immune IgG (Figure 6.23B).  Chromatin samples were 
treated with benzonase and crosslinks reversed prior to the Co-IP assay.  After 
CO-IP, samples were western blotted, and membranes probed with the antibody 
to TBP.  
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B) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  6.23 TPB may interact with di- and mono- ubiquitination. 
Immunoprecipitation with ubiqutinylation antibody FK2 (A) or non-immune IgG 
(B). Either whole cell extracts (left) or chromatin samples (right) were used. 
Chromatin samples were treated with benzonase and crosslinks reversed prior to 
the Co-IP assay.  Western blots of Co-IP samples were probed with anti-TBP 
(expected size 37 kDa).  
 
 
TBP band A 
TBP band B 
 Chapter 6 236 
 
 236 
 
Co-IP using IgG did not pull down any bands corresponding to the expected 
37kDa band, or higher mobility forms (Figure 6.23B). However, co-IP using the 
ubiquitin antibody in chromatin extracts pulled down two bands A and B, from 
pGIPZ-transduced cells. Co-IP from WCE pulled down the lower band A in wt P19 
and shHMGN2-381 samples only. Close inspection of these blots indicated that 
the lower band A has an apparent Mw of ~50 kDa, and the upper band B has an 
apparent mobility of ~60 kDa, by comparison with the 56 Kda marker. The 
calculated Mw of TBP is 37 kDa, although the apparent Mw in cell extracts varies 
between 40 and 45 kDa (Abcam manufacture), and a single ubiquitin group has a 
Mw of 8.5 kDa (Li et. al., 2015). It is possible that the lower band A corresponds 
to TBP with a single ubiquitin mark conjugated to it, and the upper band B has 
two ubiquitin marks. However, further experiments are required in order to 
investigate this further (see appendix Figure x3 and x4 the difference between 
TBP western blot in PGIPZ and PTRIPZ).  
 
 
 
6.4 Discussion  
 
The aim of this chapter was to use ChIP technology to identify Hmgn2-DNA 
interactions in the P19 EC and E14 cell line and compare with the loss of Hmgn2 
in P19 EC cell lines. Moreover, the use of western blot for input and ChIP-qPCR 
was the first stage to validate the loss of Hmgn2 on pluripotent genes such as 
Oct4 and Nanog.  
6.4.1 The effect of Hmgn2 knockdown in pluripotent stem cells 
Many studies from different tissues showed the remodelling the chromatin 
structure level could affect the core and linked histones, the regulatory factor of 
DNA assembly and epigenetic modification. These modifications regulate the 
transition period from an inactive to active genome during embryonic 
development. One of these modifications was conducted in Hmgn proteins 
knockout mouse, which caused a delay early embryonic development (Bastos et. 
al., 2008). From previous study, Knockdown of Hmgn2 and/or Hmgn1 showed 
reduction in Oct4, Sox2, and Nanog genes in P19 EC cells using siRNA (Mohan, 
2012). This may indicate that Hmgn1 and Hmgn2 binding site enhance the 
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regulatory region of these pluripotent genes. Therefore, Hmgn1 and Hmgn2 may 
act as mediator to maintain the pluripotent markers by interacting with other 
transcription factors. Hmgn2 knockdown with shRNA showed downregulation of 
Oct4 and Nanog at the protein and RNA level.  
6.4.2 Hmgn2 and H3K4me3 are enriched in Oct4 and Nanog region of P19 EC 
cells and E14 stem cells  
ENCODE data of H3K4me3 ChIP-seq from E14 cells showed enrichment in Oct4 
and Nanog at the transcription starting sites (TSS) of ESC cells. Hence the 
enrichment of H3K4me3 at the TSS of Oct4 and Nanog was investigated in mouse 
stem cells, Hmgn2 may affect at the regulatory region of Oct4 and Nanog. 
Therefore, ChIP followed by QPCR was performed to confirm any changes in 
regulatory region of Oct4 and Nanog in only P19 EC cells. Normal ChIP was 
applied in wild type P19 EC cells and E14 cells. The results show more of Hmgn2 
than Hmgn1 by 2-3 relative enrichment in E14 and P19 EC cells. Moreover, 
H3K4me3 is highly enriched in E14 cells at Oct4 and Nanog regions whereas 
H3K4me3 was found P19 EC cells less enrichment. However, in H3K27me3 there 
is more or similar level of enrichment in E14 and P19 EC cells. This may indicates 
that due to P19 EC is embryo carcinoma stem cells, more genes may be silenced. 
Since transgene silencing in P19 EC cells showed that P19 EC cells play roles in 
normal preimplantation embryos and other type of precursor cells. Therefore, it 
was concluded that both P19 EC and ES cells might have similar gene silencing 
mechanism (He et. al., 2005).  
6.4.3 Western blots from Hmgn2 knockdown input downregulated Oct4, 
Sox2, and C-myc and up-regulated Klf4  
Previously, Hmgn2 knockdown in P19 EC cells was conducted to confirm the 
down regulation of pluripotent genes such as Oct4, Sox2, and Nanog and induce 
pluripotent genes such as Klf4 and C-myc by RNAi technology (Chapter 5). 
ShHMGN2-381 and non-silencing (negative control) knockdown cells were 
selected to perform ChIP assay. After collecting chromatin samples, western blot 
for input was applied to examine the pluripotent genes expressions profile in 
these cells without adding antibodies. The results show similarity and variability 
between the chromatin and whole protein western blot in the same genes. 
Western blot results show similarity in Hmgn1 and Hmgn2. Hmgn2 knockdown 
 Chapter 6 238 
 
 238 
and over expression of Hmgn1 in shHMGN2-381 was confirmed in both protein 
and chromatin western blot. Nanog and Oct4 did not show protein or chromatin 
expression. 
6.4.4 QPCR for ChIP revealed a loss of Hmgn2 and H3K4me3 enriched 
binding and slightly enrichment of H3K27me3 in Oct4 and Nanog binding 
regions  
Beside western blot for input, QPCR-ChIP results on Hmgn2 knockdown P19 EC 
cells demonstrate three points. First, Hmgn2 showed low enrichment in Oct4 and 
nanog region whereas Hmgn1 showed high enrichment in Oct4 at position, O1 (-
1781) and O2 (-399) and Nanog at position N1 (-1081), and N2 (-219) in Hmgn2 
knockdown cell. On the other hand, H3K4me3 and H3K27me3 at the same region 
(TSS) in Oct4 and nanog showed loss of enrichment in Hmgn2 knockdown P19 EC 
cells.  
6.4.5 TBP western blot showed migrated bind leading to suspect that TBP 
may be experienced ubiquitination  
The protein and input western blot results of Hmgn2 knockdown P19 EC cells 
demonstrate there is TBP migration occurs. CO-IP of TBP was performed against 
phosphorylation (data did not show) and ubiquitination. However, the results fail 
to explain the changes in TBP protein. In addition, it is important to note that 
ChIP-QPCR was from one biological replicated only. Moreover, there is a chance 
of background raised from normal method of ChIP which was shown by 
measuring the delta CT value to input sample. Furthermore, there were 
difficulties in sonicated chromatin of Hmgn2 knockdown. 
6.5 Conclusion remark  
 
The results of this chapter showed ChIP technology for P19 EC, E14 and Hmgn2 
knockdown in only P19 EC cells. This finding may exhibit novel roles of Hmgn2 as 
safeguard for pluripotency and reprogramming mechanism due to its interaction 
with Oct4, Sox2, Nanog, Klf4 and C-myc. Hmgn2 knockdown ChIP-QPCR showed 
H3k4me3 beside Hmgn2 lost enrichment in Oct4 and Nanog region whereas 
Hmgn1 gained the enrichment at the same region. Further experiments need to 
carry out before deriving any further conclusion.  
 
 Chapter 7 239 
 
 239 
 
Chapter 7 Summary and Future work  
7.1 Summary of work presented in this thesis  
Gene transcription, genomic stability, cellular differentiation and development 
are affected by chromatin remodelling. A group of architectural proteins called 
High mobility group proteins (HMGN) are associated with nucleosome involving in 
chromatin remodelling architecture and modifying gene expression. One of the 
main critical functions of these proteins was found in the development of 
mouse, human and chicken. However, investigating the role of HMGN2 proteins 
in embryonic stem cells remains unclear. A pilot project in Dr. Katherine West 
lab previously found that Hmgn2 knockdown with siRNA technology caused 
downregulation of Sox2, Oct4 and Nanog in P19 EC cells (Mohan, 2012).  
The principle aims of this thesis were to confirm the previous results of siRNA 
knockdown tool in P19 EC cells. Using lentivirus based on shRNAmir technology. 
Hmgn2 expression in undifferentiated P19 EC cells throughout endogenous RNA 
interference process was preformed to achieve a stable, long term, and high 
level of Hmgn2 knockdown to study the role of Hmgn2 in mouse cancer stem 
cells. Oct4 and Nanog binding sites across the mouse genome during mouse 
genome of P19 EC cells and ES cells were identified by western blot of 
chromatin, qPCR-ChIP and ENCODE protein of ES cells. Moreover, western blot of 
chromatin and qPCR-ChIP was used to investigate the Hmgn2 knockdown peaks 
throughout Oct4 and Nanog binding sites besides investigating the enrichment of 
Hmgn1 and histone (H3, H3K4me3, and H3K27me3) at Oct4 and Nanog binding 
sites.  
 
7.2 The optimization of lentiviral pSLIK-CD4, pGIPZ, and pTRIPZ 
knockdown in P19 EC, Hepa and E14 cells  
 
P19 EC cells are well-characterized cell line to study cancer stem cell and stem 
cells induced to neuron, muscles and cardiac differentiation. Chapter 3 
describes the optimization condition of the undifferentiated P19 EC cells which 
were applied as main target knockdown Hmgn1 and Hmgn2 using three lentiviral 
based on shRNAmir technology. Prior to generating lentiviral particles, P19 EC 
cell was examined under puromycin and doxycycline drug concentration. 
 Chapter 7 240 
 
 240 
Doxycycline drug was used for inducible lentiviral system to induce shRNAmir 
expression. The optimal concentration for Doxycycline amount was 1 μg/ml using 
luminescent 96-well plate assay for cellular ATP and gene expression of Hmgn2 
and Oct4.  Puromycin drug was tested using puromycin kill curve and Flow 
cytometer analysis (FACS) on day 3 and 5 to identify the amount of puromycin 
concentration and check the health of the cells.  
Four shRNAmir-30 (Hmgn2-1, Hmgn1-2, Hmgn1-3, and Hmgn-scramble) were 
designed with ccdB gene and received inside pENTER-TGmiRC3. Then, shRNA was 
moved to pSLIK-CD4 (lentiviral vector) throughout gateway cloning 
recombination system. Finally pSLIK-CD4-shHmgn was created for all four Hmgn 
triggers. Generating knockdown of mmHmgn1 or mmHmgn2 proteins failed 
beyond expectation due to the low level of transduction of Hmgn2 expression in 
knockdown cells. Alternatively, pTRIPZ is another inducible lentiviral knockdown 
system was developed by open biosystem. The difference between pSLIK and 
pTRIPZ is that shRNAmir-30 is under the control of TRE promoter in pSLIK-CD4 
whereas shRNAmir-30 and red florescent protein reporters are under the control 
of TRE promoter in pTRIPZ. Moreover, The reverse tetracycline transactivator 
(rtTA3) and reporter gene are under the control of constitutively active 
promoter (UBC-i) in pSLIK system. However, the reverse tetracycline 
transactivator and drug selection are under the control of constitutive promoter 
(UBC) in pTRIPZ. PSLIK system contains inactive CMV promoter can be used to 
switch the plasmid to constitutive system rather than doxycycline inducible 
whereas pTRIPZ does not contain CMV promoter. Four shRNA-Hmgn from pGIPZ 
and shRNA-Hmgn2-1 from pSLIK-CD4 were cloned to pTRIPZ. After generating 
knockdown of Hmgn2 using pTRIPZ, the level of Hmgn2 knockdown in mRNA and 
FACS analysis was not high enough to affect the pluripotent gene (Oct4, Sox2 
and Nanog) expressions.  
Therefore, Chapter 4 represents the constitutive lentiviral system (pGIPZ) from 
open bio-system was applied to achieve high, efficient, and stable knockdown 
for Hmgn2 in P19 EC and Hepa cell lines. Hmgn2 knockdown using pGIPZ in P19 
EC and Hepa cells was very efficient. A significant reduction of Hmgn2 was 
observed by mRNA analysis. However, it was noticed that knockdown Hmgn2 in 
Hepa cells were significantly efficient and easier than P19 EC cells.  
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7.3 Characterization and identification of Hmgn2 knockdown and Hmgn2 
binding sites in undifferentiated P19 EC cells (Chapter 4 and 5) 
 
Chapter 5 describe the establishment of Hmgn2 knockdown using lentiviral pGIPZ 
in undifferentiated P19 EC cells. Five shRNAs (381, 968, 514, non-silencing and 
GAPDH) generated knockdown of Hmgn2 proteins by almost 80%-90%. Hmgn2 
knockdown cell lines showed significant upregulation of Hmgn1. This result 
indicate that Hmgn2 compensated with Hmgn1 when there is a loss of Hmgn2. 
Moreover, these knockdown cells were used to investigate in the expression of 
key pluripotent and induce pluripotent genes. Hmgn2 knockdown cells showed 
dramatic downregulation of pluripotent genes, Oct4 and Nanog whereas Sox2 
showed a clear upregulation. These results indicate that Hmgn2 play a role in 
the regulation of pluripotent genes, Oct4 and Nanog. On the other hand, the 
upregulation of Sox2 in knockdown Hmgn2 cell lines. These results showed that 
Hmgn2 may require for the regulation of Oct4 and Nanog while Sox2 
overexpression in knockdown Hmgn2 cells may be critical for maintaining the 
cancer stem cells and consequence preventing the cell differentiation. 
Moreover, knockdown the Hmgn2 in P19 EC cells showed slight reduction in 
induce pluripotent stem cell genes, Klf4 and C-myc. This result was challenging 
to demonstrate due to protease activity in protein.  
On the other hand, Chapter 6 presents the changes of Hmgn2 knockdown at the 
chromatin level. Western blot for chromatin analysis used to ensure the quality 
of chromatin and check the protein effects in knockdown Hmgn2 in P19 EC cells. 
The results showed that pluripotent markers, Oct4 and Sox2, were significantly 
reduced in Hmgn2 knockdown P19 EC cells. However, induced pluripotent 
marker Klf4 showed high expression while C-myc showed significant reduction. 
These results do not match whole protein analysis from Chapter 5. Therefore, 
These results may indicate that some of these proteins have not been affected 
at chromatin level.  
Moreover, chapter 6 describes and compares the chromatin from the knockdown 
of Hmgn2 in P19 EC cells using pGIPZ with mouse embryonic stem cell’s public 
data from the ENCODE project. ChIP data from ENCODE project highlighted the 
Oct4 and Nanog transcription starting sites because they contain an enrichment 
peak of histone for active promoter (H3K4me3) in ES cells. To confirm this data 
experimentally, qPCR for ChIP analysis applied the enrichment peak of H3K4me3 
 Chapter 7 242 
 
 242 
in Oct4 and Nanog binding site in E14 and P19 EC cells. The results showed high 
enrichment of H3K4me3 besides Hmgn2 at the same region. Knockdown Hmgn2 
in P19 EC cells used one target shHmgn2-381 and one negative control (non-
silencing). ShHmgn2-381 found to have significant reduction of Hmgn2 from 
protein and mRNA analysis (Chapter 5) and from western blot for chromatin 
(Chapter 6). Therefore, qPCR-ChIP used this target to investigate the effect of 
Hmgn2 reduction in Oct4 and Nanog binding sites. QPCR-ChIP for knockdown 
Hmgn2 P19 EC cells confirmed a loss of Hmgn2 peak in Oct4 and Nanog binding 
sites while there is clear high enrichment peak of Hmgn1 in the same region. 
Histone for active promoter (H3K4me3) showed a loss in Oct4 and Nanog binding 
sites whereas histone for Polycomb repression (H3K27me3) showed slight 
enrichment peak at the same Oct4 and Nanog region.  
Furthermore, chapter 6 attempts to investigate the western blot analysis from 
whole protein and chromatin of the general transcription factor binding 
specifically to DNA (TATA binding protein or TBP). The results showed the 
migration of TBP in knockdown Hmgn2 in P19 EC cells. an expected 
phosphorylated or ubiquitinated TBP preformed using CO-IP, but further 
investigation need to address.  
 
7.4 Future work  
Work described in this thesis aimed to understand biological roles played by a 
highly conserved non-histone chromosomal protein Hmgn2 and identify the novel 
roles in the mouse cancer stem cells. One of the main achievements of this work 
is that it allowed several new avenues for further research, some of which are 
briefly outlined below.  
 
7.4.1 Identify the difference between embryonic stem cells and epiblast stem 
cells  
P19 EC cells are considered as epiblast stem cells (EpiSCs). These epiblast stem 
cells showed two stage of embryo development: early epiblast and late epiblast.  
These epiblast stem cells are different from embryonic stem cells (ES cells) in 
epigenetic profiles and signalling responses, but they share some similarities 
with human embryonic stem cells (hESC) in gene expression and signalling 
pathways. A combine between chromatin immunoprecipitation and microarray 
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(ChIP-on-Chip) helped to understand the correlation between chromatin domain 
in epiblast stem cells and pluripotent makers such as Oct4, Sox2 and Nanog. The 
result showed Oct4 expression has two regulatory sites: distal enhancers were 
found to express stem cell from inner cell mass (ICM) whereas proximal 
enhancers were found to express epiblast stem cell from post-implantation. 
These enhancers have the ability to direct the Oct4 expression in those cells. 
This difference was observed in chimaera mice when stem cells introduced to 
pre-implantation embryo, epiblast cells did not survive as single cells and no 
committing to pre-implantation embryo was detected throughout morula 
aggregation. Moreover, epiblast stem cells can form teratomas that include 
different type of cells (Tesar et. al., 2007). P19 EC studies did not highlight if 
P19 EC cells are raised from early epiblast or late epiblast. However, it was 
mentioned that P19 EC cells similar to inner cell mass (ICM) cells. However, 
study identified the Oct4 expression is activated by proximal enhancer in P19 EC 
cells. Therefore, P19 EC cells are raised from post-implantation (late epiblast) 
(Yeom el. al., 1996).  
Defining gene expressions that involve in ES and Epiblast stem cells is important 
for better cell differentiation. Both cells express high Oct4 and Sox2, but less 
Nanog. Genes are associated with ICM stage such as Pecam1, Tbx3 and Gbx2 
express in mouse stem cells. Genes such as Otx2, Eomes, Foxa2, Brachyury(T), 
Gata6, Sox17, and Cer1 highly express in Epiblast stem cells, human ES cells, and 
early germ layers. However, Rex1 and Stella found to be down regulated in naïve 
epiblast stem cells. ChIP-on-Chip applied in three genes Stella, Nanog, Otx2 in 
mouse ES, Epiblast and human ES cells to detect the histone modification for 
active and repressive promoter (H3K4me3 and H3K27me3) at the transcription-
starting site (TSS). The results indicate that epiblast and human stem cells share 
similar epigenetic regulation of transcription. Moreover, same experiment was 
performed in Oct3/4 in the same cells showed clear difference of Oct4 
transcriptional network to maintain pluripotent epiblast stem cells (Tesar et. 
al., 2007).  
Signaling pathways is very important to detect specific genes for cellular and 
molecular process. Epiblast stem cells are able to maintain pluripotent state 
through ActivinA (Inbb)/Nodal and SMAD2/3 signaling whereas ES pluripotency is 
controlled by LIF signaling. Therefore, preventing the phosphorylation of STAT3 
at tyrosine residue 705 in JAK inhibitor showed no ES cell differentiation (Tesar 
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et. al., 2007). Moreover, growth factors FGF/MAPK and TGF-B signaling was 
detected in Epiblast post-implantation (Loh et. al., 2015). It would be helpful to 
identify and characterize epiblast stem cell genes in P19 EC cells using qRT-PCR 
for gene expression and signaling facto 
 
7.4.2 Developing pGIPZ, pSLIK and/or pTRIPZ tools to study the Hmgn2 
and/or Hmgn1 
There were several issues were observed in all the Lentiviral systems. First, 
Chapter 4 showed that P19 EC knockdown cell lines with constitutive lentivirus 
system (pGIPZ) driven by CMV promoter for 20 days became methylated. Similar 
results were found in inducible lentiviral system (pTRIPZ and pSLIK-CD4) 
(Chapter 3) that is derived by Ubc-I promoter. Therefore, replace the promoters 
from pGIPZ and pTRIPZ with GAC or A2UCOE promoter could help to solve 
methylation issue and stabilize the transgene expression. Second, inconsistence 
amount of puromycine from pGIPZ and pTRIPZ results suggested that bicistronic 
vectors from (IRES) could be an issue. Therefore, it was recommended that 
picornaviridae virus family (T2A and P2A) could be preferable choice due to its 
high eGFP expression and gene activity.    Third, the optimization of doxycycline 
in inducible lentiviral system (pTRIPZ and/or pSLIK-CD4) using shRNA for empty 
vector of pTRIPZ and/or pSLIK beside other targeting vectors could help 
determine the Hmgn2 knockdown that caused by endogenous loss of gene or 
other factors or genes. Equally, pH level in DMEM/F12 medium during culturing 
P19 EC knockdown cell lines changed to be more acidic medium. Thus, HEBES 
had helped to maintain pH level under 7.4. Moreover, lentiviral transduction 
process was preformed with two protocols: pSLIK protocol used lipofectamine 
2000 and pTRIPZ and pGIPZ protocols used Ca2PO4 transfection reagent. Both 
methods obtained low multiplicity of infection (MOI) transfection number for P19 
comparing with Hepa cells. Although Ca2PO4 showed low cytotoxicity in host cell 
(293T/17 cell line), the transfection reagents did not achieve the high 
transfection level in P19 EC cells. Therefore, it was critical to concentrate the 
viral particles to transduce P19 EC cells to obtain high MOI level, but the 
expression of shRNA derived by weak promoter should be changed at the first 
stage. Furthermore, freezing and thawing the transduced P19 EC cells with 
either pGIPZ or pTRIPZ failed to restore high and efficient knockdown due to 
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gene silencing. Finally, repeating pGIPZ and pTRIPZ lentivirus system showed a 
variable results in each time depend on the shRNA integration into the genome.  
 
7.4.3 Further investigation the knockdown P19 EC and E14 cells  
In chapter 5, a single lentiviral platform was employed for constitutive knock 
down of Hmgn2 Although more than 80% reduction in Hmgn2 protein levels was 
observed, still more investigation need to ensure that knockdown affect 
pluripotent and epiblast genes. Hence it is unclear whether the achieved Hmgn2 
knockdown levels are sufficient to mediate effect on expression of its 
pluripotent and epiblast genes from one single experiment. It is also not possible 
to distinguish between the effects of Hmgn2 activity and redundancy mediated 
by other TFs. Further studies addressing Hmgn2 function would require an 
improve of the current tool to address the above described limitation.  
Previously, it was suggested that one of the possible approaches could be to 
improve the efficiency of current RNAi mediated knockdown of Hmgn2. For 
instance, replace the CMV promoter to GAC or A2UCOE promoters and replace 
IRES to T2A or P2A. In addition, Hmgn2 mRNA could be targeted by two or more 
different shRNA. Therefore, cloning the shRNA for Hmgn2 (HMGN2-1) from pSLIK 
vector would be helpful. Then further investigation would be in gene expression 
and protein analysis to confirm gene knockdown.  However, ensuring the 
knockdown of Hmgn2 is real, it can be examined by rescue experiment using 
retrovirus or vector to overexpress Hmgn2 and examine the change in 
pluripotent and epiblast stem cells by comparing them with pluripotent stem 
cells that changes in knockdown Hmgn2. Rescue experiment was previously used 
in Hmgn1 knockout mice and mouse embryonic fibroblast (MEFs) to reintroduce 
Hmgn1 to ATM and p53 activation. Results showed that the loss of Hmgn1 reduce 
the ionizing radiation (IR) phosphorylation of SMC1, CHK1 and CHK2 which are 
ATM targets and reduces the level of p53 and MDM2. When the Hmgn1 re-
introdcued to ATM and p53, the expression of Hmgn1 increased in ATM and p53 
phosphorylation and stabilization. This help to form multi-protein the factors at 
the DSB sites which support the ATM activation (Kim et. al., 2008). 
Flow cytometer (FACS) analysis was performed in Chapter 5 for knockdown 
Hmgn2 in P19 EC cells. Moreover, culturing Hmgn2 knockdown P19 EC showed 
increase in cell proliferation (data did not show). Therefore, it was suggested 
that cell proliferative assay could help to identify if Hmgn2 knockdown EC cells 
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roles which presumably due to additional genetic events. Further investigation 
would be in cell cycles analysis. This was examined before on knockdown Hmgn2 
P19 EC cells. However, the tested cells where from thawed cells, which had 
some inactive Hmgn2 knockdown vector. The results showed that the knockdown 
Hmgn2 EC cells accumulated in the G1 phase of the cell cycle (data not shown). 
Moreover, western blot was used to detect p53, but the western blot did not 
work (data not shown). Nevertheless, these results cannot be valid due to 
thawing and methylated promoter issues. Thus, cell-cycle analysis could be 
important experiment because Knockdown EC cells did not show substantial 
apoptosis. 
Quantitative reverse transcriptase PCR (qRT-PCR) applied in knockdown Hmgn2 
P19 EC cells (chapter 5) and confirmed the reduction of Oct4 and Nanog and 
Klf4. It would be helpful to distinguish changes in gene expression occur 
between negative control (non-silencing) and knockdown Hmgn2 in epiblast and 
epiblast/ES genes. Then microarray gene expression analysis of knockdown cells, 
which could highlight the significant gene expression differences in genes 
responsible for self-renewal, cell cycle, cell migration, DNA repair, apoptosis 
and cell differentiation.  
 
7.4.3.1 Pluripotent markers regulation under the loss of Hmgn2  
It was known that HMGN1 and HMGN2 are the only non-histone protein binding 
specifically to nucleosome and it is highly dynamic proteins, which are 
associated to transcription activity, cell cycle process, and DNA repair 
mechanism. Chapter 5 showed that knockdown of Hmgn2 affect the expression 
of pluripotent genes and induce pluripotent genes. However, mouse fibroblast 
stem cells Hmgn2 knockout did not detect phenotypes changes such as eye, 
energy metabolism, haematology, immunology, and clinical chemistry. 
Moreover, 19 genes were up regulated and 29 genes were down regulated in 
Hmgn2 knockout in mouse brain whereas in mouse thymus 173 were up regulated 
and 310 were down-regulated (Deng et. al., 2015). On the other hand, this study 
found that phenotype and gene expression changes in Hmgn1 and Hmgn2 double 
knockout gene in mouse (Deng et. al., 2015). Another study found that knockout 
Hmgn1 in mice had neither phenotypic nor transcriptional effects on mouse 
embryo development. In addition, this study used two different models: 
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nonchrondrogenic MEFs and E10.5 limb bud cells to detect the interaction 
between Sox9 and Hmgn1 at chromatin level. Consequently, the results showed 
that Hmgn1 expression regulates Sox9 chromatin in limb bud (in vivo), but failed 
to detect in MEFs (in vitro) (Furasawa et. al., 2006).  However, both studies 
highlighted that whether the loss of either Hmgn1 and/or Hmgn2 is associated 
with chromatin modification. Thus, these studies focused on the region of active 
genes “Dnase hypersensitive sites” that regulates its transcription.  
Active genes in embryonic stem cells and induce pluripotent stem cells were 
tested and discussed in chapter 5 and 6. Further experiments to confirm and 
address the functional discrepancy between in vitro and in vivo in mouse Hmgn2 
and the adaptive time for cell to obtain stable knockdown or knockout mouse 
model. Hmgn2 knockdown experiments in chapter 5 showed that transduced 
cells took five-seven days to adapt with the loss of Hmgn2 in P19 EC cells 
comparing with previous studies. The significant of this study need more 
investigation in normal mouse embryonic stem cells such as E14 cells.  
Analysis of Hmgn1 expression following Hmgn2 knockdown in P19 EC cells 
showed significant up regulation in Chapter 5. This possibly may explain the 
homeostatic mechanisms between Hmgn1 and Hmgn2. Gene targeting of Sox9 
under the loss of Hmgn1 in mice produce same results although there is a lack of 
phenotype. The level of HMGN2 expression was similar to HMGN1 in wild type 
cell (Furusawa et. al., 2006). Further research is required to establish a 
precision mechanism between Hmgn1 and Hmgn2 in Sox9 location and whether 
there are other locations recruit this compensation.  
 
7.4.4 Investigating the neuronal development in P19 EC and E14 cells  
Epiblast stem cell (E 6.5) is specific to develop to three types of neurons by day 
E 7.5. Neuronal progenitor cells are the first neural committed cells and it is 
induced by signal from mesoderm and endoderm  (Hitoshi et. al., 2004). Both 
embryonic stem cells (ESCs) and epiblast stem cells (EpiSC) undergo to different 
cell culture and neuronal differentiation process (Tesar et. al., 2007).  
In vitro, epiblast first neural tissue marker genes are Sox1 and Nestin at day E 
7.0- E 8.0. Then fibroblast growth factor (FGF2) is recruited epidermal growth 
factor (EGF) and it becomes detectable at day E 8.5. Moreover, bone 
morphogenetic proteins (BMPs) inhibit the epiblast stem cells once the neural 
tube form. (Hitoshi et. al., 2004). Embryonic Stem cells derived from E 5.5-E 
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7.5, LIF-dependent primitive neural stem cells presents in the epiblast and 
neuroectodermal of E 5.5-E 7.5 mouse embryo. These cells expressed GATA 4, 
FGF5, and Sox2/1, but these cells could not detect Brachyury (mesodermal 
marker), endodermal marker (HNF4), epidermal marker (cytokeratin17) at day E 
7.5. However, downregulation of GATA 4 and FGF5 expression detect at day E 
6.5. Based on these results it showed that epiblast LIF-dependent and ES cells 
are raised proliferative neural stem cells. P19 EC cells similar to ES cells gives 
arise to three germ layers: endoderm, mesoderm and ectoderm (Hitoshi et. al., 
2004). Nerve cells derive from ectoderm layer and it forms from neuroepithelial 
germinal cells similar in function and morphology to cells in mammalian central 
nerve system. Previously P19 EC neural differentiation protocol used serum 
medium. Although this method can form neuronal population such as 
oligodendrocytes, glia cells and mature neuron, many proliferative cells (non-
neuronal cells) such as astrocytes, fibroblast and skeletal cells remain in the 
culture. Moreover, the previous protocol based on suspension cells form embryo 
bodies (Ebs) (Manzo et. al., 2012).  
A novel method allows generating more neural cells under defined medium. 
Investigating for more neural markers such as Calretinin, Calbindin, synapsin I, 
and NeuN. Moreover, this method helps to reduce the non-neuronal cells that 
reduce the neuronal number in long-term culture. In addition, more neuronal 
precursor cells increase which permit more investigation and characterization. 
The method starts with retinoic acid (RA) induction in monolayer culture. After 
the induction cells, the neuronal progenitor cells form under medium contains 
neuronal basal A medium (NBA) with supplement N2 and glutamax for five days. 
Then, neurite outgrowth cells form under NBA medium supplemented with B27, 
AraC and 2dCTD. Post-mitotic neurons become committed between culture day 
10-15 UNDER NBA supplemented with B27 and synaptic integration cells (mature 
neurons) form by day 15-20 under the same medium. During neural forming, 
genes expressions are responsible for neuronal developments were detected 
such as Gfap, NeuN, Calretinin, Calbindin, Synapsin I, and Nestin (Monzo et. al., 
2012).  
Another method for P19 neuronal differentiation had improved the previous 
method by Monzo and colleagues (2012) in cell culture medium and less culture 
time point. P19 uses RA to induce the neuronal differentiation for only two days 
under DMEM/F12 supplemented with N2, FGF8 and DAPT in adherent culture. 
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Then exogenesis form for two days under the same medium with no RA. By day 4 
synaptogenesis forms under medium NBA supplemented with B27 and AraC until 
day 6. Next, synapse maturation cells form under NBA supplemented with B27. 
During this neural differentiation several genes are detected such as Oct4, E-
cadherin, Nestin, Laminin, MAP2c, NF-L, and synapsin I in addition to pervious 
genes (Nakayama et. al., 2014). However, still proliferative non-neuronal cells 
remain an issue.  
A current explanation by Hamada-Kanazawa and colleagues (2016) suggested 
that RA induction caused an increase of BMP-4 expression while Sox6 inhibit the 
BMP-4 expression which cause more wild type P19 cells remains in the culture. 
However, an alternative method is to overexpress the Sox6 to increase the 
expression of neuronal differentiation lineage without the need to RA (Hamada-
Kanazawa et. al., 2016) using viral vector.  
 
7.4.5 Investigating P19 EC Knockdown during neuronal differentiation under 
serum free medium 
As discussed in chapter 5, Hmgn2 knock down in P19 EC cells resulted in 
downregulation of Oct4 and Nanog, and Klf4 but upregulation of Sox2 and C-myc. 
It was knockdown that Sox2 overexpression could lead to cell committed toward 
differentiation. However, drawing a conclusion based on current result presents 
significant limitation, as Hmgn2 knockdown could be vary between biological 
triplicates. Similarly, Hmgn2 knockdown in P19 during neuronal differentiation 
could be challenging due to the limitation in current knockdown system and 
differentiation protocol. Previous study showed the P19 neural development was 
investigated at day 3, 6, and 18 and knockdown during these days using siRNA 
(Mohan, 2012). The later could be knockdown P19 at embryonic stage then 
inducing these cells using RA beside inducing wild type P19 cells to neural 
development using serum free media and growth factors as supplement. Then 
confirming the key neuronal development markers would apply detection by 
immunofluorescence (IF) against Hmgn2 and neural gene makers besides qRT-
PCR analysis.  
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7.4.6 Genome wide approaches to study Hmgn2 regulatory network 
Unfortunately there is no public ENCODE region for HMGN2 binding site in mouse 
genome. However, Public ENCODE data for Oct4, Sox2 and Nanog binding sites 
from mouse embryonic stem cells is available. Therefore, investigate pluripotent 
genes using qRT-PCR and western blot for chromatin to ensure the quality of 
data are still highly demanding following Chip-seq and bioinformatics analysis, 
which ENCODE regions represents a large portion of mouse genome. This would 
permit manual data analysis, which is the first attempting of qPCR-ChIP as well 
as being readily affordable. In addition, Oct4, Sox2 and Nanog are well 
characterized in mouse stem cells.  
As discussed in Chapter 6, Hmgn2 knockdown qPCR-ChIP highlighted in two 
regions that is enriched with H3K4me3 in Oct4 and Nanog transcription-starting 
sites (TSS). QPCR-ChIP primers were designed before TSS, within TSS and after 
TSS. Moreover, shRNA for Hmgn2-381 found to be within TSS region of Oct4 and 
Nanog. Hmgn2 knockdown results revealed global loss of Hmgn2 besides loss of 
H3K4me3 across Oct4 and Nanog TSS. These results contradict with Deng and 
colleagues (2015), which showed the level of H3K4me3 and H3K4me1 from ChIP-
seq data did not changed due to either the knockout of Hmgn2 or double 
knockout of Hmgn1 and Hmgn2 although they mentioned that the loss of Hmgn1 
and Hmgn2 affects Dnase hypersensitive sites (DHSs) at the enhancer region 
(Deng et. al., 2015). In addition, enrichment peak of Hmgn1 besides modest 
enrichment peak of H3k27me3 identified at the Oct4 and Nanog TSS. These 
results have some contradictions with other studies. The enrichment of Hmgn1 
at the active genes regions such as Oct4 and Nanog due to the loss of Hmgn2 
found in the study of investigating the role of Hmgn1 in Sox9 expression. ChIP-
seq analysis found that the loss of Hmgn1 in limb bud associated with Sox9 
chromatin and significant enrichment of Hmgn2 at the same Sox9 region. This 
data suggests that during the loss of Hmgn1 in limb bud, but not in MEFs, HMGN2 
expression level is similar to normal HMGN1 (Furusawa et. al., 2006). Further 
results need to establish to confirm three points before applying comprehensive 
analysis of Hmgn2 function by combining Hmgn2 ChIP-seq analysis with RNA-seq 
data or gene expression data.  
First, further research is required to identify the epiblast stem cell gene 
expression under Hmgn2 knockdown cells. This will allow studying the effect of 
Hmgn2 during cell development since no study focused on the relationship 
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between Hmgn2 and chromatin of active genes that are important for epiblast 
identity including Oct4, Sox2 and Nanog.  
Second, identify epiblast stem cell population that can commit to neuronal 
precursor cells using cell surface markers that distinguish epiblast from 
embryonic stem cells. This step is important because epiblast stem cells have 
two options: reverse to embryonic stem cells or commit to neuronal stem cells 
and it will help to avoid proliferative cells during neuronal differentiation.  
Then, Hmgn2 knockdown in P19 EC cells besides E14 cells using modified pGIPZ 
would help to detect the loss Hmgn2 effects on epiblast and embryonic stem cell 
genes. Furthermore, qPCR-ChIP experiment is still a valid analysis to ensure the 
loss of Hmgn2 in pluripotent gene regions.  
However, it would be feasible to apply qPCR-ChIP to investigate promoter and 
super-enhancer at Dnase hypersensitive regions. In general, promoters is a DNA 
cis-regulatory elements that found in proximity of transcription starting sites to 
confirm the initiation of the transcription process while enhancers can stimulate 
the transcription level of its target gene. The interaction between promoters 
and enhancers may happen during “looping” and “tracking”: looping means that 
DNA location between enhancer and promoter form loop to increase the 
interaction and tracking occur when enhancer stimulate the RNA polymerase II 
to DNA promoter to initiate the transcription mechanism. Moreover, both 
promoter and enhancer showed high sensitivity to Dnase I digest which indicate 
the alteration of nucleosome organization leading to increase chromatin 
accessibility. In addition to promoter and enhancers, Dnase I hypersensitive sites 
include other regulatory gene complexes such as silencer and insulator (Martinez 
de Paz and Ausio, 2016). Therefore, they are highly dynamic during cells 
committing to differentiation. Previously, Deng and colleges (2015) shed the 
light toward the roles of Hmgn1 and Hmgn2 at Dnase hypersensitive sites (DHSs).  
Therefore, it will be helpful to identify the common promoters and super-
enhancers based on epiblast stem cell genes. QPCR for ChIP besides mRNA 
analysis would be the initial step to identify these genes.  
According to recent study epiblast stem cells promoters are different from 
embryonic stem cells based on signalling pathways that control the self-renewal 
and De novo DNA methylation such as methyltransferase 3a, 3b, and 3I using 
RNA-seq. Each promoter should be classified based on methylation level in 
epiblast stem cells. Epiblast hyper methylation promoters such as Dppa3 (Stella), 
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Zfp42 (Rex1), Tbx3, which found to be part of gene regulations expressed 
different in naïve from primed pluripotent cells. In addition, these promoters 
found to be linked to genes responsible for molecular transport, metabolism, 
signalling pathway and neural development. On the other hand, epiblast 
hypomethylation promoters such as Abcb1a, Aebp1, Chrna3, Cspg4, Daam2, and 
Gfra3 contribute with bivalent promoter in ESCs. These promoters play roles in 
membrane transportation, nervous system and muscle development. Besides all 
these genes, gene expression of epiblast stem cells such as Esrrb, Klf4 (from 
early epiblast stem cells) Nodal, Fgf5, Brachyury and Cer1 (late epiblast stem 
cells) should be examine including Oct4, Sox2, and Nanog (Velliard et. al., 
2014).  
Recent studies highlight on super-enhancer in stem cells. Super-enhancer (high 
level of mediators) defined as large cluster of transcriptional enhancers that are 
dynamically involve in regulatory elements deriving the gene expression 
responsible for cell identity (Whyte et. al., 2013 and Ding et. al., 2015). May be 
most of super-enhancer study focused on embryonic stem cells genes such as 
Sox2, Oct4 and Nanog and other genes such as Klf4, Essrb, C-myc that are 
involve in embryonic and early epiblast stem cells development. Therefore, it is 
challenging to reply on these studies albeit it is very important to understand 
gene selection via ChIP-seq data. However, Oct4, Sox2 and Nanog are express in 
both epiblast and embryonic stem cells, which can be used to compare with P19 
EC ChIP-seq. furthermore, nucleosome with the histone modification H3K27ac 
and H3K4me1 are enriched with active enhancers in ESCs. Another acetylated 
nucleosome found in enhancer and promoter called acetylated histone at lysine 
9 and phosphorylated at serine 10 (H3K9acS10ph) which play important roles in 
enhancer function and transcription process of drosophila (Martinez da Paz and 
Ausio, 2016).  This can be used to compare P19 EC ChIP-seq data from Sox2, 
Oct4, Nanog, and Otx2, mediator, Histone modifications and Dnase I 
hypersensitive sites to segregate super-enhancers from normal enhancers.  
 
7.4.7 Preforming the Hmgn2 knockout using CRISPR-CAS9 technology as an 
alternative effective method 
As result of the gene targeting performed in mouse stem cells, Hmgn2 mouse 
embryonic knockout become available (Deng et al., 2015). These provide a tool 
for investigating Hmgn2 function, albeit accompanied with several limitations. In 
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particular it may not be possible to investigate the role of Hmgn2 in neural gene 
regulation and development due to the long mouse breed and the possibility that 
Hmgn2 replaced with other modulators or protein complexes that are involve in 
Dnase I hypersensitive sites to maintain cell pluripotency and identity. Recent 
studies have successfully employed genome engineered clustered regularly 
interspaced palindromic repeat associated Cas9 nuclease  (CRISPR-Cas9) in order 
to perform stable gene manipulation experiment in mammalian cells (Doudna 
and Charpentier, 2014). It may therefore be possible to design CRISPR-Cas9 
targeting the full length of HMGN2 coding sequences in order to generate stable 
HMGN2 knockout in mouse stem cells (P19 EC cell and E14 cells used in this 
study). 
The CRISPR-Cas9 approach to knockout Hmgn2 can clarify if the hmgn2 present 
following the Chapter 5 and 6 described RNAi knockdown is responsible for 
changes pluripotent stem cell expression of some Hmgn2 target genes. Flowing 
the successful application of CRISPR-Cas9 described approaches; the global 
effects of disrupting Hmgn2 function can be assessed by performing whole 
genome gene expression analysis (RNA-seq).  
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Appendix 
Protein cell extract using different lysis buffer  
A.  
 
B.  
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Figure X 1 western blot and Coomassie blue for wild type P19 EC cells 
extracted with different cell extraction buffer 
A. Coomassie blue showed wild type P19 EC cells with different lysis buffer: 
cytobuster (Millipore), RIPA buffer (Millipore), lab made (provided by Dr. 
Katherine west lab), and nuclear extract (provided by Dr. Adam west lab) with 
different cell number extraction. B. western blots showed some proteins 
expression; TBP, H3, Oct4 and Hmgn2 under different lysis buffer for Wild type 
P19 EC cells. TBP and H3 were used as control for Oct4 and Hmgn2.  
ShHMGN2-381 sequence alignment from UCSC browser  
 
Figure X 2 UCSC genome browser of mouse Hmgn2 region in chromosome 4 
The data include shHMGN2-381 sequence targeting the nucleosome binding 
domain region. the sequence was mapped with E14 chip-seq data for histones 
(H3K4me3 and H3K27me3) and pluripotent genes (Oct4 and Nanog) 
(https://www.encodeproject.org). ShHMGN2-381 region was located at 
enrichment site of H3k4me3 of E14 cells.  E14 Chip-seq experiments came from 
three experiments were downloaded from ENCODE project. 
 
 
Western blot for active histone promoter H3K4me3 in Hmgn2 knockdown P19 
EC cells  
  
 
Figure X 3 Hmgn2 knockdown on P19 EC cells using lentiviral constitutive 
system 
Western blot analysis H3K4me3 on shRNA (shGAPDH, shNon-silencing, shHMGN2-
381 and shHMGN2-968) was performed on day 20. Anti-H3K4me3 antibodies were 
256 
 
 256 
detected against H3K4me3 in Hmgn2 knockdown P19 EC cells whole protein 
extract. All the knockdown cells showed normal expression comparing with H3 
and ACTIN (controls) except shHMGN2-381 did not show any H3k4me3 signal on 
day 20.  
 
Western blot for TPB protein in Hmgn2 knockdown P19 EC cell with PTRIPZ 
after Dox treatment for 5 days 
 
Figure X 4 TBP and H3 (control) western blot in Hmgn2 knockdown P19 EC cells with 
pTRIPZ after 5 days dox treatment 
(Notice that PTRIPZ did not gain high hmgn2 knockdown in FACS analysis and RT-
PCR).   
Western blot for TBP protein in Hmgn2 knockdown P19 EC cells using PGIPZ 
 
Figure X 5 TBP and H3(control) western blot in Hmgn2 knockdown P19 EC cells with PGIPZ 
lentivirus at day 10 (red), day 20 (blue) and day 25 (green) 
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